Abacavir|N|abacavir|zidovudine|Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine . 
Abacavir|N|abacavir|lamivudine|Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine . 
Abacavir|N|abacavir|lamivudine|Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine . 
Abacavir|N|abacavir|zidovudine|Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine . 
Abacavir|N|lamivudine|zidovudine|Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine . 
Abacavir|N|zidovudine|lamivudine|Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine . 
Abacavir|N|zidovudine|zidovudine|Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine . 
Abacavir|N|lamivudine|lamivudine|Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine . 
Abacavir|N|lamivudine|zidovudine|Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine . 
Abacavir|N|lamivudine|zidovudine|Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine . 
Abacavir|N|zidovudine|abacavir|No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir . 
Abacavir|N|lamivudine|abacavir|No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir . 
Abacavir|N|lamivudine|zidovudine|No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir . 
Abacavir|N|abacavir|ethanol|Abacavir has no effect on the pharmacokinetic properties of ethanol . 
Abacavir|N|methadone|abacavir|Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir . 
Abacavir|N|abacavir|abacavir|Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir . 
Abacavir|N|ethanol|abacavir|Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir . 
Abacavir|N|abacavir|methadone|Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir . 
Abacavir|N|ethanol|methadone|Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir . 
Abacavir|N|ziagen|methadone|In a study of 11 HIV-infected patients receiving methadone-maintenance therapy -LRB- 40 mg and 90 mg daily -RRB- with 600 mg of ZIAGEN twice daily -LRB- twice the currently recommended dose -RRB- , oral methadone clearance increased 22 % -LRB- 90 % CI 6 % to 42 %-RRB-. 
Abacavir|N|methadone|methadone|In a study of 11 HIV-infected patients receiving methadone-maintenance therapy -LRB- 40 mg and 90 mg daily -RRB- with 600 mg of ZIAGEN twice daily -LRB- twice the currently recommended dose -RRB- , oral methadone clearance increased 22 % -LRB- 90 % CI 6 % to 42 %-RRB-. 
Ezetimibe|N|cholestyramine|cholestyramine|Cholestyramine : Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55 %. 
Ezetimibe|N|cholestyramine|ezetimibe|Cholestyramine : Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55 %. 
Ezetimibe|N|fibrate|ezetimibe|Fibrates : The safety and effectiveness of ezetimibe administered with fibrates have not been established . 
Ezetimibe|N|fibrate|fibrate|Fibrates : The safety and effectiveness of ezetimibe administered with fibrates have not been established . 
Ezetimibe|N|ezetimibe|fibrate|Fibrates : The safety and effectiveness of ezetimibe administered with fibrates have not been established . 
Ezetimibe|N|fenofibrate|fenofibrate|Fenofibrate : In a pharmacokinetic study , concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold . 
Ezetimibe|N|fenofibrate|ezetimibe|Fenofibrate : In a pharmacokinetic study , concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold . 
Ezetimibe|N|gemfibrozil|gemfibrozil|Gemfibrozil : In a pharmacokinetic study , concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold . 
Ezetimibe|N|gemfibrozil|ezetimibe|Gemfibrozil : In a pharmacokinetic study , concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold . 
Ezetimibe|N|gemfibrozil|ezetimibe|Gemfibrozil : In a pharmacokinetic study , concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold . 
Ezetimibe|N|pravastatin|lovastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|pravastatin|lovastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|pravastatin|fluvastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|pravastatin|fluvastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|hmg-coa reductase inhibitor|pravastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|ezetimibe|pravastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|atorvastatin|pravastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|simvastatin|pravastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|lovastatin|fluvastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|lovastatin|fluvastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|hmg-coa reductase inhibitor|lovastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|ezetimibe|lovastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|atorvastatin|lovastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|simvastatin|lovastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|hmg-coa reductase inhibitor|fluvastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|ezetimibe|fluvastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|atorvastatin|fluvastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|simvastatin|fluvastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|hmg-coa reductase inhibitor|ezetimibe|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|hmg-coa reductase inhibitor|atorvastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|hmg-coa reductase inhibitor|simvastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|ezetimibe|atorvastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|ezetimibe|simvastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|atorvastatin|simvastatin|HMG-CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
Ezetimibe|N|cyclosporine|ezetimibe|Cyclosporine : The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications , including cyclosporine . 
Ezetimibe|N|cyclosporine|cyclosporine|Cyclosporine : The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications , including cyclosporine . 
Ezetimibe|N|ezetimibe|ezetimibe|Carcinogenesis , Mutagenesis , Impairment of Fertility A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day -LRB- males -RRB- and 500 mg/kg/day -LRB- females -RRB- -LRB- ~20 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe -RRB-. 
Ezetimibe|N|ezetimibe|ezetimibe|A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day -LRB- >150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe -RRB-. 
Ezetimibe|N|ezetimibe|ezetimibe|In oral -LRB- gavage -RRB- fertility studies of ezetimibe conducted in rats , there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats -LRB- ~7 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe -RRB-. 
Ezetimibe|N|ezetimibe|ezetimibe|In rabbits treated with ezetimibe , an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day -LRB- 150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe -RRB-. 
Ezetimibe|N|ezetimibe|hmg-coa reductase inhibitor|Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors -LRB- statins -RRB- in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures . 
Ezetimibe|N|ezetimibe|statin|Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors -LRB- statins -RRB- in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures . 
Ezetimibe|N|ezetimibe|ezetimibe|Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors -LRB- statins -RRB- in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures . 
Ezetimibe|N|hmg-coa reductase inhibitor|statin|Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors -LRB- statins -RRB- in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures . 
Ezetimibe|N|hmg-coa reductase inhibitor|ezetimibe|Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors -LRB- statins -RRB- in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures . 
Ezetimibe|N|statin|ezetimibe|Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors -LRB- statins -RRB- in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures . 
Ezetimibe|N|hmg-coa reductase inhibitor|hmg-coa reductase inhibitor|When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential , refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor . 
Ezetimibe|N|zetia|hmg-coa reductase inhibitor|When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential , refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor . 
Ezetimibe|N|zetia|hmg-coa reductase inhibitor|When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential , refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor . 
Fluconazole|N|short-acting benzodiazepine|hypoglycemic|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|short-acting benzodiazepine|diflucan|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|short-acting benzodiazepine|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|tacrolimu|short-acting benzodiazepine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|phenytoin|short-acting benzodiazepine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cyclosporine|short-acting benzodiazepine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|short-acting benzodiazepine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|coumarin-type anticoagulant|short-acting benzodiazepine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cisapride|short-acting benzodiazepine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|terfenadine|short-acting benzodiazepine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|theophylline|short-acting benzodiazepine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifampin|short-acting benzodiazepine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifabutin|short-acting benzodiazepine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|astemizole|short-acting benzodiazepine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|diflucan|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|tacrolimu|hypoglycemic|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|phenytoin|hypoglycemic|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cyclosporine|hypoglycemic|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|hypoglycemic|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|coumarin-type anticoagulant|hypoglycemic|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cisapride|hypoglycemic|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|terfenadine|hypoglycemic|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|theophylline|hypoglycemic|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifampin|hypoglycemic|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifabutin|hypoglycemic|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|astemizole|hypoglycemic|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|tacrolimu|diflucan|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|phenytoin|diflucan|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cyclosporine|diflucan|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|diflucan|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|coumarin-type anticoagulant|diflucan|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cisapride|diflucan|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|terfenadine|diflucan|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|theophylline|diflucan|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifampin|diflucan|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifabutin|diflucan|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|astemizole|diflucan|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|tacrolimu|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|phenytoin|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cyclosporine|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|coumarin-type anticoagulant|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cisapride|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|terfenadine|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|theophylline|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifampin|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifabutin|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|astemizole|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|phenytoin|tacrolimu|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cyclosporine|tacrolimu|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|tacrolimu|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|coumarin-type anticoagulant|tacrolimu|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cisapride|tacrolimu|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|terfenadine|tacrolimu|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|theophylline|tacrolimu|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifampin|tacrolimu|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifabutin|tacrolimu|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|astemizole|tacrolimu|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|phenytoin|cyclosporine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|phenytoin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|coumarin-type anticoagulant|phenytoin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|phenytoin|cisapride|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|phenytoin|terfenadine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|phenytoin|theophylline|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|phenytoin|rifampin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|phenytoin|rifabutin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|phenytoin|astemizole|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|cyclosporine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|coumarin-type anticoagulant|cyclosporine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cyclosporine|cisapride|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cyclosporine|terfenadine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cyclosporine|theophylline|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cyclosporine|rifampin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cyclosporine|rifabutin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cyclosporine|astemizole|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|coumarin-type anticoagulant|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|cisapride|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|terfenadine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|theophylline|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|rifampin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|rifabutin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|hypoglycemic|astemizole|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|coumarin-type anticoagulant|cisapride|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|coumarin-type anticoagulant|terfenadine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|coumarin-type anticoagulant|theophylline|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|coumarin-type anticoagulant|rifampin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|coumarin-type anticoagulant|rifabutin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|coumarin-type anticoagulant|astemizole|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|terfenadine|cisapride|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|theophylline|cisapride|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifampin|cisapride|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cisapride|rifabutin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|cisapride|astemizole|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|theophylline|terfenadine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifampin|terfenadine|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|terfenadine|rifabutin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|terfenadine|astemizole|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifampin|theophylline|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|theophylline|rifabutin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|theophylline|astemizole|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifampin|rifabutin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|rifampin|astemizole|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|astemizole|rifabutin|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|N|tolbutamide|glipizide|DIFLUCAN reduces the metabolism of tolbutamide , glyburide , and glipizide and increases the plasma concentration of these agents . 
Fluconazole|N|tolbutamide|glyburide|DIFLUCAN reduces the metabolism of tolbutamide , glyburide , and glipizide and increases the plasma concentration of these agents . 
Fluconazole|N|glyburide|glipizide|DIFLUCAN reduces the metabolism of tolbutamide , glyburide , and glipizide and increases the plasma concentration of these agents . 
Fluconazole|N|glyburide|glipizide|DIFLUCAN reduces the metabolism of tolbutamide , glyburide , and glipizide and increases the plasma concentration of these agents . 
Fluconazole|N|diflucan|sulfonylurea|When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents , blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary . 
Fluconazole|N|sulfonylurea oral hypoglycemic agent|sulfonylurea|When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents , blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary . 
Fluconazole|N|coumarin-type anticoagulant|diflucan|Coumarin-type anticoagulants : Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants . 
Fluconazole|N|coumarin-type anticoagulant|coumarin-type anticoagulant|Coumarin-type anticoagulants : Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants . 
Fluconazole|N|azole antifungal|warfarin|In post-marketing experience , as with other azole antifungals , bleeding events -LRB- bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena -RRB- have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin . 
Fluconazole|N|azole antifungal|fluconazole|In post-marketing experience , as with other azole antifungals , bleeding events -LRB- bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena -RRB- have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin . 
Fluconazole|N|phenytoin|phenytoin|Phenytoin : DIFLUCAN increases the plasma concentrations of phenytoin . 
Fluconazole|N|phenytoin|diflucan|Phenytoin : DIFLUCAN increases the plasma concentrations of phenytoin . 
Fluconazole|N|phenytoin|phenytoin|Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended . 
Fluconazole|N|phenytoin|diflucan|Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended . 
Fluconazole|N|cyclosporine|diflucan|Cyclosporine : DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment . 
Fluconazole|N|cyclosporine|cyclosporine|Cyclosporine : DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment . 
Fluconazole|N|cyclosporine|diflucan|Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine . 
Fluconazole|N|cyclosporine|cyclosporine|Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine . 
Fluconazole|N|rifampin|rifampin|Rifampin : Rifampin enhances the metabolism of concurrently administered DIFLUCAN . 
Fluconazole|N|rifampin|diflucan|Rifampin : Rifampin enhances the metabolism of concurrently administered DIFLUCAN . 
Fluconazole|N|theophylline|theophylline|Theophylline : DIFLUCAN increases the serum concentrations of theophylline . 
Fluconazole|N|theophylline|diflucan|Theophylline : DIFLUCAN increases the serum concentrations of theophylline . 
Fluconazole|N|theophylline|diflucan|Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended . 
Fluconazole|N|theophylline|theophylline|Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended . 
Fluconazole|N|terfenadine|terfenadine|Terfenadine : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine , interaction studies have been performed . 
Fluconazole|N|terfenadine|azole antifungal|Terfenadine : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine , interaction studies have been performed . 
Fluconazole|N|fluconazole|terfenadine|Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly . 
Fluconazole|N|fluconazole|diflucan|Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly . 
Fluconazole|N|cisapride|cisapride|Cisapride : There have been reports of cardiac events , including torsade de pointes in patients to whom fluconazole and cisapride were coadministered . 
Fluconazole|N|cisapride|fluconazole|Cisapride : There have been reports of cardiac events , including torsade de pointes in patients to whom fluconazole and cisapride were coadministered . 
Fluconazole|N|fluconazole|cisapride|A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval . 
Fluconazole|N|cisapride|cisapride|A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval . 
Fluconazole|N|astemizole|fluconazole|Astemizole : The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs . 
Fluconazole|N|astemizole|astemizole|Astemizole : The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs . 
Fluconazole|N|rifabutin|rifabutin|Rifabutin : There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered . 
Fluconazole|N|rifabutin|fluconazole|Rifabutin : There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered . 
Fluconazole|N|tacrolimu|fluconazole|Tacrolimus : There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered . 
Fluconazole|N|tacrolimu|tacrolimu|Tacrolimus : There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered . 
Fluconazole|N|short-acting benzodiazepine|midazolam|Short-acting Benzodiazepines : Following oral administration of midazolam , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects . 
Fluconazole|N|midazolam|midazolam|Short-acting Benzodiazepines : Following oral administration of midazolam , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects . 
Fluconazole|N|short-acting benzodiazepine|midazolam|Short-acting Benzodiazepines : Following oral administration of midazolam , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects . 
Fluconazole|N|short-acting benzodiazepine|fluconazole|Short-acting Benzodiazepines : Following oral administration of midazolam , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects . 
Fluconazole|N|fluconazole|midazolam|Short-acting Benzodiazepines : Following oral administration of midazolam , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects . 
Fluconazole|N|midazolam|fluconazole|This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously . 
Fluconazole|N|fluconazole|fluconazole|This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously . 
Fluconazole|N|short-acting benzodiazepine|benzodiazepine|If short-acting benzodiazepines , which are metabolized by the cytochrome P450 system , are concomitantly administered with fluconazole , consideration should be given to decreasing the benzodiazepine dosage , and the patients should be appropriately monitored . 
Fluconazole|N|fluconazole|benzodiazepine|If short-acting benzodiazepines , which are metabolized by the cytochrome P450 system , are concomitantly administered with fluconazole , consideration should be given to decreasing the benzodiazepine dosage , and the patients should be appropriately monitored . 
Fluconazole|N|ethinyl estradiol|levonorgestrel|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|N|ethinyl estradiol|contraceptive|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|N|ethinyl estradiol|ethinyl estradiol|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|N|ethinyl estradiol|levonorgestrel|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|N|levonorgestrel|contraceptive|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|N|levonorgestrel|ethinyl estradiol|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|N|levonorgestrel|levonorgestrel|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|N|contraceptive|ethinyl estradiol|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|N|contraceptive|levonorgestrel|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|N|fluconazole|contraceptive|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|N|ethinyl estradiol|levonorgestrel|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|N|fluconazole|ethinyl estradiol|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|N|fluconazole|levonorgestrel|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|N|ethinyl estradiol|levonorgestrel|however , in some patients there were decreases up to 47 % and 33 % of ethinyl estradiol and levonorgestrel levels . 
Fluconazole|N|levonorgestrel|fluconazole|The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation . 
Fluconazole|N|ethinyl estradiol|fluconazole|The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation . 
Fluconazole|N|ethinyl estradiol|levonorgestrel|The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation . 
Fluconazole|N|ethinyl estradiol|levonorgestrel|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Fluconazole|N|fluconazole|levonorgestrel|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Fluconazole|N|levonorgestrel|levonorgestrel|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Fluconazole|N|ethinyl estradiol|levonorgestrel|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Fluconazole|N|fluconazole|levonorgestrel|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Fluconazole|N|fluconazole|ethinyl estradiol|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Fluconazole|N|levonorgestrel|ethinyl estradiol|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Fluconazole|N|ethinyl estradiol|ethinyl estradiol|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Fluconazole|N|fluconazole|ethinyl estradiol|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Fluconazole|N|levonorgestrel|fluconazole|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Fluconazole|N|ethinyl estradiol|fluconazole|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Fluconazole|N|fluconazole|fluconazole|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Fluconazole|N|ethinyl estradiol|levonorgestrel|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Mazindol|N|parnate|phenelzine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|parnate|phenelzine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|marplan|parnate|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|tranylcypromine|parnate|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|parnate|nardil|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|parnate|nardil|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|maoi|parnate|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|isocarboxazid|parnate|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|monoamine oxidase inhibitor|parnate|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|marplan|phenelzine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|tranylcypromine|phenelzine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|tranylcypromine|phenelzine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|phenelzine|nardil|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|maoi|phenelzine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|isocarboxazid|phenelzine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|monoamine oxidase inhibitor|phenelzine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|marplan|tranylcypromine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|marplan|nardil|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|maoi|marplan|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|isocarboxazid|marplan|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|monoamine oxidase inhibitor|marplan|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|tranylcypromine|nardil|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|tranylcypromine|nardil|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|maoi|tranylcypromine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|isocarboxazid|tranylcypromine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|monoamine oxidase inhibitor|tranylcypromine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|maoi|nardil|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|isocarboxazid|nardil|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|monoamine oxidase inhibitor|nardil|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|maoi|isocarboxazid|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|monoamine oxidase inhibitor|maoi|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|monoamine oxidase inhibitor|isocarboxazid|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|N|guanethidine|ismelin|Mazindol may reduce the effects of guanethidine -LRB- Ismelin-RRB-. 
Mazindol|N|nortriptyline|pamelor|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|sinequan|pamelor|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|doxepin|pamelor|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|asendin|pamelor|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amoxapine|pamelor|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|pamelor|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|pamelor|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|pamelor|anafranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|pamelor|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|pamelor|tofranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|pamelor|clomipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|pamelor|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|pamelor|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|pamelor|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|pamelor|imipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|pamelor|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|sinequan|nortriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|doxepin|nortriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|asendin|nortriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amoxapine|nortriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|nortriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|nortriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|nortriptyline|anafranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|nortriptyline|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|nortriptyline|tofranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|nortriptyline|clomipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|nortriptyline|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|nortriptyline|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|nortriptyline|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|nortriptyline|imipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|nortriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|doxepin|sinequan|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|asendin|sinequan|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amoxapine|sinequan|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|sinequan|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|sinequan|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|sinequan|anafranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|sinequan|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|sinequan|tofranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|sinequan|clomipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|sinequan|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|sinequan|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|sinequan|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|sinequan|imipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|sinequan|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|asendin|doxepin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amoxapine|doxepin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|doxepin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|doxepin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|doxepin|anafranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|doxepin|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|doxepin|tofranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|doxepin|clomipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|doxepin|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|doxepin|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|doxepin|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|doxepin|imipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|doxepin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amoxapine|asendin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|asendin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|asendin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|asendin|anafranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|asendin|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|asendin|tofranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|asendin|clomipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|asendin|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|asendin|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|asendin|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|asendin|imipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|asendin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|amoxapine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|amoxapine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amoxapine|anafranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amoxapine|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amoxapine|tofranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amoxapine|clomipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amoxapine|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amoxapine|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amoxapine|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amoxapine|imipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|amoxapine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|elavil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|anafranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|tofranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|clomipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|elavil|imipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|elavil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|anafranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|tofranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|clomipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|amitriptyline|imipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|amitriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|anafranil|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|anafranil|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tofranil|anafranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|clomipramine|anafranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|anafranil|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|anafranil|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|anafranil|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|anafranil|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|anafranil|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|imipramine|anafranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|anafranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tofranil|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|clomipramine|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|clomipramine|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|protriptyline|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|protriptyline|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|protriptyline|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|protriptyline|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|imipramine|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|protriptyline|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tofranil|clomipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tofranil|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tofranil|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tofranil|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|imipramine|tofranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|tofranil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|clomipramine|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|clomipramine|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|clomipramine|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|clomipramine|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|clomipramine|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|imipramine|clomipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|clomipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|vivactil|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|desipramine|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|imipramine|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|norpramin|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|vivactil|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|vivactil|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|imipramine|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|vivactil|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|imipramine|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|desipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mazindol|N|tricyclic antidepressant|imipramine|Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline -LRB- Elavil -RRB- , amoxapine -LRB- Asendin -RRB- , doxepin -LRB- Sinequan -RRB- , nortriptyline -LRB- Pamelor -RRB- , imipramine -LRB- Tofranil -RRB- , clomipramine -LRB- Anafranil -RRB- , protriptyline -LRB- Vivactil -RRB- , or desipramine -LRB- Norpramin-RRB-. 
Mebendazole|N|mebendazole|mebendazole|Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole . 
Mebendazole|N|cimetidine|mebendazole|Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole . 
Mecamylamine|N|antibiotic|sulfonamide|Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers . 
Mecamylamine|N|antihypertensive drug|alcohol|The action of Mecamylamine may be potentiated by anesthesia , other antihypertensive drugs and alcohol . 
Medroxyprogesterone|N|depo-subq provera 104|mpa|Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA . 
Medroxyprogesterone|N|aminoglutethimide|mpa|Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA . 
Megestrol|N|zidovudine|rifabutin|Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs . 
Megestrol|N|zidovudine|megestrol acetate|Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs . 
Megestrol|N|rifabutin|megestrol acetate|Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs . 
Megestrol|N|megestrol acetate|indinavir|A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters -LRB- ~36 % for Cmax and ~28 % for AUC -RRB- of indinavir . 
Megestrol|N|indinavir|indinavir|A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters -LRB- ~36 % for Cmax and ~28 % for AUC -RRB- of indinavir . 
Megestrol|N|rifabutin|megestrol acetate|The effects of indinavir , zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied . 
Megestrol|N|zidovudine|megestrol acetate|The effects of indinavir , zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied . 
Megestrol|N|indinavir|megestrol acetate|The effects of indinavir , zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied . 
Megestrol|N|zidovudine|rifabutin|The effects of indinavir , zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied . 
Megestrol|N|zidovudine|rifabutin|The effects of indinavir , zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied . 
Megestrol|N|indinavir|rifabutin|The effects of indinavir , zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied . 
Megestrol|N|indinavir|zidovudine|The effects of indinavir , zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied . 
Melatonin|N|aspirin|nsaid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|benzodiazepene|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|fluoxetine|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|beta blocker|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|fluvoxamine|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|aspirin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|benzodiazepene|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|fluoxetine|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|beta blocker|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|fluvoxamine|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|nsaid|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|progestin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|progestin|benzodiazepene|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|progestin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|progestin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|progestin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|progestin|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluoxetine|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|beta blocker|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluvoxamine|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|benzodiazepene|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|progestin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluoxetine|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|beta blocker|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluvoxamine|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|benzodiazepene|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|corticosteroid|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|corticosteroid|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|corticosteroid|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|corticosteroid|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|corticosteroid|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|corticosteroid|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|progestin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluoxetine|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|beta blocker|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluvoxamine|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|benzodiazepene|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|benzodiazepene|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|benzodiazepene|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|progestin|benzodiazepene|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluoxetine|benzodiazepene|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|benzodiazepene|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|beta blocker|benzodiazepene|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|benzodiazepene|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluvoxamine|benzodiazepene|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|benzodiazepene|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|corticosteroid|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|progestin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluoxetine|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|beta blocker|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluvoxamine|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|progestin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluoxetine|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|beta blocker|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluvoxamine|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|progestin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluoxetine|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|beta blocker|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluvoxamine|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluoxetine|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|beta blocker|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluvoxamine|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|fluoxetine|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|beta blocker|fluoxetine|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|fluoxetine|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluvoxamine|fluoxetine|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|fluoxetine|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|beta blocker|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluvoxamine|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|beta blocker|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluvoxamine|beta blocker|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|beta blocker|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|fluvoxamine|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|melatonin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|N|melatonin|fluvoxamine|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Meloxicam|N|ace inhibitor|angiotensin-converting enzyme (ace) inhibitor|ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme -LRB- ACE -RRB- inhibitors . 
Meloxicam|N|ace inhibitor|nsaid|ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme -LRB- ACE -RRB- inhibitors . 
Meloxicam|N|aspirin|meloxicam|Aspirin : Concomitant administration of aspirin -LRB- 1000 mg TID -RRB- to healthy volunteers tended to increase the AUC -LRB- 10 % -RRB- and Cmax -LRB- 24 % -RRB- of meloxicam . 
Meloxicam|N|aspirin|aspirin|Aspirin : Concomitant administration of aspirin -LRB- 1000 mg TID -RRB- to healthy volunteers tended to increase the AUC -LRB- 10 % -RRB- and Cmax -LRB- 24 % -RRB- of meloxicam . 
Meloxicam|N|nsaid|meloxicam|however , as with other NSAIDs , concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects . 
Meloxicam|N|mobic|mobic|Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications , compared to use of MOBIC alone . 
Meloxicam|N|aspirin|mobic|Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications , compared to use of MOBIC alone . 
Meloxicam|N|mobic|aspirin|MOBIC is not a substitute for aspirin for cardiovascular prophylaxis . 
Meloxicam|N|cholestyramine|meloxicam|Cholestyramine : Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50 %. 
Meloxicam|N|cholestyramine|cholestyramine|Cholestyramine : Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50 %. 
Meloxicam|N|cimetidine|cimetidine|Cimetidine : Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam . 
Meloxicam|N|cimetidine|meloxicam|Cimetidine : Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam . 
Meloxicam|N|cimetidine|meloxicam|Cimetidine : Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam . 
Meloxicam|N|meloxicam|digoxin|Digoxin : Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses . 
Meloxicam|N|digoxin|digoxin|Digoxin : Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses . 
Meloxicam|N|digoxin|meloxicam|Digoxin : Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses . 
Meloxicam|N|digoxin|meloxicam|In vitro testing found no protein binding drug interaction between digoxin and meloxicam . 
Meloxicam|N|furosemide|nsaid|Furosemide : Clinical studies , as well as post-marketing observations , have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients . 
Meloxicam|N|furosemide|thiazide diuretic|Furosemide : Clinical studies , as well as post-marketing observations , have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients . 
Meloxicam|N|furosemide|furosemide|Furosemide : Clinical studies , as well as post-marketing observations , have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients . 
Meloxicam|N|furosemide|thiazide diuretic|Furosemide : Clinical studies , as well as post-marketing observations , have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients . 
Meloxicam|N|furosemide|meloxicam|Studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect . 
Meloxicam|N|furosemide|meloxicam|Furosemide : single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam . 
Meloxicam|N|lithium|lithium|Lithium : In clinical trials , NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance . 
Meloxicam|N|nsaid|lithium|Lithium : In clinical trials , NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance . 
Meloxicam|N|lithium|lithium|Lithium : In clinical trials , NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance . 
Meloxicam|N|lithium|lithium|Lithium : In clinical trials , NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance . 
Meloxicam|N|lithium|nsaid|Lithium : In clinical trials , NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance . 
Meloxicam|N|lithium|lithium|In a study conducted in healthy subjects , mean pre-dose lithium concentration and AUC were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone . 
Meloxicam|N|meloxicam|lithium|In a study conducted in healthy subjects , mean pre-dose lithium concentration and AUC were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone . 
Meloxicam|N|lithium|lithium|In a study conducted in healthy subjects , mean pre-dose lithium concentration and AUC were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone . 
Meloxicam|N|lithium|meloxicam|In a study conducted in healthy subjects , mean pre-dose lithium concentration and AUC were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone . 
Meloxicam|N|lithium|lithium|In a study conducted in healthy subjects , mean pre-dose lithium concentration and AUC were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone . 
Meloxicam|N|methotrexate|meloxicam|Methotrexate : A study in 13 rheumatoid arthritis -LRB- RA -RRB- patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly . 
Meloxicam|N|methotrexate|methotrexate|Methotrexate : A study in 13 rheumatoid arthritis -LRB- RA -RRB- patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly . 
Meloxicam|N|meloxicam|methotrexate|Methotrexate : A study in 13 rheumatoid arthritis -LRB- RA -RRB- patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly . 
Meloxicam|N|meloxicam|methotrexate|Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate . 
Meloxicam|N|methotrexate|meloxicam|In vitro , methotrexate did not displace meloxicam from its human serum binding sites . 
Meloxicam|N|warfarin|mobic|Warfarin : Anticoagulant activity should be monitored , particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents , since these patients are at an increased risk of bleeding . 
Meloxicam|N|warfarin|warfarin|Warfarin : Anticoagulant activity should be monitored , particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents , since these patients are at an increased risk of bleeding . 
Meloxicam|N|meloxicam|warfarin|The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR -LRB- International Normalized Ratio -RRB- between 1.2 and 1.8 . 
Meloxicam|N|warfarin|warfarin|The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR -LRB- International Normalized Ratio -RRB- between 1.2 and 1.8 . 
Meloxicam|N|meloxicam|warfarin|The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR -LRB- International Normalized Ratio -RRB- between 1.2 and 1.8 . 
Meloxicam|N|meloxicam|warfarin|In these subjects , meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time . 
Meloxicam|N|meloxicam|warfarin|In these subjects , meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time . 
Meloxicam|N|warfarin|warfarin|In these subjects , meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time . 
Meloxicam|N|mobic|warfarin|Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced . 
Meloxicam|N|warfarin|warfarin|Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced . 
Melphalan|N|alkeran|melphalan|DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis . 
Melphalan|N|live organism vaccine|melphalan|DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis . 
Melphalan|N|alkeran|live organism vaccine|DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis . 
Melphalan|N|alkeran|nalidixic acid|DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis . 
Melphalan|N|live organism vaccine|nalidixic acid|DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis . 
Mepenzolate|N|sympathomimetic agent|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|sympathomimetic agent|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|nitrite|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|nitrate|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|nitrate|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|meperidine|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|meperidine|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|benzodiazepine|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|benzodiazepine|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|mao inhibitor|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|mao inhibitor|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|narcotic analgesic|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|narcotic analgesic|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|nitrite|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|nitrate|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|nitrate|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|meperidine|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|meperidine|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|benzodiazepine|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|benzodiazepine|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|mao inhibitor|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|mao inhibitor|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|narcotic analgesic|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|narcotic analgesic|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|nitrite|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|quinidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|antipsychotic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|antipsychotic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|antihistamine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|antihistamine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|quinidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|quinidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|phenothiazine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|phenothiazine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|benzodiazepine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|benzodiazepine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|quinidine|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|nitrite|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|nitrate|nitrite|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|nitrite|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|meperidine|nitrite|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|nitrite|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|nitrite|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|nitrite|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|benzodiazepine|nitrite|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|mao inhibitor|nitrite|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|narcotic analgesic|nitrite|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|antipsychotic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|antipsychotic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|antihistamine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|antihistamine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|antiarrhythmic agents of class i|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|antiarrhythmic agents of class i|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|phenothiazine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|phenothiazine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|benzodiazepine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|benzodiazepine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antiarrhythmic agents of class i|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|meperidine|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|meperidine|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|benzodiazepine|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|benzodiazepine|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|mao inhibitor|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|mao inhibitor|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|narcotic analgesic|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|narcotic analgesic|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|antipsychotic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|antipsychotic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|antipsychotic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|antipsychotic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|phenothiazine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|benzodiazepine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|benzodiazepine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antipsychotic agent|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|benzodiazepine|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|benzodiazepine|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|mao inhibitor|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|mao inhibitor|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|narcotic analgesic|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|antihistamine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|antihistamine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|phenothiazine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|phenothiazine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|benzodiazepine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|benzodiazepine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|antihistamine|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|phenothiazine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|phenothiazine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|benzodiazepine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|benzodiazepine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|amantadine|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|benzodiazepine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|benzodiazepine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|phenothiazine|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|benzodiazepine|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|benzodiazepine|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|benzodiazepine|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|benzodiazepine|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|mao inhibitor|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|N|mao inhibitor|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Meperidine|N|phenothiazine|tranquilizer|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|phenothiazine|tranquilizer|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|phenothiazine|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|phenothiazine|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|anesthetic|phenothiazine|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|central nervous system depressant|phenothiazine|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|phenothiazine|tricyclic antidepressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|phenothiazine|tricyclic antidepressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|phenothiazine|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|phenothiazine|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|phenothiazine|alcohol|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|phenothiazine|sedative-hypnotic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|phenothiazine|sedative-hypnotic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|phenothiazine|barbiturate|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|phenothiazine|barbiturate|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|tranquilizer|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|tranquilizer|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|anesthetic|tranquilizer|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|central nervous system depressant|tranquilizer|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|tranquilizer|tricyclic antidepressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|tranquilizer|tricyclic antidepressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|tranquilizer|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|tranquilizer|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|tranquilizer|alcohol|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|tranquilizer|sedative-hypnotic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|tranquilizer|sedative-hypnotic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|tranquilizer|barbiturate|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|tranquilizer|barbiturate|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|anesthetic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|anesthetic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|central nervous system depressant|narcotic analgesic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|central nervous system depressant|narcotic analgesic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|tricyclic antidepressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|tricyclic antidepressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|alcohol|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|alcohol|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|sedative-hypnotic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|sedative-hypnotic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|barbiturate|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|narcotic analgesic|barbiturate|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|central nervous system depressant|anesthetic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|anesthetic|tricyclic antidepressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|anesthetic|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|anesthetic|alcohol|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|anesthetic|sedative-hypnotic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|anesthetic|barbiturate|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|central nervous system depressant|meperidine|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|central nervous system depressant|tricyclic antidepressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|central nervous system depressant|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|central nervous system depressant|alcohol|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|central nervous system depressant|sedative-hypnotic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|central nervous system depressant|barbiturate|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|tricyclic antidepressant|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|tricyclic antidepressant|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|tricyclic antidepressant|alcohol|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|sedative-hypnotic|tricyclic antidepressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|sedative-hypnotic|tricyclic antidepressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|barbiturate|tricyclic antidepressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|barbiturate|tricyclic antidepressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|cns depressant|alcohol|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|sedative-hypnotic|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|sedative-hypnotic|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|barbiturate|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|barbiturate|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|sedative-hypnotic|alcohol|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|barbiturate|alcohol|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|N|sedative-hypnotic|barbiturate|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Mephenytoin|N|anticonvulsant|valproic acid|Those anticonvulsants include divalproex sodium , valproic acid , and phenobarbital . 
Mephenytoin|N|anticonvulsant|divalproex sodium|Those anticonvulsants include divalproex sodium , valproic acid , and phenobarbital . 
Mephenytoin|N|anticonvulsant|phenobarbital|Those anticonvulsants include divalproex sodium , valproic acid , and phenobarbital . 
Mephenytoin|N|divalproex sodium|valproic acid|Those anticonvulsants include divalproex sodium , valproic acid , and phenobarbital . 
Mephenytoin|N|valproic acid|phenobarbital|Those anticonvulsants include divalproex sodium , valproic acid , and phenobarbital . 
Mephenytoin|N|valproic acid|phenobarbital|Those anticonvulsants include divalproex sodium , valproic acid , and phenobarbital . 
Mephenytoin|N|divalproex sodium|phenobarbital|Those anticonvulsants include divalproex sodium , valproic acid , and phenobarbital . 
Mephenytoin|N|furosemide|theophylline|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|anti-infective medicine|theophylline|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|anti-infective medicine|theophylline|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|warfarin|theophylline|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|warfarin|theophylline|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|theophylline|mephenytoin|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|steroid medication|theophylline|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|steroid medication|theophylline|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|anti-infective medicine|furosemide|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|anti-infective medicine|furosemide|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|warfarin|furosemide|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|warfarin|furosemide|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|furosemide|mephenytoin|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|steroid medication|furosemide|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|steroid medication|furosemide|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|warfarin|anti-infective medicine|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|anti-infective medicine|mephenytoin|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|anti-infective medicine|mephenytoin|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|steroid medication|anti-infective medicine|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|warfarin|mephenytoin|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|warfarin|mephenytoin|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|steroid medication|warfarin|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|mephenytoin|mephenytoin|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|steroid medication|mephenytoin|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|N|steroid medication|mephenytoin|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mequitazine|N|cns depressant|antichlolinergic|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|cns depressant|tca|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|cns depressant|maoi|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|cns depressant|alcohol|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|antichlolinergic|tca|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|antichlolinergic|tca|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|antichlolinergic|maoi|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|antichlolinergic|maoi|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|antichlolinergic|alcohol|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|antichlolinergic|alcohol|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|tca|maoi|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|tca|maoi|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|tca|alcohol|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|tca|alcohol|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|maoi|alcohol|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|N|maoi|alcohol|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Meropenem|N|probenecid|meropenem|Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem . 
Meropenem|N|meropenem|meropenem|Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem . 
Meropenem|N|valproic acid|valproate|There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels -LRB- therapeutic range considered to be 50 to 100 g/mL total valproate -RRB-. 
Meropenem|N|meropenem|valproate|There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels -LRB- therapeutic range considered to be 50 to 100 g/mL total valproate -RRB-. 
Metaraminol|N|aramine|digitali|ARAMINE should be used with caution in digitalized patients , since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias . 
Metaraminol|N|aramine|sympathomimetic amine|ARAMINE should be used with caution in digitalized patients , since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias . 
Metaraminol|N|monoamine oxidase inhibitor|tricyclic antidepressant|Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines . 
Metaxalone|N|alcohol|barbiturate|SKELAXIN may enhance the effects of alcohol , barbiturates and other CNS depressants . 
Metaxalone|N|barbiturate|cns depressant|SKELAXIN may enhance the effects of alcohol , barbiturates and other CNS depressants . 
Metaxalone|N|alcohol|cns depressant|SKELAXIN may enhance the effects of alcohol , barbiturates and other CNS depressants . 
Methazolamide|N|methazolamide|carbonic anhydrase inhibitor|Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors . 
Methazolamide|N|methazolamide|aspirin|Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors . 
Methazolamide|N|aspirin|carbonic anhydrase inhibitor|Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors . 
Methazolamide|N|aspirin|aspirin|Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors . 
Methimazole|N|anticoagulant|methimazole|Anticoagulants -LRB- oral -RRB- : The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole . 
Methimazole|N|anticoagulant|anticoagulant|Anticoagulants -LRB- oral -RRB- : The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole . 
Methimazole|N|digitalis glycoside|digitalis glycoside|Digitalis glycosides : Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid ; 
Methimazole|N|theophylline|theophylline|Theophylline : Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid ; 
Methimazole|N|theophylline|theophylline|Theophylline : Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid ; 
Methimazole|N|theophylline|theophylline|Theophylline : Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid ; 
Methotrimeprazine|N|opioid|opioid|Dosages of concomitantly administered opioids should be reduced by approximately half , because levomepromazine amplifies the therapeutic actions and side-effects of opioids . 
Methotrimeprazine|N|tramadol|ultram|Combination with tramadol -LRB- Ultram -RRB- is associated with increased risk of seizures . 
Methotrimeprazine|N|benzodiazepine|barbiturate|Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates . 
Methotrimeprazine|N|tricyclic antidepressant|antiparkinsonian-agent|Exert particular caution in combining levomepromazine with other anticholinergic drugs -LRB- tricyclic antidepressants and antiparkinsonian-agents -RRB- : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 
Methotrimeprazine|N|anticholinergic drug|tricyclic antidepressant|Exert particular caution in combining levomepromazine with other anticholinergic drugs -LRB- tricyclic antidepressants and antiparkinsonian-agents -RRB- : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 
Methotrimeprazine|N|anticholinergic drug|antiparkinsonian-agent|Exert particular caution in combining levomepromazine with other anticholinergic drugs -LRB- tricyclic antidepressants and antiparkinsonian-agents -RRB- : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 
Methotrimeprazine|N|ephedrine|amphetamine|Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine . 
Methotrimeprazine|N|caffeine|amphetamine|Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine . 
Methotrimeprazine|N|caffeine|amphetamine|Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine . 
Methsuximide|N|phenytoin|phenobarbital|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methsuximide|N|celontin|phenobarbital|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methsuximide|N|methsuximide|phenobarbital|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methsuximide|N|antiepileptic drug|phenobarbital|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methsuximide|N|celontin|phenytoin|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methsuximide|N|methsuximide|phenytoin|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methsuximide|N|antiepileptic drug|phenytoin|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methsuximide|N|celontin|methsuximide|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methsuximide|N|celontin|methsuximide|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methsuximide|N|methsuximide|methsuximide|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methsuximide|N|antiepileptic drug|methsuximide|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methyclothiazide|N|steroid|acth|Hypokalemia may develop during concomitant use of steroids or ACTH . 
Methyclothiazide|N|lithium|lithium|Lithium renal clearance is reduced by thiazides , increasing the risk of lithium toxicity . 
Methyclothiazide|N|thiazide|lithium|Lithium renal clearance is reduced by thiazides , increasing the risk of lithium toxicity . 
Methyclothiazide|N|ganglionic adrenergic blocking drug|peripheral adrenergic blocking drug|Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs . 
Methyldopa|N|lithium|lithium|When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity . 
Methyldopa|N|methyldopa|lithium|When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity . 
Methyldopa|N|ferrous sulfate|ferrous gluconate|Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate . 
Methyldopa|N|ferrous sulfate|ferrous gluconate|Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended . 
Methyldopa|N|methyldopa|vma|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|vma|vma|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|vma|vma|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|vma|vanillylmandelic acid|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|vma|vanillin|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|vma|vanillin|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|methyldopa|vma|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|methyldopa|vma|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|methyldopa|vanillylmandelic acid|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|methyldopa|vanillin|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|methyldopa|vanillin|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|vanillylmandelic acid|vma|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|vanillylmandelic acid|vma|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|vma|vanillin|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|vanillylmandelic acid|vanillin|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methyldopa|N|vanillylmandelic acid|vanillin|Methyldopa does not interfere with measurement of VMA -LRB- vanillylmandelic acid -RRB- , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
Methylergonovine|N|ergot alkaloid drug|dihydroergotamine|CYP 3A4 Inhibitors -LRB- e.g. Macrolide Antibiotics and Protease Inhibitors -RRB- There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs -LRB- e.g. dihydroergotamine and ergotamine -RRB- and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 
Methylergonovine|N|macrolide antibiotic|ergot alkaloid drug|CYP 3A4 Inhibitors -LRB- e.g. Macrolide Antibiotics and Protease Inhibitors -RRB- There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs -LRB- e.g. dihydroergotamine and ergotamine -RRB- and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 
Methylergonovine|N|protease inhibitor|ergot alkaloid drug|CYP 3A4 Inhibitors -LRB- e.g. Macrolide Antibiotics and Protease Inhibitors -RRB- There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs -LRB- e.g. dihydroergotamine and ergotamine -RRB- and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 
Methylergonovine|N|ergot alkaloid drug|ergotamine|CYP 3A4 Inhibitors -LRB- e.g. Macrolide Antibiotics and Protease Inhibitors -RRB- There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs -LRB- e.g. dihydroergotamine and ergotamine -RRB- and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 
Methylergonovine|N|macrolide antibiotic|dihydroergotamine|CYP 3A4 Inhibitors -LRB- e.g. Macrolide Antibiotics and Protease Inhibitors -RRB- There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs -LRB- e.g. dihydroergotamine and ergotamine -RRB- and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 
Methylergonovine|N|protease inhibitor|dihydroergotamine|CYP 3A4 Inhibitors -LRB- e.g. Macrolide Antibiotics and Protease Inhibitors -RRB- There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs -LRB- e.g. dihydroergotamine and ergotamine -RRB- and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 
Methylergonovine|N|dihydroergotamine|ergotamine|CYP 3A4 Inhibitors -LRB- e.g. Macrolide Antibiotics and Protease Inhibitors -RRB- There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs -LRB- e.g. dihydroergotamine and ergotamine -RRB- and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 
Methylergonovine|N|macrolide antibiotic|protease inhibitor|CYP 3A4 Inhibitors -LRB- e.g. Macrolide Antibiotics and Protease Inhibitors -RRB- There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs -LRB- e.g. dihydroergotamine and ergotamine -RRB- and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 
Methylergonovine|N|macrolide antibiotic|ergotamine|CYP 3A4 Inhibitors -LRB- e.g. Macrolide Antibiotics and Protease Inhibitors -RRB- There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs -LRB- e.g. dihydroergotamine and ergotamine -RRB- and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 
Methylergonovine|N|protease inhibitor|ergotamine|CYP 3A4 Inhibitors -LRB- e.g. Macrolide Antibiotics and Protease Inhibitors -RRB- There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs -LRB- e.g. dihydroergotamine and ergotamine -RRB- and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities . 
Methylergonovine|N|ketoconazole|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|azole antifungal|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|erythromycin|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|macrolide antibiotic|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|itraconazole|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|reverse transcriptase inhibitor|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|hiv protease inhibitor|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|hiv protease inhibitor|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|clarithromycin|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|troleandomycin|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|nelfinavir|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|nelfinavir|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|delavirdine|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|delavirdine|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|ritonavir|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|ritonavir|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|indinavir|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|indinavir|itraconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|azole antifungal|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|erythromycin|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|macrolide antibiotic|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|ketoconazole|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|reverse transcriptase inhibitor|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|hiv protease inhibitor|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|hiv protease inhibitor|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|clarithromycin|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|troleandomycin|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|nelfinavir|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|nelfinavir|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|delavirdine|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|delavirdine|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|ritonavir|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|ritonavir|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|indinavir|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|indinavir|ketoconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|erythromycin|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|macrolide antibiotic|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|azole antifungal|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|reverse transcriptase inhibitor|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|hiv protease inhibitor|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|hiv protease inhibitor|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|clarithromycin|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|troleandomycin|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|nelfinavir|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|nelfinavir|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|delavirdine|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|delavirdine|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|ritonavir|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|ritonavir|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|indinavir|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|indinavir|azole antifungal|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|macrolide antibiotic|erythromycin|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|erythromycin|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|erythromycin|reverse transcriptase inhibitor|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|erythromycin|hiv protease inhibitor|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|erythromycin|clarithromycin|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|erythromycin|troleandomycin|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|erythromycin|nelfinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|erythromycin|delavirdine|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|erythromycin|ritonavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|erythromycin|indinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|macrolide antibiotic|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|macrolide antibiotic|reverse transcriptase inhibitor|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|macrolide antibiotic|hiv protease inhibitor|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|macrolide antibiotic|clarithromycin|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|macrolide antibiotic|troleandomycin|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|macrolide antibiotic|nelfinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|macrolide antibiotic|delavirdine|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|macrolide antibiotic|ritonavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|macrolide antibiotic|indinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|reverse transcriptase inhibitor|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|hiv protease inhibitor|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|hiv protease inhibitor|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|clarithromycin|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|troleandomycin|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|nelfinavir|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|nelfinavir|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|delavirdine|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|delavirdine|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|ritonavir|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|ritonavir|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|indinavir|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|indinavir|voriconazole|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|hiv protease inhibitor|reverse transcriptase inhibitor|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|clarithromycin|reverse transcriptase inhibitor|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|troleandomycin|reverse transcriptase inhibitor|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|reverse transcriptase inhibitor|nelfinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|reverse transcriptase inhibitor|delavirdine|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|reverse transcriptase inhibitor|ritonavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|reverse transcriptase inhibitor|indinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|clarithromycin|hiv protease inhibitor|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|troleandomycin|hiv protease inhibitor|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|hiv protease inhibitor|nelfinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|hiv protease inhibitor|delavirdine|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|hiv protease inhibitor|ritonavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|hiv protease inhibitor|indinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|troleandomycin|clarithromycin|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|clarithromycin|nelfinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|clarithromycin|delavirdine|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|clarithromycin|ritonavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|clarithromycin|indinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|troleandomycin|nelfinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|troleandomycin|delavirdine|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|troleandomycin|ritonavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|troleandomycin|indinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|nelfinavir|delavirdine|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|ritonavir|nelfinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|indinavir|nelfinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|ritonavir|delavirdine|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|indinavir|delavirdine|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|ritonavir|indinavir|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics -LRB- e.g. , erythromycin , troleandomycin , clarithromycin -RRB- , HIV protease or reverse transcriptase inhibitors -LRB- e.g. , ritonavir , indinavir , nelfinavir , delavirdine -RRB- or azole antifungals -LRB- e.g. , ketoconazole , itraconazole , voriconazole -RRB-. 
Methylergonovine|N|saquinavir|nefazodone|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|saquinavir|fluconazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|saquinavir|fluoxetine|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|saquinavir|fluvoxamine|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|saquinavir|zileuton|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|saquinavir|clotrimazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|nefazodone|fluconazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|nefazodone|fluconazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|nefazodone|fluoxetine|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|nefazodone|fluoxetine|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|nefazodone|fluvoxamine|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|nefazodone|fluvoxamine|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|nefazodone|zileuton|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|nefazodone|zileuton|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|nefazodone|clotrimazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|nefazodone|clotrimazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluconazole|fluoxetine|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluconazole|fluoxetine|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluconazole|fluvoxamine|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluconazole|fluvoxamine|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluconazole|zileuton|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluconazole|zileuton|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluconazole|clotrimazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluconazole|clotrimazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluoxetine|fluvoxamine|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluoxetine|fluvoxamine|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluoxetine|zileuton|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluoxetine|zileuton|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluoxetine|clotrimazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluoxetine|clotrimazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluvoxamine|zileuton|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluvoxamine|zileuton|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluvoxamine|clotrimazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|fluvoxamine|clotrimazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|zileuton|clotrimazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|zileuton|clotrimazole|Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
Methylergonovine|N|vasoconstrictor|ergot alkaloid|Caution should be exercised when Methergine -LRB- methylergonovine maleate -RRB- is used concurrently with other vasoconstrictors or ergot alkaloids . 
Methylergonovine|N|methylergonovine maleate|ergot alkaloid|Caution should be exercised when Methergine -LRB- methylergonovine maleate -RRB- is used concurrently with other vasoconstrictors or ergot alkaloids . 
Methylergonovine|N|methergine|methylergonovine maleate|Caution should be exercised when Methergine -LRB- methylergonovine maleate -RRB- is used concurrently with other vasoconstrictors or ergot alkaloids . 
Methylphenidate|N|tricyclic drug|clomipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|imipramine|clomipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|coumarin anticoagulant|clomipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|clomipramine|desipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|anticonvulsant|clomipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|primidone|clomipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenylbutazone|clomipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenobarbital|clomipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|diphenylhydantoin|clomipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|tricyclic drug|imipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|coumarin anticoagulant|tricyclic drug|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|tricyclic drug|desipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|anticonvulsant|tricyclic drug|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|anticonvulsant|tricyclic drug|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|primidone|tricyclic drug|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|primidone|tricyclic drug|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenylbutazone|tricyclic drug|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenylbutazone|tricyclic drug|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenobarbital|tricyclic drug|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenobarbital|tricyclic drug|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|diphenylhydantoin|tricyclic drug|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|diphenylhydantoin|tricyclic drug|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|coumarin anticoagulant|imipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|imipramine|desipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|anticonvulsant|imipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|primidone|imipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenylbutazone|imipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenobarbital|imipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|diphenylhydantoin|imipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|coumarin anticoagulant|desipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|coumarin anticoagulant|anticonvulsant|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|coumarin anticoagulant|primidone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|coumarin anticoagulant|phenylbutazone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|coumarin anticoagulant|phenobarbital|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|coumarin anticoagulant|diphenylhydantoin|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|anticonvulsant|desipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|primidone|desipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenylbutazone|desipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenobarbital|desipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|diphenylhydantoin|desipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|anticonvulsant|primidone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|anticonvulsant|phenylbutazone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|anticonvulsant|phenylbutazone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|anticonvulsant|phenobarbital|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|anticonvulsant|diphenylhydantoin|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|primidone|phenylbutazone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|primidone|phenylbutazone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenobarbital|primidone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|diphenylhydantoin|primidone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenobarbital|phenylbutazone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenobarbital|phenylbutazone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|diphenylhydantoin|phenylbutazone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|diphenylhydantoin|phenylbutazone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|phenobarbital|diphenylhydantoin|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|N|methylphenidate|clonidine|The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated . 
Methylphenidate|N|methylphenidate|alpha-2 agonist|The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated . 
Methylphenidate|N|clonidine|alpha-2 agonist|The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated . 
Methylprednisolone|N|phenobarbital|rifampin|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|N|phenytoin|rifampin|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|N|phenytoin|rifampin|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|N|methylprednisolone|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|N|phenobarbital|phenytoin|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|N|troleandomycin|ketoconazole|Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance . 
Methylprednisolone|N|salicylate|methylprednisolone|This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn . 
Methylprednisolone|N|salicylate|salicylate|This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn . 
Methylprednisolone|N|methylprednisolone|anticoagulant|The effect of methylprednisolone on oral anticoagulants is variable . 
Methylscopolamine|N|mao inhibitor|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|absorbent-type anti-diarrhea medicine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|kaolin|pectin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|furazolidone|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|amantadine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antihistamine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|quinidine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|kaolin|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|potassium chloride|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|kaolin|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antacid|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|kaolin|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|diphenhydramine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|anticholinergic|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|mao inhibitor|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|linezolid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|phenelzine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|isocarboxazid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|tranylcypromine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|furazolidone|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|selegiline|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|amantadine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|antihistamine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|quinidine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|diphenhydramine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|mao inhibitor|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|mao inhibitor|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|linezolid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|phenelzine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|isocarboxazid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|tranylcypromine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|furazolidone|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|selegiline|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|amantadine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|antihistamine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|quinidine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|diphenhydramine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tricyclic|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|tricyclic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|absorbent-type anti-diarrhea medicine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|furazolidone|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|amantadine|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antihistamine|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|quinidine|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|absorbent-type anti-diarrhea medicine|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|potassium chloride|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|absorbent-type anti-diarrhea medicine|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antacid|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|absorbent-type anti-diarrhea medicine|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|diphenhydramine|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|anticholinergic|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|linezolid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|isocarboxazid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|tranylcypromine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|furazolidone|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|selegiline|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|amantadine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|antihistamine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|quinidine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|diphenhydramine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|linezolid|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|linezolid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|furazolidone|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|amantadine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antihistamine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|quinidine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|kaolin|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|potassium chloride|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|kaolin|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antacid|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|kaolin|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|diphenhydramine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|anticholinergic|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|isocarboxazid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|tranylcypromine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|furazolidone|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|selegiline|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|amantadine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|antihistamine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|quinidine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|diphenhydramine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenelzine|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|phenelzine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|isocarboxazid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|furazolidone|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|selegiline|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|amantadine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|antihistamine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|quinidine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|diphenhydramine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|isocarboxazid|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|isocarboxazid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|furazolidone|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|selegiline|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|amantadine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|antihistamine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|quinidine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|diphenhydramine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|tranylcypromine|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|tranylcypromine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|furazolidone|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|furazolidone|amantadine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|furazolidone|antihistamine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|furazolidone|quinidine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|furazolidone|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|furazolidone|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|furazolidone|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|furazolidone|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|furazolidone|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|furazolidone|diphenhydramine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|furazolidone|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|furazolidone|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|amantadine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|antihistamine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|quinidine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|diphenhydramine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|selegiline|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|selegiline|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|amantadine|antihistamine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|quinidine|amantadine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|amantadine|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|amantadine|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|amantadine|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|amantadine|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|amantadine|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|amantadine|diphenhydramine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|amantadine|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|amantadine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|quinidine|antihistamine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antihistamine|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antihistamine|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antihistamine|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antihistamine|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antihistamine|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antihistamine|diphenhydramine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antihistamine|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|antihistamine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|quinidine|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|quinidine|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|quinidine|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|quinidine|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|quinidine|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|quinidine|diphenhydramine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|quinidine|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|quinidine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|potassium chloride|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenothiazine|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antacid|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|phenothiazine|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|diphenhydramine|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|anticholinergic|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|potassium chloride|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|potassium chloride|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|potassium chloride|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|diphenhydramine|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|anticholinergic|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antacid|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|chlorpromazine|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|diphenhydramine|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|anticholinergic|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antacid|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|diphenhydramine|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|anticholinergic|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|diphenhydramine|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|anticholinergic|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|diphenhydramine|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|diphenhydramine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|antidepressant|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|N|methscopolamine|antidepressant|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methyprylon|N|alcohol|cns depression-producing drug|Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications . 
Methysergide|N|sumatriptan|nicotine|Concurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine -LRB- e.g. smoking -RRB- may result in enhanced vasoconstriction . 
Methysergide|N|sumatriptan|nicotine|Concurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine -LRB- e.g. smoking -RRB- may result in enhanced vasoconstriction . 
Methysergide|N|ergot alkaloid|nicotine|Concurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine -LRB- e.g. smoking -RRB- may result in enhanced vasoconstriction . 
Methysergide|N|vasoconstrictor agent|nicotine|Concurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine -LRB- e.g. smoking -RRB- may result in enhanced vasoconstriction . 
Methysergide|N|ergot alkaloid|sumatriptan|Concurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine -LRB- e.g. smoking -RRB- may result in enhanced vasoconstriction . 
Methysergide|N|vasoconstrictor agent|sumatriptan|Concurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine -LRB- e.g. smoking -RRB- may result in enhanced vasoconstriction . 
Methysergide|N|vasoconstrictor agent|ergot alkaloid|Concurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine -LRB- e.g. smoking -RRB- may result in enhanced vasoconstriction . 
Metoclopramide|N|anticholinergic drug|narcotic analgesic|The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics . 
Metoclopramide|N|narcotic|tranquilizer|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|narcotic|tranquilizer|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|sedative|narcotic|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|sedative|narcotic|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|hypnotic|narcotic|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|hypnotic|narcotic|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|alcohol|narcotic|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|sedative|tranquilizer|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|sedative|tranquilizer|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|hypnotic|tranquilizer|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|hypnotic|tranquilizer|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|alcohol|tranquilizer|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|sedative|hypnotic|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|sedative|hypnotic|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|alcohol|sedative|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|alcohol|hypnotic|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|N|digoxin|acetaminophen|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|digoxin|tetracycline|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|digoxin|levodopa|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|digoxin|ethanol|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|digoxin|cyclosporine|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|metoclopramide|tetracycline|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|metoclopramide|levodopa|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|metoclopramide|ethanol|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|metoclopramide|cyclosporine|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|acetaminophen|tetracycline|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|acetaminophen|levodopa|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|acetaminophen|ethanol|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|acetaminophen|cyclosporine|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|tetracycline|levodopa|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|tetracycline|ethanol|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|tetracycline|cyclosporine|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|levodopa|ethanol|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|levodopa|cyclosporine|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|N|ethanol|cyclosporine|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metolazone|N|diuretic|metolazone|Diuretics : Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes . 
Metolazone|N|diuretic|loop diuretic|Diuretics : Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes . 
Metolazone|N|diuretic|furosemide|Diuretics : Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes . 
Metolazone|N|furosemide|loop diuretic|Diuretics : Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes . 
Metolazone|N|antihypertensive|antihypertensive drug|Other Antihypertensives : When MYKROX Tablets are used with other antihypertensive drugs , care must be taken , especially during initial therapy . 
Metolazone|N|antihypertensive|mykrox|Other Antihypertensives : When MYKROX Tablets are used with other antihypertensive drugs , care must be taken , especially during initial therapy . 
Metolazone|N|narcotic|metolazone|Alcohol , Barbiturates , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 
Metolazone|N|narcotic|metolazone|Alcohol , Barbiturates , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 
Metolazone|N|alcohol|narcotic|Alcohol , Barbiturates , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 
Metolazone|N|barbiturate|narcotic|Alcohol , Barbiturates , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 
Metolazone|N|alcohol|metolazone|Alcohol , Barbiturates , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 
Metolazone|N|alcohol|metolazone|Alcohol , Barbiturates , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 
Metolazone|N|barbiturate|metolazone|Alcohol , Barbiturates , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 
Metolazone|N|barbiturate|metolazone|Alcohol , Barbiturates , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 
Metolazone|N|alcohol|barbiturate|Alcohol , Barbiturates , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 
Metolazone|N|digitalis glycoside|diuretic|Digitalis Glycosides : Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis . 
Metolazone|N|digitalis glycoside|digitali|Digitalis Glycosides : Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis . 
Metolazone|N|corticosteroid|acth|Corticosteroids or ACTH : May increase the risk of hypokalemia and increase salt and water retention . 
Metolazone|N|lithium|lithium|Lithium : Serum lithium levels may increase . 
Metolazone|N|curariform drug|diuretic|Curariform Drugs : Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs -LRB- such as tubocurarine -RRB- the most serious effect would be respiratory depression which could proceed to apnea . 
Metolazone|N|curariform drug|curariform drug|Curariform Drugs : Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs -LRB- such as tubocurarine -RRB- the most serious effect would be respiratory depression which could proceed to apnea . 
Metolazone|N|curariform drug|tubocurarine|Curariform Drugs : Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs -LRB- such as tubocurarine -RRB- the most serious effect would be respiratory depression which could proceed to apnea . 
Metolazone|N|curariform drug|tubocurarine|Curariform Drugs : Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs -LRB- such as tubocurarine -RRB- the most serious effect would be respiratory depression which could proceed to apnea . 
Metolazone|N|salicylate|non-steroidal anti-inflammatory drug|Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs : May decrease the antihypertensive effects of MYKROX Tablets . 
Metolazone|N|sympathomimetic|norepinephrine|Sympathomimetics : Metolazone may decrease arterial responsiveness to norepinephrine , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use . 
Metolazone|N|sympathomimetic|metolazone|Sympathomimetics : Metolazone may decrease arterial responsiveness to norepinephrine , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use . 
Metolazone|N|anticoagulant|metolazone|Anticoagulants : Metolazone , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to anticoagulants ; 
Metolazone|N|anticoagulant|thiazide-like diuretic|Anticoagulants : Metolazone , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to anticoagulants ; 
Metolazone|N|anticoagulant|anticoagulant|Anticoagulants : Metolazone , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to anticoagulants ; 
Metolazone|N|metolazone|thiazide-like diuretic|Anticoagulants : Metolazone , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to anticoagulants ; 
Metolazone|N|thiazide-like diuretic|anticoagulant|Anticoagulants : Metolazone , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to anticoagulants ; 
Metronidazole|N|coumarin|warfarin|Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin , resulting in a prolongation of prothrombin time . 
Metronidazole|N|metronidazole|metronidazole|Drug interactions should be kept in mind when METROGEL -LRB- metronidazole gel -RRB- , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical metronidazole administration because of low absorption . 
Metronidazole|N|metronidazole|metronidazole|Drug interactions should be kept in mind when METROGEL -LRB- metronidazole gel -RRB- , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical metronidazole administration because of low absorption . 
Metronidazole|N|metrogel|metronidazole|Drug interactions should be kept in mind when METROGEL -LRB- metronidazole gel -RRB- , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical metronidazole administration because of low absorption . 
Metronidazole|N|metrogel|metronidazole|Drug interactions should be kept in mind when METROGEL -LRB- metronidazole gel -RRB- , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical metronidazole administration because of low absorption . 
Metronidazole|N|metrogel|metronidazole|Drug interactions should be kept in mind when METROGEL -LRB- metronidazole gel -RRB- , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical metronidazole administration because of low absorption . 
Metyrapone|N|acetaminophen|acetaminophen|Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity . 
Metyrosine|N|phenothiazine|haloperidol|Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis . 
Metyrosine|N|alcohol|cns depressant|Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects . 
Mexiletine|N|mexitil|mexiletine|Since MEXITIL is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes , inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations . 
Mexiletine|N|propafenone|mexiletine|In another formal study -LRB- n = 8 extensive and n = 7 poor metabolizers of CYP2D6 -RRB- , coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group . 
Mexiletine|N|propafenone|mexiletine|In this crossover steady state study , the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine . 
Mexiletine|N|mexiletine|propafenone|Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS , QTc , RR , and PR intervals than propafenone alone . 
Mexiletine|N|mexiletine|propafenone|Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS , QTc , RR , and PR intervals than propafenone alone . 
Mexiletine|N|propafenone|propafenone|Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS , QTc , RR , and PR intervals than propafenone alone . 
Mexiletine|N|mexiletine|mexiletine|When concomitant administration of either of these two drugs with mexiletine is initiated , the dose of mexiletine should be slowly titrated to desired effect . 
Mexiletine|N|mexitil|antihypertensive|In a large compassionate use program Mexitil has been used concurrently with commonly employed antianginal , antihypertensive , and anticoagulant drugs without observed interactions . 
Mexiletine|N|mexitil|anticoagulant drug|In a large compassionate use program Mexitil has been used concurrently with commonly employed antianginal , antihypertensive , and anticoagulant drugs without observed interactions . 
Mexiletine|N|antihypertensive|anticoagulant drug|In a large compassionate use program Mexitil has been used concurrently with commonly employed antianginal , antihypertensive , and anticoagulant drugs without observed interactions . 
Mexiletine|N|antiarrhythmic|propranolol|A variety of antiarrhythmics such as quinidine or propranolol were also added , sometimes with improved control of ventricular ectopy . 
Mexiletine|N|quinidine|propranolol|A variety of antiarrhythmics such as quinidine or propranolol were also added , sometimes with improved control of ventricular ectopy . 
Mexiletine|N|antiarrhythmic|quinidine|A variety of antiarrhythmics such as quinidine or propranolol were also added , sometimes with improved control of ventricular ectopy . 
Mexiletine|N|rifampin|phenobarbital|When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 
Mexiletine|N|phenytoin|rifampin|When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 
Mexiletine|N|rifampin|mexitil|When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 
Mexiletine|N|phenytoin|phenobarbital|When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 
Mexiletine|N|phenobarbital|mexitil|When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 
Mexiletine|N|phenytoin|mexitil|When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 
Mexiletine|N|mexitil|mexitil|When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 
Mexiletine|N|benzodiazepine|mexitil|In a formal study , benzodiazepines were shown not to affect Mexitil plasma concentrations . 
Mexiletine|N|digoxin|propranolol|ECG intervals -LRB- PR , QRS , and QT -RRB- were not affected by concurrent Mexitil and digoxin , diuretics , or propranolol . 
Mexiletine|N|digoxin|propranolol|ECG intervals -LRB- PR , QRS , and QT -RRB- were not affected by concurrent Mexitil and digoxin , diuretics , or propranolol . 
Mexiletine|N|diuretic|propranolol|ECG intervals -LRB- PR , QRS , and QT -RRB- were not affected by concurrent Mexitil and digoxin , diuretics , or propranolol . 
Mexiletine|N|diuretic|propranolol|ECG intervals -LRB- PR , QRS , and QT -RRB- were not affected by concurrent Mexitil and digoxin , diuretics , or propranolol . 
Mexiletine|N|mexitil|propranolol|ECG intervals -LRB- PR , QRS , and QT -RRB- were not affected by concurrent Mexitil and digoxin , diuretics , or propranolol . 
Mexiletine|N|digoxin|diuretic|ECG intervals -LRB- PR , QRS , and QT -RRB- were not affected by concurrent Mexitil and digoxin , diuretics , or propranolol . 
Mexiletine|N|digoxin|diuretic|ECG intervals -LRB- PR , QRS , and QT -RRB- were not affected by concurrent Mexitil and digoxin , diuretics , or propranolol . 
Mexiletine|N|mexitil|digoxin|ECG intervals -LRB- PR , QRS , and QT -RRB- were not affected by concurrent Mexitil and digoxin , diuretics , or propranolol . 
Mexiletine|N|mexitil|diuretic|ECG intervals -LRB- PR , QRS , and QT -RRB- were not affected by concurrent Mexitil and digoxin , diuretics , or propranolol . 
Mexiletine|N|cimetidine|mexitil|Concurrent administration of cimetidine and Mexitil has been reported to increase , decrease , or leave unchanged Mexitil plasma levels ; 
Mexiletine|N|cimetidine|mexitil|Concurrent administration of cimetidine and Mexitil has been reported to increase , decrease , or leave unchanged Mexitil plasma levels ; 
Mexiletine|N|mexitil|mexitil|Concurrent administration of cimetidine and Mexitil has been reported to increase , decrease , or leave unchanged Mexitil plasma levels ; 
Mexiletine|N|mexitil|mexitil|Concurrent administration of cimetidine and Mexitil has been reported to increase , decrease , or leave unchanged Mexitil plasma levels ; 
Mexiletine|N|mexitil|digoxin|Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 
Mexiletine|N|digoxin|mexitil|Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 
Mexiletine|N|digoxin|magnesium-aluminum hydroxide|Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 
Mexiletine|N|digoxin|digoxin|Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 
Mexiletine|N|mexitil|mexitil|Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 
Mexiletine|N|mexitil|magnesium-aluminum hydroxide|Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 
Mexiletine|N|mexitil|digoxin|Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 
Mexiletine|N|magnesium-aluminum hydroxide|mexitil|Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 
Mexiletine|N|mexitil|digoxin|Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 
Mexiletine|N|mexitil|theophylline|Concurrent use of Mexitil and theophylline may lead to increased plasma theophylline levels . 
Mexiletine|N|theophylline|theophylline|Concurrent use of Mexitil and theophylline may lead to increased plasma theophylline levels . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|theophylline|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|theophylline|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|theophylline|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|theophylline|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|theophylline|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|theophylline|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|theophylline|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|mexitil|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|N|theophylline|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mibefradil|N|terfenadine|cyclosporine|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|terfenadine|tricyclic antidepressant|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|terfenadine|astemizole|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|terfenadine|cisapride|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|cyclosporine|tricyclic antidepressant|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|cyclosporine|tricyclic antidepressant|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|astemizole|cyclosporine|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|astemizole|cyclosporine|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|cisapride|cyclosporine|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|cisapride|cyclosporine|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|astemizole|tricyclic antidepressant|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|astemizole|tricyclic antidepressant|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|cisapride|tricyclic antidepressant|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|cisapride|tricyclic antidepressant|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|astemizole|cisapride|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|N|astemizole|cisapride|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Micafungin|N|mycophenolate mofetil|cyclosporine|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycamine|cyclosporine|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|cyclosporine|nifedipine|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|cyclosporine|sirolimu|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|cyclosporine|prednisolone|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|cyclosporine|tacrolimu|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|cyclosporine|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|cyclosporine|ritonavir|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|cyclosporine|fluconazole|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycamine|mycophenolate mofetil|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycophenolate mofetil|nifedipine|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycophenolate mofetil|sirolimu|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycophenolate mofetil|prednisolone|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycophenolate mofetil|tacrolimu|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycophenolate mofetil|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycophenolate mofetil|ritonavir|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycophenolate mofetil|fluconazole|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycamine|nifedipine|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycamine|sirolimu|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycamine|prednisolone|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycamine|tacrolimu|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycamine|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycamine|ritonavir|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|mycamine|fluconazole|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|sirolimu|nifedipine|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|sirolimu|nifedipine|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|prednisolone|nifedipine|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|prednisolone|nifedipine|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|tacrolimu|nifedipine|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|tacrolimu|nifedipine|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|nifedipine|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|nifedipine|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|nifedipine|ritonavir|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|nifedipine|ritonavir|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|nifedipine|fluconazole|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|nifedipine|fluconazole|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|prednisolone|sirolimu|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|prednisolone|sirolimu|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|tacrolimu|sirolimu|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|tacrolimu|sirolimu|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|sirolimu|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|sirolimu|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|sirolimu|ritonavir|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|sirolimu|ritonavir|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|sirolimu|fluconazole|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|sirolimu|fluconazole|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|tacrolimu|prednisolone|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|tacrolimu|prednisolone|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|prednisolone|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|prednisolone|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|prednisolone|ritonavir|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|prednisolone|ritonavir|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|prednisolone|fluconazole|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|prednisolone|fluconazole|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|tacrolimu|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|tacrolimu|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|tacrolimu|ritonavir|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|tacrolimu|ritonavir|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|tacrolimu|fluconazole|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|tacrolimu|fluconazole|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|ritonavir|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|ritonavir|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|fluconazole|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|fluconazole|rifampin|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|fluconazole|ritonavir|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|fluconazole|ritonavir|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
Micafungin|N|tacrolimu|prednisolone|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|tacrolimu|prednisolone|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|cyclosporine|prednisolone|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|mycophenolate mofetil|prednisolone|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|prednisolone|fluconazole|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|prednisolone|fluconazole|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|mycamine|prednisolone|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|cyclosporine|tacrolimu|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|mycophenolate mofetil|tacrolimu|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|tacrolimu|fluconazole|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|tacrolimu|fluconazole|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|mycamine|tacrolimu|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|mycophenolate mofetil|cyclosporine|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|cyclosporine|fluconazole|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|mycamine|cyclosporine|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|mycophenolate mofetil|fluconazole|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|mycamine|mycophenolate mofetil|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|mycamine|fluconazole|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
Micafungin|N|mycamine|sirolimu|Sirolimus AUC was increased by 21 % with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone . 
Micafungin|N|sirolimu|sirolimu|Sirolimus AUC was increased by 21 % with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone . 
Micafungin|N|mycamine|nifedipine|Nifedipine AUC and Cmax were increased by 18 % and 42 % , respectively , in the presence of steady-state MYCAMINE compared with nifedipine alone . 
Micafungin|N|nifedipine|nifedipine|Nifedipine AUC and Cmax were increased by 18 % and 42 % , respectively , in the presence of steady-state MYCAMINE compared with nifedipine alone . 
Micafungin|N|mycamine|sirolimu|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|mycamine|nifedipine|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|mycamine|sirolimu|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|mycamine|nifedipine|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|sirolimu|sirolimu|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|nifedipine|sirolimu|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|sirolimu|nifedipine|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|sirolimu|sirolimu|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|sirolimu|nifedipine|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|sirolimu|nifedipine|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|sirolimu|nifedipine|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|sirolimu|sirolimu|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|sirolimu|nifedipine|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|nifedipine|nifedipine|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|nifedipine|sirolimu|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|nifedipine|nifedipine|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|sirolimu|nifedipine|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|nifedipine|nifedipine|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|nifedipine|sirolimu|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|N|nifedipine|sirolimu|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Midazolam|N|azole antimycotic|macrolide antibiotic|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|N|calcium channel antagonist|macrolide antibiotic|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|N|calcium channel antagonist|macrolide antibiotic|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|N|protease inhibitor|macrolide antibiotic|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|N|protease inhibitor|macrolide antibiotic|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|N|azole antimycotic|calcium channel antagonist|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|N|azole antimycotic|protease inhibitor|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|N|protease inhibitor|calcium channel antagonist|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|N|protease inhibitor|calcium channel antagonist|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|N|diltiazem|itraconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|diltiazem|itraconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|verapamil|itraconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|verapamil|itraconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|ketoconazole|itraconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|ketoconazole|itraconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|fluconazole|itraconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|fluconazole|itraconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|erythromycin|itraconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|diltiazem|verapamil|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|diltiazem|verapamil|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|diltiazem|ketoconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|diltiazem|ketoconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|diltiazem|fluconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|diltiazem|fluconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|erythromycin|diltiazem|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|verapamil|ketoconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|verapamil|ketoconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|verapamil|fluconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|verapamil|fluconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|erythromycin|verapamil|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|ketoconazole|fluconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|ketoconazole|fluconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|erythromycin|ketoconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|erythromycin|fluconazole|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|N|ritonavir|nelfinavir|Although not studied , the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam . 
Midazolam|N|rifampin|carbamazepine|Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . 
Midazolam|N|carbamazepine|phenytoin|Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . 
Midazolam|N|carbamazepine|phenytoin|Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . 
Midazolam|N|rifampin|phenytoin|Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . 
Midazolam|N|sedative|methylphenidate|The difficulty in achieving adequate sedation may have been the result of decreased absorption of the sedatives due to both the gastrointestinal effects and stimulant effects of methylphenidate . 
Midazolam|N|morphine|droperidol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|narcotic|droperidol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|fentanyl|droperidol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|meperidine|droperidol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|ketamine|droperidol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|ketamine|droperidol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|propofol|droperidol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|secobarbital|droperidol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|secobarbital|droperidol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|nitrous oxide|droperidol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|nitrous oxide|droperidol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|narcotic|morphine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|morphine|fentanyl|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|morphine|fentanyl|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|morphine|meperidine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|morphine|meperidine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|morphine|ketamine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|morphine|propofol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|morphine|secobarbital|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|morphine|nitrous oxide|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|narcotic|fentanyl|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|narcotic|meperidine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|narcotic|ketamine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|narcotic|propofol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|narcotic|secobarbital|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|narcotic|nitrous oxide|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|meperidine|fentanyl|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|meperidine|fentanyl|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|fentanyl|ketamine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|fentanyl|propofol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|fentanyl|secobarbital|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|fentanyl|nitrous oxide|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|meperidine|ketamine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|meperidine|propofol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|meperidine|secobarbital|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|meperidine|nitrous oxide|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|propofol|ketamine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|ketamine|secobarbital|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|ketamine|secobarbital|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|ketamine|nitrous oxide|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|ketamine|nitrous oxide|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|propofol|secobarbital|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|propofol|nitrous oxide|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|nitrous oxide|secobarbital|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|nitrous oxide|secobarbital|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|N|diazepam|hydroxyzine|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|diazepam|hydroxyzine|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|hydroxyzine|anesthetic|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|hydroxyzine|muscle relaxant|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|hydroxyzine|muscle relaxant|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|atropine|hydroxyzine|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|glycopyrrolate|hydroxyzine|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|glycopyrrolate|hydroxyzine|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|scopolamine|hydroxyzine|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|scopolamine|hydroxyzine|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|diazepam|anesthetic|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|diazepam|muscle relaxant|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|diazepam|muscle relaxant|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|atropine|diazepam|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|glycopyrrolate|diazepam|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|glycopyrrolate|diazepam|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|scopolamine|diazepam|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|scopolamine|diazepam|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|muscle relaxant|anesthetic|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|atropine|anesthetic|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|glycopyrrolate|anesthetic|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|scopolamine|anesthetic|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|atropine|muscle relaxant|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|glycopyrrolate|muscle relaxant|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|glycopyrrolate|muscle relaxant|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|scopolamine|muscle relaxant|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|scopolamine|muscle relaxant|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|atropine|glycopyrrolate|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|atropine|scopolamine|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|scopolamine|glycopyrrolate|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midazolam|N|scopolamine|glycopyrrolate|No significant adverse interactions with common premedications -LRB- such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants -RRB- or local anesthetics have been observed . 
Midodrine|N|phenylephrine|dihydroergotamine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|phenylephrine|phenylpropanolamine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|phenylephrine|ephedrine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|phenylephrine|pseudoephedrine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|phenylephrine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|phenylephrine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|phenylpropanolamine|dihydroergotamine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|phenylpropanolamine|dihydroergotamine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|ephedrine|dihydroergotamine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|ephedrine|dihydroergotamine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|pseudoephedrine|dihydroergotamine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|pseudoephedrine|dihydroergotamine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|dihydroergotamine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|dihydroergotamine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|ephedrine|phenylpropanolamine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|ephedrine|phenylpropanolamine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|pseudoephedrine|phenylpropanolamine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|pseudoephedrine|phenylpropanolamine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|phenylpropanolamine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|phenylpropanolamine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|pseudoephedrine|ephedrine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|pseudoephedrine|ephedrine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|ephedrine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|ephedrine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|pseudoephedrine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|pseudoephedrine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|proamatine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|N|proamatine|fludrocortisone acetate|ProAmatine has been used in patients concomitantly treated with salt-retaining steroid therapy -LRB- i.e. , fludrocortisone acetate -RRB- , with or without salt supplementation . 
Midodrine|N|triamterene|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|triamterene|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|flecainide|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|flecainide|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|procainamide|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|procainamide|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|alpha-adrenergic blocking agent|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|terazosin|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|prazosin|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|cimetidine|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|cimetidine|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|ranitidine|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|ranitidine|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|doxazosin|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|metformin|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|triamterene|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|triamterene|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|procainamide|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|procainamide|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|alpha-adrenergic blocking agent|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|terazosin|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|prazosin|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|cimetidine|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|cimetidine|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|ranitidine|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|ranitidine|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|doxazosin|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|metformin|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|procainamide|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|procainamide|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|alpha-adrenergic blocking agent|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|terazosin|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|prazosin|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|cimetidine|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|cimetidine|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|ranitidine|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|ranitidine|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|doxazosin|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|metformin|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|alpha-adrenergic blocking agent|procainamide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|procainamide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|terazosin|procainamide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|prazosin|procainamide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|cimetidine|procainamide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|cimetidine|procainamide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|ranitidine|procainamide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|ranitidine|procainamide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|doxazosin|procainamide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|procainamide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|metformin|procainamide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|alpha-adrenergic blocking agent|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|alpha-adrenergic blocking agent|terazosin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|alpha-adrenergic blocking agent|prazosin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|alpha-adrenergic blocking agent|cimetidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|alpha-adrenergic blocking agent|ranitidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|alpha-adrenergic blocking agent|doxazosin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|alpha-adrenergic blocking agent|desglymidodrine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|alpha-adrenergic blocking agent|metformin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|terazosin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|prazosin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|cimetidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|ranitidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|doxazosin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|proamatine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|desglymidodrine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|metformin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|prazosin|terazosin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|terazosin|cimetidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|terazosin|ranitidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|terazosin|doxazosin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|terazosin|doxazosin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|terazosin|desglymidodrine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|terazosin|metformin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|prazosin|cimetidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|prazosin|ranitidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|prazosin|doxazosin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|prazosin|desglymidodrine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|prazosin|metformin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|cimetidine|ranitidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|cimetidine|ranitidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|doxazosin|cimetidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|cimetidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|metformin|cimetidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|doxazosin|ranitidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|ranitidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|metformin|ranitidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|doxazosin|desglymidodrine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|doxazosin|metformin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|desglymidodrine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|N|proamatine|metformin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Mifepristone|N|mifepristone|mifepristone|Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism -LRB- increasing serum levels of mifepristone -RRB-. 
Mifepristone|N|mifepristone|ketoconazole|Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism -LRB- increasing serum levels of mifepristone -RRB-. 
Mifepristone|N|mifepristone|itraconazole|Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism -LRB- increasing serum levels of mifepristone -RRB-. 
Mifepristone|N|mifepristone|erythromycin|Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism -LRB- increasing serum levels of mifepristone -RRB-. 
Mifepristone|N|ketoconazole|itraconazole|Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism -LRB- increasing serum levels of mifepristone -RRB-. 
Mifepristone|N|ketoconazole|erythromycin|Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism -LRB- increasing serum levels of mifepristone -RRB-. 
Mifepristone|N|itraconazole|erythromycin|Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism -LRB- increasing serum levels of mifepristone -RRB-. 
Mifepristone|N|itraconazole|erythromycin|Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism -LRB- increasing serum levels of mifepristone -RRB-. 
Mifepristone|N|rifampin|dexamethasone|Furthermore , rifampin , dexamethasone , St. 
Mifepristone|N|phenobarbital|carbamazepine|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Mifepristone|N|carbamazepine|mifepristone|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Mifepristone|N|anticonvulsant|carbamazepine|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Mifepristone|N|phenytoin|carbamazepine|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Mifepristone|N|phenobarbital|mifepristone|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Mifepristone|N|anticonvulsant|phenobarbital|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Mifepristone|N|phenytoin|phenobarbital|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Mifepristone|N|mifepristone|mifepristone|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Mifepristone|N|anticonvulsant|mifepristone|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Mifepristone|N|phenytoin|mifepristone|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Mifepristone|N|anticonvulsant|phenytoin|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Miglustat|N|zavesca|cerezyme|While co-administration of ZAVESCA appeared to increase the clearance of Cerezyme by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme . 
Miglustat|N|cerezyme|cerezyme|While co-administration of ZAVESCA appeared to increase the clearance of Cerezyme by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme . 
Miglustat|N|cerezyme|imiglucerase|Combination therapy with Cerezyme -LRB- imiglucerase -RRB- and ZAVESCA is not indicated . 
Minocycline|N|anticoagulant|anticoagulant|Because tetracyclines have been shown to depress plasma prothrombin activity , patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage . 
Minocycline|N|anticoagulant|anticoagulant|Because tetracyclines have been shown to depress plasma prothrombin activity , patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage . 
Minocycline|N|tetracycline|anticoagulant|Because tetracyclines have been shown to depress plasma prothrombin activity , patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage . 
Minocycline|N|penicillin|tetracycline class drug|Since bacteriostatic drugs may interfere with the bactericidal action of penicillin , it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin . 
Minocycline|N|penicillin|penicillin|Since bacteriostatic drugs may interfere with the bactericidal action of penicillin , it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin . 
Minocycline|N|antacid|aluminum|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|N|tetracycline|antacid|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|N|antacid|iron|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|N|antacid|magnesium|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|N|antacid|calcium|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|N|aluminum|iron|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|N|aluminum|magnesium|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|N|aluminum|calcium|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|N|magnesium|iron|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|N|calcium|iron|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|N|calcium|iron|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|N|calcium|magnesium|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|N|tetracycline|contraceptive|Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective . 
Minocycline|N|contraceptive|contraceptive|Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective . 
Minoxidil|N|guanethidine|guanethidine|Interaction with Guanethidine : Although minoxidil does not itself cause orthostatic hypotension , its administration to patients already receiving guanethidine can result in profound orthostatic effects . 
Minoxidil|N|guanethidine|minoxidil|Interaction with Guanethidine : Although minoxidil does not itself cause orthostatic hypotension , its administration to patients already receiving guanethidine can result in profound orthostatic effects . 
Mirtazapine|N|remeron soltab|mirtazapine|Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of REMERON SolTab -LRB- mirtazapine -RRB- Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes . 
Mirtazapine|N|mirtazapine|mirtazapine|While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes , an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes , the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied . 
Mirtazapine|N|mirtazapine|remeron soltab|While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes , an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes , the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied . 
Mirtazapine|N|mirtazapine|remeron soltab|While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes , an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes , the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied . 
Mirtazapine|N|alcohol|alcohol|Alcohol : Concomitant administration of alcohol -LRB- equivalent to 60 g -RRB- had a minimal effect on plasma levels of mirtazapine -LRB- 15 mg -RRB- in 6 healthy male subjects . 
Mirtazapine|N|alcohol|mirtazapine|Alcohol : Concomitant administration of alcohol -LRB- equivalent to 60 g -RRB- had a minimal effect on plasma levels of mirtazapine -LRB- 15 mg -RRB- in 6 healthy male subjects . 
Mirtazapine|N|remeron soltab|diazepam|Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam : Concomitant administration of diazepam -LRB- 15 mg -RRB- had a minimal effect on plasma levels of mirtazapine -LRB- 15 mg -RRB- in 12 healthy subjects . 
Mirtazapine|N|remeron soltab|diazepam|Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam : Concomitant administration of diazepam -LRB- 15 mg -RRB- had a minimal effect on plasma levels of mirtazapine -LRB- 15 mg -RRB- in 12 healthy subjects . 
Mirtazapine|N|remeron soltab|mirtazapine|Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam : Concomitant administration of diazepam -LRB- 15 mg -RRB- had a minimal effect on plasma levels of mirtazapine -LRB- 15 mg -RRB- in 12 healthy subjects . 
Mirtazapine|N|alcohol|diazepam|Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam : Concomitant administration of diazepam -LRB- 15 mg -RRB- had a minimal effect on plasma levels of mirtazapine -LRB- 15 mg -RRB- in 12 healthy subjects . 
Mirtazapine|N|alcohol|diazepam|Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam : Concomitant administration of diazepam -LRB- 15 mg -RRB- had a minimal effect on plasma levels of mirtazapine -LRB- 15 mg -RRB- in 12 healthy subjects . 
Mirtazapine|N|alcohol|mirtazapine|Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam : Concomitant administration of diazepam -LRB- 15 mg -RRB- had a minimal effect on plasma levels of mirtazapine -LRB- 15 mg -RRB- in 12 healthy subjects . 
Mirtazapine|N|diazepam|diazepam|Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam : Concomitant administration of diazepam -LRB- 15 mg -RRB- had a minimal effect on plasma levels of mirtazapine -LRB- 15 mg -RRB- in 12 healthy subjects . 
Mirtazapine|N|diazepam|mirtazapine|Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam : Concomitant administration of diazepam -LRB- 15 mg -RRB- had a minimal effect on plasma levels of mirtazapine -LRB- 15 mg -RRB- in 12 healthy subjects . 
Mitotane|N|warfarin|warfarin|Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for warfarin . 
Mitotane|N|mitotane|warfarin|Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for warfarin . 
Mitotane|N|anticoagulant|mitotane|Therefore , physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants . 
Mitotane|N|anticoagulant|coumarin-type anticoagulant|Therefore , physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants . 
Mivacurium|N|mivacron|succinylcholine|Although MIVACRON -LRB- a mixture of three stereoisomers -RRB- has been administered safely following succinylcholine-facilitated tracheal intubation , the interaction between MIVACRON and succinylcholine has not been systematically studied . 
Mivacurium|N|mivacron|mivacron|Although MIVACRON -LRB- a mixture of three stereoisomers -RRB- has been administered safely following succinylcholine-facilitated tracheal intubation , the interaction between MIVACRON and succinylcholine has not been systematically studied . 
Mivacurium|N|mivacron|succinylcholine|Although MIVACRON -LRB- a mixture of three stereoisomers -RRB- has been administered safely following succinylcholine-facilitated tracheal intubation , the interaction between MIVACRON and succinylcholine has not been systematically studied . 
Mivacurium|N|mivacron|succinylcholine|The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied . 
Mivacurium|N|mivacron|succinylcholine|The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied . 
Mivacurium|N|succinylcholine|succinylcholine|The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied . 
Mivacurium|N|mivacron|nondepolarizing neuromuscular blocking agent|There are no clinical data on the use of MIVACRON with other nondepolarizing neuromuscular blocking agents . 
Mivacurium|N|oxide|oxygen|Isoflurane and enflurane -LRB- administered with nitrous oxide/oxygen to achieve 1.25 M.C. 
Mivacurium|N|enflurane|nitrous oxide|Isoflurane and enflurane -LRB- administered with nitrous oxide/oxygen to achieve 1.25 M.C. 
Mivacurium|N|enflurane|nitrous oxide|Isoflurane and enflurane -LRB- administered with nitrous oxide/oxygen to achieve 1.25 M.C. 
Mivacurium|N|isoflurane|nitrous oxide|Isoflurane and enflurane -LRB- administered with nitrous oxide/oxygen to achieve 1.25 M.C. 
Mivacurium|N|enflurane|nitrous oxide|Isoflurane and enflurane -LRB- administered with nitrous oxide/oxygen to achieve 1.25 M.C. 
Mivacurium|N|enflurane|nitrous oxide|Isoflurane and enflurane -LRB- administered with nitrous oxide/oxygen to achieve 1.25 M.C. 
Mivacurium|N|isoflurane|nitrous oxide|Isoflurane and enflurane -LRB- administered with nitrous oxide/oxygen to achieve 1.25 M.C. 
Mivacurium|N|isoflurane|enflurane|Isoflurane and enflurane -LRB- administered with nitrous oxide/oxygen to achieve 1.25 M.C. 
Mivacurium|N|enflurane|isoflurane|A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane . 
Mivacurium|N|mivacron|enflurane|A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane . 
Mivacurium|N|mivacron|isoflurane|A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane . 
Mivacurium|N|anesthetic|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|anesthetic|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|procainamide|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|procainamide|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|sodium colistimethate|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lithium|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lithium|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|magnesium|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|magnesium|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|polymyxin|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lincomycin|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|clindamycin|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|colistin|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|antibiotic|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|aminoglycoside|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|anesthetic|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|anesthetic|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|sodium colistimethate|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lithium|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lithium|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|magnesium|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|magnesium|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|polymyxin|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lincomycin|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|clindamycin|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|colistin|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|antibiotic|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|aminoglycoside|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|sodium colistimethate|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lithium|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lithium|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|magnesium|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|magnesium|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|polymyxin|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lincomycin|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|clindamycin|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|colistin|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|antibiotic|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|aminoglycoside|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|sodium colistimethate|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|sodium colistimethate|magnesium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|polymyxin|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|polymyxin|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lincomycin|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lincomycin|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|clindamycin|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|clindamycin|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|colistin|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|colistin|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|antibiotic|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|aminoglycoside|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|magnesium|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|magnesium|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|polymyxin|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lincomycin|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|clindamycin|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|colistin|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|antibiotic|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|aminoglycoside|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|polymyxin|magnesium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lincomycin|magnesium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|clindamycin|magnesium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|colistin|magnesium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|antibiotic|magnesium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|aminoglycoside|magnesium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|magnesium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|magnesium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|polymyxin|lincomycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|polymyxin|lincomycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|polymyxin|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|polymyxin|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|polymyxin|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|polymyxin|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|antibiotic|polymyxin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|aminoglycoside|polymyxin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|polymyxin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|polymyxin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|polymyxin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|polymyxin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lincomycin|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lincomycin|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lincomycin|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|lincomycin|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|antibiotic|lincomycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|aminoglycoside|lincomycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|lincomycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|lincomycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|lincomycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|lincomycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|clindamycin|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|clindamycin|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|antibiotic|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|aminoglycoside|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|antibiotic|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|aminoglycoside|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|bacitracin|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|antibiotic|aminoglycoside|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|antibiotic|tetracycline|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|antibiotic|bacitracin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|aminoglycoside|tetracycline|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|aminoglycoside|bacitracin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|bacitracin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|tetracycline|bacitracin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|nondepolarizing agent|mivacron|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|N|contraceptive|glucocorticoid|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|glucocorticoid|carbamazepine|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|glucocorticoid|carbamazepine|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|glucocorticoid|phenytoin|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|glucocorticoid|phenytoin|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|glucocorticoid|neuromuscular blocking agent|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|glucocorticoid|neuromuscular blocking agent|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|glucocorticoid|monoamine oxidase inhibitor|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|glucocorticoid|monoamine oxidase inhibitor|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|contraceptive|carbamazepine|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|contraceptive|carbamazepine|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|contraceptive|phenytoin|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|contraceptive|phenytoin|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|contraceptive|neuromuscular blocking agent|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|contraceptive|neuromuscular blocking agent|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|contraceptive|monoamine oxidase inhibitor|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|mivacron|carbamazepine|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|mivacron|phenytoin|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|mivacron|neuromuscular blocking agent|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|phenytoin|carbamazepine|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|monoamine oxidase inhibitor|carbamazepine|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|monoamine oxidase inhibitor|carbamazepine|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|monoamine oxidase inhibitor|phenytoin|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|monoamine oxidase inhibitor|phenytoin|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|monoamine oxidase inhibitor|neuromuscular blocking agent|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|monoamine oxidase inhibitor|neuromuscular blocking agent|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|N|phenytoin|carbamazepine|While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher . 
Mivacurium|N|edrophonium|neostigmine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|edrophonium|neostigmine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|edrophonium|polymyxin b|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|edrophonium|bacitracin|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|edrophonium|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|corticosteroid|edrophonium|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|phenytoin|edrophonium|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|edrophonium|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|edrophonium|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|antibiotic|edrophonium|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|antibiotic|edrophonium|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|cisplatin|edrophonium|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|edrophonium|procaine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|edrophonium|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|edrophonium|succinylcholine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|edrophonium|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|neostigmine|polymyxin b|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|neostigmine|bacitracin|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|neostigmine|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|corticosteroid|neostigmine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|phenytoin|neostigmine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|neostigmine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|neostigmine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|antibiotic|neostigmine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|antibiotic|neostigmine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|cisplatin|neostigmine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|neostigmine|procaine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|neostigmine|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|neostigmine|succinylcholine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|neostigmine|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|polymyxin b|bacitracin|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|polymyxin b|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|corticosteroid|polymyxin b|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|phenytoin|polymyxin b|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|polymyxin b|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|antibiotic|polymyxin b|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|cisplatin|polymyxin b|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|polymyxin b|procaine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|polymyxin b|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|polymyxin b|succinylcholine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|polymyxin b|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|bacitracin|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|corticosteroid|bacitracin|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|phenytoin|bacitracin|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|bacitracin|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|antibiotic|bacitracin|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|cisplatin|bacitracin|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|bacitracin|procaine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|bacitracin|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|bacitracin|succinylcholine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|bacitracin|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|corticosteroid|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|phenytoin|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|antibiotic|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|cisplatin|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|anesthetic|procaine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|anesthetic|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|anesthetic|succinylcholine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|anesthetic|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|corticosteroid|phenytoin|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|corticosteroid|carbamazepine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|corticosteroid|antibiotic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|corticosteroid|cisplatin|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|corticosteroid|procaine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|corticosteroid|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|corticosteroid|succinylcholine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|corticosteroid|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|phenytoin|carbamazepine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|phenytoin|antibiotic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|phenytoin|cisplatin|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|phenytoin|procaine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|phenytoin|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|phenytoin|succinylcholine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|phenytoin|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|antibiotic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|antibiotic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|cisplatin|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|procaine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|succinylcholine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|carbamazepine|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|antibiotic|cisplatin|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|antibiotic|procaine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|antibiotic|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|antibiotic|succinylcholine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|antibiotic|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|cisplatin|procaine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|cisplatin|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|cisplatin|succinylcholine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|cisplatin|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|procaine|anesthetic|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|procaine|succinylcholine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|procaine|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|anesthetic|succinylcholine|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|anesthetic|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|succinylcholine|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Mivacurium|N|succinylcholine|muscle relaxant|Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
Moexipril|N|diuretic|ace inhibitor|Diuretics : Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started . 
Moexipril|N|univasc|moexpril|The possibility of hypotensive effects with UNIVASC can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC . If this is not possible , the starting dose of moexpril should be reduced .. 
Moexipril|N|univasc|univasc|The possibility of hypotensive effects with UNIVASC can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC . If this is not possible , the starting dose of moexpril should be reduced .. 
Moexipril|N|univasc|moexpril|The possibility of hypotensive effects with UNIVASC can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC . If this is not possible , the starting dose of moexpril should be reduced .. 
Moexipril|N|potassium|potassium-sparing diuretic|Potassium Supplements and Potassium-Sparing Diuretics : UNIVASC can increase serum potassium because it decreases aldosterone secretion . 
Moexipril|N|potassium|univasc|Potassium Supplements and Potassium-Sparing Diuretics : UNIVASC can increase serum potassium because it decreases aldosterone secretion . 
Moexipril|N|potassium-sparing diuretic|univasc|Potassium Supplements and Potassium-Sparing Diuretics : UNIVASC can increase serum potassium because it decreases aldosterone secretion . 
Moexipril|N|potassium-sparing diuretic|amiloride|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|N|potassium-sparing diuretic|potassium|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|N|potassium-sparing diuretic|spironolactone|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|N|potassium-sparing diuretic|triamterene|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|N|amiloride|potassium|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|N|spironolactone|amiloride|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|N|triamterene|amiloride|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|N|spironolactone|potassium|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|N|triamterene|potassium|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|N|spironolactone|triamterene|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|N|anticoagulant|anticoagulant|Oral Anticoagulants : Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect . 
Moexipril|N|anticoagulant|warfarin|Oral Anticoagulants : Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect . 
Moexipril|N|warfarin|anticoagulant|Oral Anticoagulants : Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect . 
Moexipril|N|lithium|lithium|Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium . 
Moexipril|N|lithium|lithium|Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium . 
Moexipril|N|lithium|lithium|Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium . 
Moexipril|N|lithium|ace inhibitor|Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium . 
Moexipril|N|lithium|lithium|Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium . 
Moexipril|N|lithium|lithium|Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium . 
Moexipril|N|lithium|ace inhibitor|Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium . 
Moexipril|N|lithium|ace inhibitor|Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium . 
Moexipril|N|lithium|lithium|Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium . 
Moexipril|N|hydrochlorothiazide|cimetidine|Other Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine . 
Moexipril|N|digoxin|cimetidine|Other Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine . 
Moexipril|N|digoxin|cimetidine|Other Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine . 
Moexipril|N|univasc|cimetidine|Other Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine . 
Moexipril|N|hydrochlorothiazide|digoxin|Other Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine . 
Moexipril|N|univasc|hydrochlorothiazide|Other Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine . 
Moexipril|N|univasc|digoxin|Other Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine . 
Moexipril|N|calcium-channel-blocking agent|diuretic|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|univasc|diuretic|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|diuretic|hypoglycemic agent|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|diuretic|hypoglycemic agent|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|diuretic|digoxin|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|diuretic|digoxin|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|diuretic|h2 blocker|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|diuretic|h2 blocker|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|univasc|calcium-channel-blocking agent|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|calcium-channel-blocking agent|hypoglycemic agent|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|calcium-channel-blocking agent|digoxin|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|calcium-channel-blocking agent|h2 blocker|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|univasc|hypoglycemic agent|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|univasc|digoxin|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|univasc|h2 blocker|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|digoxin|hypoglycemic agent|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|digoxin|hypoglycemic agent|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|h2 blocker|hypoglycemic agent|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|h2 blocker|hypoglycemic agent|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|h2 blocker|digoxin|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Moexipril|N|h2 blocker|digoxin|UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents . 
Montelukast|N|montelukast|theophylline|Montelukast at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State - did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline -LRB- predominantly a cytochrome P450 1A2 substrate -RRB-. 
Montelukast|N|warfarin|warfarin|- did not change the pharmacokinetic profile of warfarin -LRB- a substrate of cytochromes P450 2A6 and 2C9 -RRB- or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the INR -LRB- International Normalized Ratio -RRB-. 
Montelukast|N|terfenadine|fexofenadine|- did not change the plasma concentration profile of terfenadine -LRB- a substrate of cytochrome P450 3A4 -RRB- or fexofenadine , its carboxylated metabolite , and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily . 
Montelukast|N|fexofenadine|terfenadine|- did not change the plasma concentration profile of terfenadine -LRB- a substrate of cytochrome P450 3A4 -RRB- or fexofenadine , its carboxylated metabolite , and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily . 
Montelukast|N|terfenadine|terfenadine|- did not change the plasma concentration profile of terfenadine -LRB- a substrate of cytochrome P450 3A4 -RRB- or fexofenadine , its carboxylated metabolite , and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily . 
Montelukast|N|montelukast|norethindrone|Montelukast at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg . 
Montelukast|N|montelukast|contraceptive|Montelukast at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg . 
Montelukast|N|montelukast|estradiol|Montelukast at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg . 
Montelukast|N|contraceptive|norethindrone|Montelukast at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg . 
Montelukast|N|norethindrone|estradiol|Montelukast at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg . 
Montelukast|N|contraceptive|estradiol|Montelukast at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg . 
Montelukast|N|prednisone|prednisolone|- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone . 
Montelukast|N|prednisolone|prednisolone|- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone . 
Montelukast|N|prednisone|prednisolone|- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone . 
Montelukast|N|prednisolone|prednisone|- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone . 
Montelukast|N|prednisone|prednisone|- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone . 
Montelukast|N|prednisone|prednisolone|- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone . 
Montelukast|N|phenobarbital|montelukast|Phenobarbital , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10-mg dose of montelukast . 
Montelukast|N|phenobarbital|montelukast|Phenobarbital , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10-mg dose of montelukast . 
Montelukast|N|montelukast|montelukast|Phenobarbital , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10-mg dose of montelukast . 
Montelukast|N|phenobarbital|rifampin|It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as phenobarbital or rifampin , are co-administered with montelukast . 
Montelukast|N|montelukast|theophylline|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|theophylline|ethinyl estradiol|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|theophylline|terfenadine|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|theophylline|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|theophylline|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|theophylline|prednisone|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|theophylline|prednisolone|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|theophylline|contraceptive|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|theophylline|norethindrone|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|montelukast|ethinyl estradiol|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|montelukast|terfenadine|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|montelukast|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|montelukast|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|montelukast|prednisone|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|montelukast|prednisolone|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|montelukast|contraceptive|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|montelukast|norethindrone|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|ethinyl estradiol|terfenadine|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|ethinyl estradiol|terfenadine|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|ethinyl estradiol|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|ethinyl estradiol|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|ethinyl estradiol|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|ethinyl estradiol|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|ethinyl estradiol|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|ethinyl estradiol|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisolone|ethinyl estradiol|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisolone|ethinyl estradiol|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|contraceptive|ethinyl estradiol|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|norethindrone|ethinyl estradiol|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|terfenadine|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|terfenadine|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|terfenadine|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|terfenadine|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|terfenadine|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|terfenadine|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisolone|terfenadine|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisolone|terfenadine|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|contraceptive|terfenadine|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|contraceptive|terfenadine|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|norethindrone|terfenadine|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|norethindrone|terfenadine|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|digoxin|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|digoxin|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisolone|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisolone|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|contraceptive|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|contraceptive|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|norethindrone|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|norethindrone|digoxin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisolone|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisolone|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|contraceptive|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|contraceptive|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|norethindrone|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|norethindrone|warfarin|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|prednisolone|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|prednisolone|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|contraceptive|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|contraceptive|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|norethindrone|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisone|norethindrone|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisolone|contraceptive|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisolone|contraceptive|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisolone|norethindrone|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|prednisolone|norethindrone|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|contraceptive|norethindrone|In drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives -LRB- norethindrone 1 mg/ethinyl estradiol 35 mcg -RRB- , terfenadine , digoxin , and warfarin . 
Montelukast|N|thyroid hormone|sedative hypnotic|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|sedative hypnotic|benzodiazepine|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|sedative hypnotic|benzodiazepine|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|sedative hypnotic|non-steroidal anti-inflammatory agent|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|sedative hypnotic|non-steroidal anti-inflammatory agent|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|sedative hypnotic|decongestant|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|sedative hypnotic|decongestant|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|thyroid hormone|benzodiazepine|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|thyroid hormone|non-steroidal anti-inflammatory agent|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|thyroid hormone|decongestant|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|non-steroidal anti-inflammatory agent|benzodiazepine|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|non-steroidal anti-inflammatory agent|benzodiazepine|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|benzodiazepine|decongestant|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|benzodiazepine|decongestant|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|non-steroidal anti-inflammatory agent|decongestant|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|non-steroidal anti-inflammatory agent|decongestant|These medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants . 
Montelukast|N|phenobarbital|montelukast|Phenobarbital , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10-mg dose of montelukast . 
Montelukast|N|phenobarbital|montelukast|Phenobarbital , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10-mg dose of montelukast . 
Montelukast|N|montelukast|montelukast|Phenobarbital , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10-mg dose of montelukast . 
Montelukast|N|phenobarbital|rifampin|It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as phenobarbital or rifampin , are co-administered with montelukast . 
Morphine|N|cns depressant|alcohol|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|alcohol|antihistaminic|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|alcohol|sedative|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|central nervous system depressant|alcohol|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|alcohol|psychotropic drug|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|cns depressant|antihistaminic|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|cns depressant|sedative|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|central nervous system depressant|cns depressant|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|cns depressant|psychotropic drug|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|sedative|antihistaminic|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|sedative|antihistaminic|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|central nervous system depressant|antihistaminic|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|antihistaminic|psychotropic drug|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|antihistaminic|psychotropic drug|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|central nervous system depressant|sedative|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|sedative|psychotropic drug|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|sedative|psychotropic drug|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|central nervous system depressant|morphine|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|central nervous system depressant|psychotropic drug|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|N|mixed agonist/antagonist opioid analgesic|agonist/antagonist analgesic|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|mixed agonist/antagonist opioid analgesic|pentazocine|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|mixed agonist/antagonist opioid analgesic|nalbuphine|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|mixed agonist/antagonist opioid analgesic|butorphanol|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|mixed agonist/antagonist opioid analgesic|buprenorphine|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|mixed agonist/antagonist opioid analgesic|opioid agonist analgesic|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|mixed agonist/antagonist opioid analgesic|opioid agonist analgesic|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|agonist/antagonist analgesic|pentazocine|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|agonist/antagonist analgesic|nalbuphine|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|agonist/antagonist analgesic|butorphanol|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|agonist/antagonist analgesic|buprenorphine|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|pentazocine|nalbuphine|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|pentazocine|butorphanol|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|pentazocine|buprenorphine|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|nalbuphine|butorphanol|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|nalbuphine|butorphanol|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|nalbuphine|buprenorphine|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|nalbuphine|buprenorphine|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|butorphanol|buprenorphine|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|N|butorphanol|buprenorphine|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Mycophenolic acid|N|antacid|antacid|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|antacid|antacid|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|antacid|magnesium|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|antacid|magnesium|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|antacid|myfortic|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|antacid|myfortic|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|magnesium|antacid|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|magnesium|antacid|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|myfortic|antacid|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|myfortic|antacid|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|antacid|myfortic|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|antacid|myfortic|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|magnesium|aluminum|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|magnesium|myfortic|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|magnesium|myfortic|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|myfortic|myfortic|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|N|cyclosporine|myfortic|Cyclosporine : When studied in stable renal transplant patients , cyclosporine , USP -LRB- MODIFIED -RRB- pharmacokinetics were unaffected by steady state dosing of Myfortic . 
Mycophenolic acid|N|cyclosporine|cyclosporine|Cyclosporine : When studied in stable renal transplant patients , cyclosporine , USP -LRB- MODIFIED -RRB- pharmacokinetics were unaffected by steady state dosing of Myfortic . 
Mycophenolic acid|N|cyclosporine|myfortic|Cyclosporine : When studied in stable renal transplant patients , cyclosporine , USP -LRB- MODIFIED -RRB- pharmacokinetics were unaffected by steady state dosing of Myfortic . 
Mycophenolic acid|N|ganciclovir|myfortic|Acyclovir/Ganciclovir : may be taken with Myfortic ; 
Mycophenolic acid|N|ganciclovir|myfortic|Acyclovir/Ganciclovir : may be taken with Myfortic ; 
Mycophenolic acid|N|acyclovir|ganciclovir|Acyclovir/Ganciclovir : may be taken with Myfortic ; 
Mycophenolic acid|N|acyclovir|ganciclovir|Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two . 
Mycophenolic acid|N|acyclovir|mpag|Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two . 
Mycophenolic acid|N|acyclovir|mpag|Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two . 
Mycophenolic acid|N|azathioprine|mycophenolate mofetil|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|mycophenolate mofetil|mycophenolate mofetil|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|azathioprine|mycophenolate mofetil|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|mycophenolate mofetil|mycophenolate mofetil|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|azathioprine|mycophenolate mofetil|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|mycophenolate mofetil|azathioprine|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|azathioprine|azathioprine|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|mycophenolate mofetil|azathioprine|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|azathioprine|azathioprine|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|mycophenolate mofetil|myfortic|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|azathioprine|myfortic|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|mycophenolate mofetil|myfortic|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|azathioprine|myfortic|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|azathioprine|mycophenolate mofetil|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|mycophenolate mofetil|mycophenolate mofetil|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|azathioprine|mycophenolate mofetil|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|mycophenolate mofetil|azathioprine|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|azathioprine|azathioprine|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|azathioprine|mycophenolate mofetil|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|N|cholestyramine|mpa|Cholestyramine and Drugs that Bind Bile Acids : These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil . 
Mycophenolic acid|N|mpa|mycophenolate mofetil|Cholestyramine and Drugs that Bind Bile Acids : These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil . 
Mycophenolic acid|N|cholestyramine|mycophenolate mofetil|Cholestyramine and Drugs that Bind Bile Acids : These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil . 
Mycophenolic acid|N|myfortic|myfortic|Therefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . 
Mycophenolic acid|N|myfortic|myfortic|Therefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . 
Mycophenolic acid|N|cholestyramine|myfortic|Therefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . 
Mycophenolic acid|N|cholestyramine|myfortic|Therefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . 
Mycophenolic acid|N|activated charcoal|myfortic|Therefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . 
Mycophenolic acid|N|cholestyramine|activated charcoal|Therefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . 
Mycophenolic acid|N|cholestyramine|activated charcoal|Therefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . 
Mycophenolic acid|N|contraceptive|myfortic|Oral Contraceptives : Given the different metabolism of Myfortic and oral contraceptives , no drug interaction between these two classes of drug is expected . 
Mycophenolic acid|N|contraceptive|contraceptive|Oral Contraceptives : Given the different metabolism of Myfortic and oral contraceptives , no drug interaction between these two classes of drug is expected . 
Mycophenolic acid|N|myfortic|contraceptive|Oral Contraceptives : Given the different metabolism of Myfortic and oral contraceptives , no drug interaction between these two classes of drug is expected . 
Mycophenolic acid|N|live vaccine|live attenuated vaccine|Live Vaccines : During treatment with Myfortic , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective . 
Mycophenolic acid|N|live vaccine|myfortic|Live Vaccines : During treatment with Myfortic , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective . 
Mycophenolic acid|N|mpag|mpa|Interference of MPAG hydrolysis may lead to less MPA available for absorption . 
Ondansetron|N|ondansetron|ondansetron|Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes -LRB- CYP3A4 , CYP2D6 , CYP1A2 -RRB- , inducers or inhibitors of these enzymes may change the clearance and , hence , the half-life of ondansetron . 
Ondansetron|N|carbamazepine|rifampicin|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|phenytoin|rifampicin|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|rifampicin|ondansetron|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|rifampicin|rifampicin|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|rifampicin|carbamazepine|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|rifampicin|phenytoin|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|rifampicin|ondansetron|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|phenytoin|carbamazepine|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|carbamazepine|ondansetron|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|carbamazepine|rifampicin|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|carbamazepine|carbamazepine|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|carbamazepine|phenytoin|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|carbamazepine|ondansetron|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|phenytoin|ondansetron|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|phenytoin|rifampicin|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|phenytoin|carbamazepine|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|phenytoin|phenytoin|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|phenytoin|ondansetron|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|ondansetron|ondansetron|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|carbamazepine|rifampicin|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|carbamazepine|rifampicin|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|phenytoin|rifampicin|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|phenytoin|carbamazepine|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|N|ondansetron|tramadol|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|ondansetron|ondansetron|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|ondansetron|tramadol|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|ondansetron|ondansetron|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|ondansetron|tramadol|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|ondansetron|ondansetron|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|tramadol|ondansetron|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|tramadol|tramadol|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|tramadol|ondansetron|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|tramadol|tramadol|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|tramadol|ondansetron|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|ondansetron|tramadol|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|ondansetron|ondansetron|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|ondansetron|tramadol|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|ondansetron|ondansetron|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|tramadol|ondansetron|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|tramadol|tramadol|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|tramadol|ondansetron|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|ondansetron|ondansetron|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|tramadol|ondansetron|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Ondansetron|N|etoposide|ondansetron|In humans , carmustine , etoposide , and cisplatin do not affect the pharmacokinetics of ondansetron . 
Ondansetron|N|cisplatin|ondansetron|In humans , carmustine , etoposide , and cisplatin do not affect the pharmacokinetics of ondansetron . 
Ondansetron|N|carmustine|ondansetron|In humans , carmustine , etoposide , and cisplatin do not affect the pharmacokinetics of ondansetron . 
Ondansetron|N|etoposide|cisplatin|In humans , carmustine , etoposide , and cisplatin do not affect the pharmacokinetics of ondansetron . 
Ondansetron|N|etoposide|cisplatin|In humans , carmustine , etoposide , and cisplatin do not affect the pharmacokinetics of ondansetron . 
Ondansetron|N|carmustine|etoposide|In humans , carmustine , etoposide , and cisplatin do not affect the pharmacokinetics of ondansetron . 
Ondansetron|N|carmustine|cisplatin|In humans , carmustine , etoposide , and cisplatin do not affect the pharmacokinetics of ondansetron . 
Ondansetron|N|ondansetron|methotrexate|ondansetron did not increase blood levels of high-dose methotrexate . 
Orciprenaline|N|alupent|metaproterenol sulfate|Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent -LRB- metaproterenol sulfate USP -RRB- because they may have additive effects . 
Orciprenaline|N|monoamine oxidase inhibitor|tricyclic antidepressant|Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated . 
Orciprenaline|N|tricyclic antidepressant|beta adrenergic agonist|Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated . 
Orciprenaline|N|monoamine oxidase inhibitor|beta adrenergic agonist|Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated . 
Orciprenaline|N|beta adrenergic agonist|beta adrenergic agonist|Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated . 
Orlistat|N|orlistat|orlistat|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|orlistat|orlistat|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|alcohol|orlistat|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|alcohol|orlistat|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|xenical|orlistat|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|alcohol|orlistat|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|alcohol|orlistat|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|alcohol|orlistat|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|xenical|orlistat|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|alcohol|orlistat|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|alcohol|alcohol|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|xenical|alcohol|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|alcohol|alcohol|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|xenical|alcohol|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|alcohol|alcohol|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|alcohol|xenical|Alcohol : In a multiple-dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol -LRB- e.g. , approximately 3 glasses of wine -RRB- did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics -LRB- fecal fat excretion -RRB- , or systemic exposure to orlistat . 
Orlistat|N|cyclosporine|xenical|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|xenical|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|xenical|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|xenical|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|xenical|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|xenical|xenical|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|xenical|xenical|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|xenical|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|xenical|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|xenical|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|xenical|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|xenical|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|xenical|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|cyclosporine|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|N|xenical|digoxin|Digoxin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the pharmacokinetics of a single dose of digoxin . 
Orlistat|N|digoxin|xenical|Digoxin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the pharmacokinetics of a single dose of digoxin . 
Orlistat|N|xenical|xenical|Digoxin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the pharmacokinetics of a single dose of digoxin . 
Orlistat|N|digoxin|digoxin|Digoxin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the pharmacokinetics of a single dose of digoxin . 
Orlistat|N|xenical|digoxin|Digoxin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the pharmacokinetics of a single dose of digoxin . 
Orlistat|N|digoxin|xenical|Digoxin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the pharmacokinetics of a single dose of digoxin . 
Orlistat|N|fat-soluble vitamin supplement|beta-carotene|Fat-soluble Vitamin Supplements and Analogues : A pharmacokinetic interaction study showed a 30 % reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL . 
Orlistat|N|fat-soluble vitamin supplement|xenical|Fat-soluble Vitamin Supplements and Analogues : A pharmacokinetic interaction study showed a 30 % reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL . 
Orlistat|N|vitamin d|vitamin k|The effect of orlistat on the absorption of supplemental vitamin D , vitamin A , and nutritionally-derived vitamin K is not known at this time . 
Orlistat|N|vitamin a|vitamin k|The effect of orlistat on the absorption of supplemental vitamin D , vitamin A , and nutritionally-derived vitamin K is not known at this time . 
Orlistat|N|vitamin a|vitamin k|The effect of orlistat on the absorption of supplemental vitamin D , vitamin A , and nutritionally-derived vitamin K is not known at this time . 
Orlistat|N|orlistat|vitamin k|The effect of orlistat on the absorption of supplemental vitamin D , vitamin A , and nutritionally-derived vitamin K is not known at this time . 
Orlistat|N|vitamin d|vitamin a|The effect of orlistat on the absorption of supplemental vitamin D , vitamin A , and nutritionally-derived vitamin K is not known at this time . 
Orlistat|N|orlistat|vitamin d|The effect of orlistat on the absorption of supplemental vitamin D , vitamin A , and nutritionally-derived vitamin K is not known at this time . 
Orlistat|N|orlistat|vitamin a|The effect of orlistat on the absorption of supplemental vitamin D , vitamin A , and nutritionally-derived vitamin K is not known at this time . 
Orlistat|N|glyburide|orlistat|Glyburide : In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics -LRB- blood glucose-lowering -RRB- of glyburide . 
Orlistat|N|glyburide|orlistat|Glyburide : In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics -LRB- blood glucose-lowering -RRB- of glyburide . 
Orlistat|N|glyburide|glyburide|Glyburide : In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics -LRB- blood glucose-lowering -RRB- of glyburide . 
Orlistat|N|orlistat|orlistat|Glyburide : In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics -LRB- blood glucose-lowering -RRB- of glyburide . 
Orlistat|N|orlistat|glyburide|Glyburide : In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics -LRB- blood glucose-lowering -RRB- of glyburide . 
Orlistat|N|orlistat|glyburide|Glyburide : In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics -LRB- blood glucose-lowering -RRB- of glyburide . 
Orlistat|N|xenical|xenical|Nifedipine -LRB- extended-release tablets -RRB- : In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the bioavailability of nifedipine -LRB- extended-release tablets -RRB-. 
Orlistat|N|xenical|nifedipine|Nifedipine -LRB- extended-release tablets -RRB- : In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the bioavailability of nifedipine -LRB- extended-release tablets -RRB-. 
Orlistat|N|nifedipine|xenical|Nifedipine -LRB- extended-release tablets -RRB- : In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the bioavailability of nifedipine -LRB- extended-release tablets -RRB-. 
Orlistat|N|xenical|nifedipine|Nifedipine -LRB- extended-release tablets -RRB- : In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the bioavailability of nifedipine -LRB- extended-release tablets -RRB-. 
Orlistat|N|nifedipine|xenical|Nifedipine -LRB- extended-release tablets -RRB- : In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the bioavailability of nifedipine -LRB- extended-release tablets -RRB-. 
Orlistat|N|nifedipine|nifedipine|Nifedipine -LRB- extended-release tablets -RRB- : In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the bioavailability of nifedipine -LRB- extended-release tablets -RRB-. 
Orlistat|N|contraceptive|xenical|Oral Contraceptives : In 20 normal-weight female subjects , the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives . 
Orlistat|N|xenical|contraceptive|Oral Contraceptives : In 20 normal-weight female subjects , the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives . 
Orlistat|N|contraceptive|contraceptive|Oral Contraceptives : In 20 normal-weight female subjects , the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives . 
Orlistat|N|xenical|phenytoin|Phenytoin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days , XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin . 
Orlistat|N|xenical|phenytoin|Phenytoin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days , XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin . 
Orlistat|N|phenytoin|phenytoin|Phenytoin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days , XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin . 
Orlistat|N|xenical|xenical|Phenytoin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days , XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin . 
Orlistat|N|phenytoin|xenical|Phenytoin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days , XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin . 
Orlistat|N|phenytoin|xenical|Phenytoin : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days , XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin . 
Orlistat|N|pravastatin|pravastatin|Pravastatin : In a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not affect the pharmacokinetics of pravastatin . 
Orlistat|N|xenical|pravastatin|Pravastatin : In a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not affect the pharmacokinetics of pravastatin . 
Orlistat|N|xenical|pravastatin|Pravastatin : In a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not affect the pharmacokinetics of pravastatin . 
Orlistat|N|pravastatin|xenical|Pravastatin : In a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not affect the pharmacokinetics of pravastatin . 
Orlistat|N|pravastatin|xenical|Pravastatin : In a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not affect the pharmacokinetics of pravastatin . 
Orlistat|N|xenical|xenical|Pravastatin : In a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not affect the pharmacokinetics of pravastatin . 
Orlistat|N|warfarin|warfarin|Warfarin : In 12 normal-weight subjects , administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics -LRB- both R- and S-enantiomers -RRB- or pharmacodynamics -LRB- prothrombin time and serum Factor VII -RRB-. 
Orlistat|N|xenical|warfarin|Warfarin : In 12 normal-weight subjects , administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics -LRB- both R- and S-enantiomers -RRB- or pharmacodynamics -LRB- prothrombin time and serum Factor VII -RRB-. 
Orlistat|N|warfarin|xenical|Warfarin : In 12 normal-weight subjects , administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics -LRB- both R- and S-enantiomers -RRB- or pharmacodynamics -LRB- prothrombin time and serum Factor VII -RRB-. 
Orlistat|N|xenical|xenical|Although undercarboxylated osteocalcin , a marker of vitamin K nutritional status , was unaltered with XENICAL administration , vitamin K levels tended to decline in subjects taking XENICAL . 
Orlistat|N|xenical|xenical|Therefore , as vitamin K absorption may be decreased with XENICAL , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 
Orlistat|N|xenical|xenical|Therefore , as vitamin K absorption may be decreased with XENICAL , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 
Orlistat|N|xenical|warfarin|Therefore , as vitamin K absorption may be decreased with XENICAL , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 
Orlistat|N|vitamin k|xenical|Therefore , as vitamin K absorption may be decreased with XENICAL , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 
Orlistat|N|vitamin k|xenical|Therefore , as vitamin K absorption may be decreased with XENICAL , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 
Orlistat|N|vitamin k|warfarin|Therefore , as vitamin K absorption may be decreased with XENICAL , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 
Oxacillin|N|antibiotic|penicillin|Tetracycline , a bacteriostatic antibiotic , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided . 
Oxacillin|N|tetracycline|antibiotic|Tetracycline , a bacteriostatic antibiotic , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided . 
Oxaliplatin|N|eloxatin|5-fu|No pharmacokinetic interaction between 85 mg/m2 ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks . 
Oxandrolone|N|anticoagulant|anticoagulant|Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants . 
Oxandrolone|N|anticoagulant|anabolic steroid|Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants . 
Oxandrolone|N|warfarin|oxandrolone|Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 
Oxandrolone|N|warfarin|warfarin|Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 
Oxandrolone|N|warfarin|s-warfarin|Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 
Oxandrolone|N|warfarin|r-warfarin|Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 
Oxandrolone|N|oxandrolone|s-warfarin|Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 
Oxandrolone|N|oxandrolone|r-warfarin|Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 
Oxandrolone|N|warfarin|s-warfarin|Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 
Oxandrolone|N|warfarin|r-warfarin|Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 
Oxandrolone|N|s-warfarin|r-warfarin|Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 
Oxandrolone|N|warfarin|warfarin|A 5.5-fold decrease in the mean warfarin dose from 6.13 mg/day to 1.13 mg/day -LRB- approximately 80-85 % reduction of warfarin dose -RRB- , was necessary to maintain a target INR of 1.5 . 
Oxandrolone|N|warfarin|warfarin|When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin , the INR or prothrombin time -LRB- PT -RRB- should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved . 
Oxandrolone|N|oxandrolone|warfarin|When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin , the INR or prothrombin time -LRB- PT -RRB- should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved . 
Oxandrolone|N|hypoglycemic agent|oxandrolone|Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents . 
Oxandrolone|N|hypoglycemic agent|hypoglycemic agent|Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents . 
Oxandrolone|N|adrenal steroid|acth|Adrenal steroids or ACTH In patients with edema , concomitant administration with adrenal cortical steroids or ACTH may increase the edema . 
Oxandrolone|N|adrenal steroid|adrenal cortical steroid|Adrenal steroids or ACTH In patients with edema , concomitant administration with adrenal cortical steroids or ACTH may increase the edema . 
Oxandrolone|N|adrenal steroid|acth|Adrenal steroids or ACTH In patients with edema , concomitant administration with adrenal cortical steroids or ACTH may increase the edema . 
Oxandrolone|N|acth|adrenal cortical steroid|Adrenal steroids or ACTH In patients with edema , concomitant administration with adrenal cortical steroids or ACTH may increase the edema . 
Oxandrolone|N|acth|acth|Adrenal steroids or ACTH In patients with edema , concomitant administration with adrenal cortical steroids or ACTH may increase the edema . 
Oxandrolone|N|adrenal cortical steroid|acth|Adrenal steroids or ACTH In patients with edema , concomitant administration with adrenal cortical steroids or ACTH may increase the edema . 
Oxandrolone|N|adrenal cortical steroid|acth|Adrenal steroids or ACTH In patients with edema , concomitant administration with adrenal cortical steroids or ACTH may increase the edema . 
Oxybutynin|N|oxybutynin chloride|ditropan xl|Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole , a potent CYP3A4 inhibitor . 
Oxybutynin|N|oxybutynin chloride|ketoconazole|Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole , a potent CYP3A4 inhibitor . 
Oxybutynin|N|antimycotic agent|clarithromycin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|antimycotic agent|itraconazole|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|antimycotic agent|miconazole|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|antimycotic agent|macrolide antibiotic|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|antimycotic agent|erythromycin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|itraconazole|clarithromycin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|miconazole|clarithromycin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|macrolide antibiotic|clarithromycin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|erythromycin|clarithromycin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|itraconazole|miconazole|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|itraconazole|macrolide antibiotic|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|itraconazole|erythromycin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|miconazole|macrolide antibiotic|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|miconazole|erythromycin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|macrolide antibiotic|erythromycin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|N|antacid|antacid|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|antacid|aluminum hydroxide|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|antacid|magnesium hydroxide|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|antacid|simethicone|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|antacid|oxybutynin|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|antacid|desethyloxybutynin|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|antacid|aluminum hydroxide|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|antacid|magnesium hydroxide|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|antacid|simethicone|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|antacid|oxybutynin|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|antacid|desethyloxybutynin|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|aluminum hydroxide|magnesium hydroxide|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|aluminum hydroxide|simethicone|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|aluminum hydroxide|oxybutynin|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|aluminum hydroxide|desethyloxybutynin|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|magnesium hydroxide|simethicone|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|magnesium hydroxide|simethicone|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|magnesium hydroxide|oxybutynin|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|magnesium hydroxide|desethyloxybutynin|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|simethicone|oxybutynin|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|simethicone|desethyloxybutynin|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxybutynin|N|oxybutynin|desethyloxybutynin|Concurrent ingestion of antacid -LRB- 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone -RRB- did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
Oxymorphone|N|cns depressant|hypnotic|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|cns depressant|sedative|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|cns depressant|tranquilizer|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|cns depressant|anesthetic|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|cns depressant|phenothiazine|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|cns depressant|opioid|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|cns depressant|tricyclic antidepressant|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|cns depressant|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|cns depressant|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|sedative|hypnotic|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|tranquilizer|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|tranquilizer|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|anesthetic|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|anesthetic|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|phenothiazine|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|phenothiazine|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|opioid|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|opioid|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|tricyclic antidepressant|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|tricyclic antidepressant|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|hypnotic|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|sedative|tranquilizer|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|sedative|anesthetic|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|sedative|phenothiazine|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|sedative|opioid|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|sedative|tricyclic antidepressant|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|sedative|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|sedative|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tranquilizer|anesthetic|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tranquilizer|anesthetic|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tranquilizer|phenothiazine|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tranquilizer|phenothiazine|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tranquilizer|opioid|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tranquilizer|opioid|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tranquilizer|tricyclic antidepressant|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tranquilizer|tricyclic antidepressant|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tranquilizer|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tranquilizer|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tranquilizer|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tranquilizer|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|anesthetic|phenothiazine|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|anesthetic|phenothiazine|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|anesthetic|opioid|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|anesthetic|opioid|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|anesthetic|tricyclic antidepressant|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|anesthetic|tricyclic antidepressant|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|anesthetic|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|anesthetic|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|anesthetic|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|anesthetic|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|phenothiazine|opioid|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|phenothiazine|opioid|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|phenothiazine|tricyclic antidepressant|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|phenothiazine|tricyclic antidepressant|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|phenothiazine|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|phenothiazine|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|phenothiazine|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|phenothiazine|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|opioid|tricyclic antidepressant|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|opioid|tricyclic antidepressant|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|opioid|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|opioid|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|opioid|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|opioid|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tricyclic antidepressant|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tricyclic antidepressant|monoamine oxidase (mao) inhibitor|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tricyclic antidepressant|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|tricyclic antidepressant|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|monoamine oxidase (mao) inhibitor|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Oxymorphone|N|monoamine oxidase (mao) inhibitor|alcohol|The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase -LRB- MAO -RRB- inhibitors , and alcohol may produce additive CNS depressant effects . 
Paliperidone|N|invega|paliperidone|Potential for INVEGA to Affect Other Drugs Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes . 
Paliperidone|N|paliperidone|invega|Given the primary CNS effects of paliperidone , INVEGA should be used with caution in combination with other centrally acting drugs and alcohol . 
Paliperidone|N|centrally acting drug|alcohol|Given the primary CNS effects of paliperidone , INVEGA should be used with caution in combination with other centrally acting drugs and alcohol . 
Paliperidone|N|levodopa|dopamine agonist|Paliperidone may antagonize the effect of levodopa and other dopamine agonists . 
Paliperidone|N|invega|paliperidone|Potential for Other Drugs to Affect INVEGA Paliperidone is not a substrate of CYP1A2 , CYP2A6 , CYP2C9 , and CYP2C19 , so that an interaction with inhibitors or inducers of these isozymes is unlikely . 
Pantoprazole|N|pantoprazole|cisapride|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|theophylline|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|caffeine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|antipyrine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|ethanol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|diazepam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|carbamazepine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|glyburide|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|piroxicam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|diclofenac|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|digoxin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|desmethyldiazepam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|naproxen|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|cisapride|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|caffeine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|antipyrine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|ethanol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|diazepam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|carbamazepine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|glyburide|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|piroxicam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|diclofenac|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|digoxin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|desmethyldiazepam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|naproxen|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|cisapride|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|caffeine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|antipyrine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|ethanol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|diazepam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|carbamazepine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|glyburide|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|piroxicam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|diclofenac|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|digoxin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|desmethyldiazepam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|naproxen|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|theophylline|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|caffeine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|ethanol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|diazepam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|carbamazepine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|glyburide|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|piroxicam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|diclofenac|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|digoxin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|desmethyldiazepam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|naproxen|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|caffeine|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|contraceptive|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethanol|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|glyburide|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|digoxin|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|contraceptive|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|contraceptive|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|contraceptive|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|contraceptive|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|contraceptive|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|contraceptive|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|contraceptive|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|contraceptive|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|contraceptive|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|contraceptive|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|ethanol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|diazepam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|carbamazepine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|glyburide|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|piroxicam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|diclofenac|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|digoxin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|desmethyldiazepam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|naproxen|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|antipyrine|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethanol|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|glyburide|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|digoxin|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|levonorgestrel|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|levonorgestrel|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|levonorgestrel|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|levonorgestrel|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|levonorgestrel|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|levonorgestrel|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|levonorgestrel|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|levonorgestrel|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|levonorgestrel|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|levonorgestrel|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|ethanol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|ethanol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethanol|glyburide|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|ethanol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|ethanol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|digoxin|ethanol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|ethanol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|ethanol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethanol|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethanol|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethanol|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethanol|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethanol|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethanol|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethanol|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethanol|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethanol|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|diazepam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|glyburide|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|piroxicam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|diclofenac|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|digoxin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|desmethyldiazepam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|naproxen|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diazepam|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|glyburide|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|piroxicam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|diclofenac|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|digoxin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|desmethyldiazepam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|naproxen|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|carbamazepine|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|glyburide|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|glyburide|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|digoxin|glyburide|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|glyburide|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|glyburide|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|glyburide|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|glyburide|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|glyburide|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|glyburide|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|glyburide|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|glyburide|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|glyburide|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|glyburide|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|glyburide|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|piroxicam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|digoxin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|piroxicam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|piroxicam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|piroxicam|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|digoxin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|diclofenac|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|naproxen|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|diclofenac|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|digoxin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|digoxin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|digoxin|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|digoxin|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|digoxin|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|digoxin|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|digoxin|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|digoxin|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|digoxin|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|digoxin|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|digoxin|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|naproxen|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|desmethyldiazepam|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|ethinyl estradiol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|naproxen|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|nifedipine|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|metoprolol|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethinyl estradiol|phenytoin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|phenytoin|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|phenytoin|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|phenytoin|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|phenytoin|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|phenytoin|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|metoprolol|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethinyl estradiol|nifedipine|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|nifedipine|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|nifedipine|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|nifedipine|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|nifedipine|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|nifedipine|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethinyl estradiol|metoprolol|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|metoprolol|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|metoprolol|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|metoprolol|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|metoprolol|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|metoprolol|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethinyl estradiol|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethinyl estradiol|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethinyl estradiol|warfarin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethinyl estradiol|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|ethinyl estradiol|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|metronidazole|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|metronidazole|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|warfarin|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|midazolam|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|clarithromycin|metronidazole|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|warfarin|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|midazolam|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|clarithromycin|amoxicillin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|warfarin|midazolam|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|warfarin|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|midazolam|clarithromycin|Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam -LRB- and its active metabolite , desmethyldiazepam -RRB- , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive -LRB- levonorgestrel/ethinyl estradiol -RRB- , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
Pantoprazole|N|pantoprazole|pantoprazole|Therefore , when coadministered with pantoprazole , adjustment of the dosage of pantoprazole or of such drugs may not be necessary . 
Pantoprazole|N|proton pump inhibitor|pantoprazole|There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors , including pantoprazole , and warfarin concomitantly . 
Pantoprazole|N|ketoconazole|ampicillin|Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability -LRB- eg , ketoconazole , ampicillin esters , and iron salts -RRB-. 
Pantoprazole|N|ketoconazole|ampicillin|Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability -LRB- eg , ketoconazole , ampicillin esters , and iron salts -RRB-. 
Pantoprazole|N|ketoconazole|iron|Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability -LRB- eg , ketoconazole , ampicillin esters , and iron salts -RRB-. 
Pantoprazole|N|ketoconazole|iron|Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability -LRB- eg , ketoconazole , ampicillin esters , and iron salts -RRB-. 
Pantoprazole|N|ampicillin|iron|Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability -LRB- eg , ketoconazole , ampicillin esters , and iron salts -RRB-. 
Pantoprazole|N|ampicillin|iron|Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability -LRB- eg , ketoconazole , ampicillin esters , and iron salts -RRB-. 
Pantoprazole|N|thc|proton pump inhibitor|Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol -LRB- THC -RRB- in patients receiving most proton pump inhibitors , including pantoprazole . 
Pantoprazole|N|tetrahydrocannabinol|thc|Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol -LRB- THC -RRB- in patients receiving most proton pump inhibitors , including pantoprazole . 
Pantoprazole|N|thc|pantoprazole|Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol -LRB- THC -RRB- in patients receiving most proton pump inhibitors , including pantoprazole . 
Pantoprazole|N|tetrahydrocannabinol|proton pump inhibitor|Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol -LRB- THC -RRB- in patients receiving most proton pump inhibitors , including pantoprazole . 
Pantoprazole|N|proton pump inhibitor|pantoprazole|Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol -LRB- THC -RRB- in patients receiving most proton pump inhibitors , including pantoprazole . 
Pantoprazole|N|tetrahydrocannabinol|pantoprazole|Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol -LRB- THC -RRB- in patients receiving most proton pump inhibitors , including pantoprazole . 
Paricalcitol|N|saquinavir|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|saquinavir|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|telithromycin|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|telithromycin|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|atazanavir|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|nefazodone|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|nefazodone|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|indinavir|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|indinavir|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ritonavir|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ritonavir|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|itraconazole|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|itraconazole|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|nelfinavir|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|nelfinavir|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|saquinavir|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|saquinavir|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|atazanavir|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|nefazodone|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|indinavir|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ritonavir|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|itraconazole|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|nelfinavir|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|atazanavir|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|nefazodone|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|nefazodone|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|indinavir|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|indinavir|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ritonavir|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ritonavir|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|itraconazole|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|itraconazole|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|nelfinavir|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|nelfinavir|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|atazanavir|nefazodone|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|atazanavir|clarithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|atazanavir|indinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|atazanavir|ritonavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|atazanavir|itraconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|atazanavir|nelfinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|atazanavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|atazanavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|atazanavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|atazanavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|atazanavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|nefazodone|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|nefazodone|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|indinavir|nefazodone|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|nefazodone|ritonavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|itraconazole|nefazodone|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|nefazodone|nelfinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|nefazodone|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|nefazodone|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|nefazodone|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|nefazodone|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|nefazodone|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|indinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|indinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|ritonavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|ritonavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|itraconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|itraconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|nelfinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|clarithromycin|nelfinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|clarithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|clarithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|clarithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|clarithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|clarithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|indinavir|ritonavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|indinavir|itraconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|indinavir|nelfinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|indinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|indinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|indinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|indinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|indinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|itraconazole|ritonavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|nelfinavir|ritonavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|ritonavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|ritonavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|ritonavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|ritonavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|ritonavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|itraconazole|nelfinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|itraconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|itraconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|itraconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|itraconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|itraconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|nelfinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|nelfinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|nelfinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|nelfinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|nelfinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|ketoconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|paricalcitol|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|ketoconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|paricalcitol|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|paricalcitol|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|paricalcitol|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|ketoconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|ketoconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|ketoconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|paricalcitol|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|paricalcitol|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|ketoconazole|ketoconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|paricalcitol|ketoconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|N|fat-soluble vitamin|zemplar|Drugs that impair intestinal absorption of fat-soluble vitamins , such as cholestyramine , may interfere with the absorption of Zemplar Capsules . 
Paricalcitol|N|fat-soluble vitamin|zemplar|Drugs that impair intestinal absorption of fat-soluble vitamins , such as cholestyramine , may interfere with the absorption of Zemplar Capsules . 
Peginterferon alfa-2b|N|methadone|methadone|In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone , treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16 % in methadone AUC ; 
Peginterferon alfa-2b|N|peg-intron|methadone|In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone , treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16 % in methadone AUC ; 
Pegvisomant|N|insulin|hypoglycemic|Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT . 
Pegvisomant|N|pegvisomant|opioid|In clinical studies , patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids . 
Pegvisomant|N|opioid|opioid|In clinical studies , patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids . 
Pemetrexed|N|ibuprofen|ibuprofen|Although ibuprofen -LRB- 400 mg qid -RRB- can be administered with ALIMTA in patients with normal renal function -LRB- creatinine clearance 80 mL/min -RRB- , caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency -LRB- creatinine clearance from 45 to 79 mL/min -RRB-. 
Pemetrexed|N|alimta|ibuprofen|Although ibuprofen -LRB- 400 mg qid -RRB- can be administered with ALIMTA in patients with normal renal function -LRB- creatinine clearance 80 mL/min -RRB- , caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency -LRB- creatinine clearance from 45 to 79 mL/min -RRB-. 
Pemetrexed|N|ibuprofen|alimta|Although ibuprofen -LRB- 400 mg qid -RRB- can be administered with ALIMTA in patients with normal renal function -LRB- creatinine clearance 80 mL/min -RRB- , caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency -LRB- creatinine clearance from 45 to 79 mL/min -RRB-. 
Pemetrexed|N|alimta|alimta|Although ibuprofen -LRB- 400 mg qid -RRB- can be administered with ALIMTA in patients with normal renal function -LRB- creatinine clearance 80 mL/min -RRB- , caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency -LRB- creatinine clearance from 45 to 79 mL/min -RRB-. 
Pemetrexed|N|ibuprofen|alimta|Although ibuprofen -LRB- 400 mg qid -RRB- can be administered with ALIMTA in patients with normal renal function -LRB- creatinine clearance 80 mL/min -RRB- , caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency -LRB- creatinine clearance from 45 to 79 mL/min -RRB-. 
Pemetrexed|N|nsaid|alimta|In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives , all patients taking these NSAIDs should interrupt dosing for at least 5 days before , the day of , and 2 days following ALIMTA administration . 
Pemetrexed|N|alimta|alimta|In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives , all patients taking these NSAIDs should interrupt dosing for at least 5 days before , the day of , and 2 days following ALIMTA administration . 
Pemetrexed|N|nsaid|nsaid|In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives , all patients taking these NSAIDs should interrupt dosing for at least 5 days before , the day of , and 2 days following ALIMTA administration . 
Pemetrexed|N|alimta|nsaid|In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives , all patients taking these NSAIDs should interrupt dosing for at least 5 days before , the day of , and 2 days following ALIMTA administration . 
Pemetrexed|N|alimta|nsaid|In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives , all patients taking these NSAIDs should interrupt dosing for at least 5 days before , the day of , and 2 days following ALIMTA administration . 
Pemoline|N|cylert|pemoline|The interaction of CYLERT -LRB- pemoline -RRB- with other drugs has not been studied in humans . 
Penicillin G|N|bacteriostatic antibiotic|tetracycline|Concurrent administration of bacteriostatic antibiotics -LRB- e.g. , erythromycin , tetracycline -RRB- may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth . 
Penicillin G|N|bacteriostatic antibiotic|erythromycin|Concurrent administration of bacteriostatic antibiotics -LRB- e.g. , erythromycin , tetracycline -RRB- may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth . 
Penicillin G|N|erythromycin|tetracycline|Concurrent administration of bacteriostatic antibiotics -LRB- e.g. , erythromycin , tetracycline -RRB- may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth . 
Penicillin G|N|penicillin|penicillin|Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins . 
Penicillin G|N|penicillin|penicillin|Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins . 
Penicillin G|N|probenecid|penicillin|Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins . 
Penicillin G|N|probenecid|penicillin|Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins . 
Penicillin G|N|penicillin|penicillin|Displacement of penicillin from plasma protein binding sites will elevate the level of free penicillin in the serum . 
Pentazocine|N|alcohol|pentazocine|Usage with Alcohol : Due to the potential for increased CNS depressants effects , alcohol should be used with caution in patients who are currently receiving pentazocine . 
Pentazocine|N|alcohol|pentazocine|Usage with Alcohol : Due to the potential for increased CNS depressants effects , alcohol should be used with caution in patients who are currently receiving pentazocine . 
Pentazocine|N|alcohol|alcohol|Usage with Alcohol : Due to the potential for increased CNS depressants effects , alcohol should be used with caution in patients who are currently receiving pentazocine . 
Pentoxifylline|N|anticoagulant|platelet aggregation inhibitor|Although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors . 
Pentoxifylline|N|theophylline|theophylline|Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals . 
Pentoxifylline|N|theophylline|theophylline|Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals . 
Pentoxifylline|N|trental|theophylline|Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals . 
Pentoxifylline|N|trental|theophylline|Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals . 
Pentoxifylline|N|theophylline|theophylline|Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals . 
Pentoxifylline|N|trental|antihypertensive drug|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|trental|antidiabetic agent|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|trental|diuretic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|trental|digitali|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|trental|beta blocker|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|trental|antiarrhythmic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|antihypertensive drug|antidiabetic agent|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|antihypertensive drug|diuretic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|antihypertensive drug|digitali|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|antihypertensive drug|beta blocker|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|antihypertensive drug|antiarrhythmic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|diuretic|antidiabetic agent|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|diuretic|antidiabetic agent|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|digitali|antidiabetic agent|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|digitali|antidiabetic agent|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|beta blocker|antidiabetic agent|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|beta blocker|antidiabetic agent|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|antidiabetic agent|antiarrhythmic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|antidiabetic agent|antiarrhythmic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|digitali|diuretic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|digitali|diuretic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|beta blocker|diuretic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|beta blocker|diuretic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|diuretic|antiarrhythmic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|diuretic|antiarrhythmic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|beta blocker|digitali|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|beta blocker|digitali|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|digitali|antiarrhythmic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|digitali|antiarrhythmic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|beta blocker|antiarrhythmic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pentoxifylline|N|beta blocker|antiarrhythmic|TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
Pergolide|N|neuroleptic|dopamine agonist|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|phenothiazine|dopamine agonist|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|dopamine antagonist|dopamine agonist|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|metoclopramide|dopamine agonist|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|permax|dopamine agonist|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|butyrophenone|dopamine agonist|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|thioxanthine|dopamine agonist|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|neuroleptic|phenothiazine|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|dopamine antagonist|neuroleptic|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|neuroleptic|metoclopramide|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|neuroleptic|butyrophenone|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|neuroleptic|thioxanthine|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|dopamine antagonist|phenothiazine|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|phenothiazine|metoclopramide|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|phenothiazine|butyrophenone|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|phenothiazine|thioxanthine|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|dopamine antagonist|metoclopramide|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|dopamine antagonist|butyrophenone|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|dopamine antagonist|thioxanthine|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|butyrophenone|metoclopramide|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|thioxanthine|metoclopramide|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|butyrophenone|thioxanthine|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|N|pergolide mesylate|pergolide mesylate|Because pergolide mesylate is approximately 90 % bound to plasma proteins , caution should be exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding . 
Perindopril|N|diuretic|diuretic|Diuretics : Patients on diuretics , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of ACEON Tablets therapy . 
Perindopril|N|diuretic|aceon|Diuretics : Patients on diuretics , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of ACEON Tablets therapy . 
Perindopril|N|perindopril|diuretic|The rate and extent of perindopril absorption and elimination are not affected by concomitant diuretics . 
Perindopril|N|perindoprilat|diuretic|The bioavailability of perindoprilat was reduced by diuretics , however , and this was associated with a decrease in plasma ACE inhibition . 
Perindopril|N|potassium-sparing diuretic|aceon|Potassium Supplements and Potassium-Sparing Diuretics : ACEON Tablets may increase serum potassium because of its potential to decrease aldosterone production . 
Perindopril|N|potassium|potassium-sparing diuretic|Potassium Supplements and Potassium-Sparing Diuretics : ACEON Tablets may increase serum potassium because of its potential to decrease aldosterone production . 
Perindopril|N|potassium|aceon|Potassium Supplements and Potassium-Sparing Diuretics : ACEON Tablets may increase serum potassium because of its potential to decrease aldosterone production . 
Perindopril|N|potassium|indomethacin|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|potassium|indomethacin|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|amiloride|potassium|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|triamterene|potassium|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|potassium-sparing diuretic|potassium|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|spironolactone|potassium|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|potassium|heparin|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|potassium|heparin|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|potassium|cyclosporine|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|potassium|cyclosporine|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|amiloride|indomethacin|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|triamterene|indomethacin|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|potassium-sparing diuretic|indomethacin|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|spironolactone|indomethacin|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|indomethacin|heparin|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|indomethacin|cyclosporine|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|amiloride|triamterene|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|amiloride|triamterene|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|potassium-sparing diuretic|amiloride|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|spironolactone|amiloride|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|amiloride|heparin|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|amiloride|cyclosporine|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|potassium-sparing diuretic|triamterene|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|spironolactone|triamterene|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|triamterene|heparin|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|triamterene|cyclosporine|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|potassium-sparing diuretic|spironolactone|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|potassium-sparing diuretic|heparin|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|potassium-sparing diuretic|cyclosporine|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|spironolactone|heparin|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|spironolactone|cyclosporine|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|heparin|cyclosporine|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|heparin|cyclosporine|Use of potassium-sparing diuretics -LRB- spironolactone , amiloride , triamterene and others -RRB- , potassium supplements or other drugs capable of increasing serum potassium -LRB- indomethacin , heparin , cyclosporine and others -RRB- can increase the risk of hyperkalemia . 
Perindopril|N|lithium|lithium|Lithium : Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy . 
Perindopril|N|lithium|lithium|Lithium : Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy . 
Perindopril|N|lithium|lithium|Lithium : Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy . 
Perindopril|N|lithium|lithium|Lithium : Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy . 
Perindopril|N|lithium|lithium|Lithium : Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy . 
Perindopril|N|lithium|lithium|Lithium : Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy . 
Perindopril|N|diuretic|lithium|Use of a diuretic may further increase the risk of lithium toxicity . 
Perindopril|N|digoxin|digoxin|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|N|digoxin|digoxin|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|N|digoxin|aceon|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|N|digoxin|perindopril|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|N|digoxin|perindopril|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|N|digoxin|digoxin|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|N|digoxin|aceon|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|N|digoxin|perindopril|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|N|digoxin|perindopril|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|N|aceon|digoxin|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|N|aceon|perindopril|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|N|aceon|perindopril|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|N|perindopril|perindoprilat|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|N|gentamicin|gentamicin|Gentamicin : Animal data have suggested the possibility of interaction between perindopril and gentamicin . 
Perindopril|N|gentamicin|perindopril|Gentamicin : Animal data have suggested the possibility of interaction between perindopril and gentamicin . 
Perindopril|N|aceon|perindopril|Food Interaction : Oral administration of ACEON Tablets with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state . 
Perindopril|N|perindopril|perindoprilat|However , the extent of biotransformation of perindopril to the active metabolite , perindoprilat , is reduced approximately 43 % , resulting in a reduction in the plasma ACE inhibition curve of approximately 20 % , probably clinically insignificant . 
Phenylephrine|N|vasopressor|metaraminol|Vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all . 
Phenylephrine|N|mao inhibitor|sympathomimetic pressor amine|MAO Inhibitors : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors -LRB- MAOI-RRB-. 
Phenylephrine|N|mao inhibitor|monoamine oxidase inhibitor|MAO Inhibitors : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors -LRB- MAOI-RRB-. 
Phenylephrine|N|monoamine oxidase inhibitor|maoi|MAO Inhibitors : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors -LRB- MAOI-RRB-. 
Phenylephrine|N|mao inhibitor|maoi|MAO Inhibitors : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors -LRB- MAOI-RRB-. 
Phenylpropanolamine|N|vasopressor|metaraminol|Vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all . 
Phenylpropanolamine|N|mao inhibitor|sympathomimetic pressor amine|MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors -LRB- MAOI-RRB-. 
Phenylpropanolamine|N|mao inhibitor|monoamine oxidase inhibitor|MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors -LRB- MAOI-RRB-. 
Phenylpropanolamine|N|mao inhibitor|maoi|MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors -LRB- MAOI-RRB-. 
Phenylpropanolamine|N|monoamine oxidase inhibitor|maoi|MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors -LRB- MAOI-RRB-. 
Pilocarpine|N|atropine|ipratropium|These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication -LRB- e.g. , atropine , inhaled ipratropium -RRB-. 
Pilocarpine|N|acetylsalicylic acid|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|acetylsalicylic acid|conjugated estrogen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|acetylsalicylic acid|calcium|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|acetylsalicylic acid|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|acetylsalicylic acid|ibuprofen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|acetylsalicylic acid|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|acetylsalicylic acid|hydroxychloroquine sulfate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|acetylsalicylic acid|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|acetylsalicylic acid|medroxyprogesterone acetate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|acetylsalicylic acid|levothyroxine sodium|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|acetylsalicylic acid|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|acetylsalicylic acid|methotrexate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|naproxen|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|naproxen|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|naproxen|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|naproxen|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|naproxen|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|naproxen|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|medroxyprogesterone acetate|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|medroxyprogesterone acetate|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|multivitamin|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|multivitamin|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|methotrexate|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|methotrexate|naproxen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|conjugated estrogen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|conjugated estrogen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|ibuprofen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|ibuprofen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|hydroxychloroquine sulfate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|hydroxychloroquine sulfate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|medroxyprogesterone acetate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|medroxyprogesterone acetate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|levothyroxine sodium|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|levothyroxine sodium|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|methotrexate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|conjugated estrogen|methotrexate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|ibuprofen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|ibuprofen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|hydroxychloroquine sulfate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|hydroxychloroquine sulfate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|medroxyprogesterone acetate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|medroxyprogesterone acetate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|levothyroxine sodium|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|levothyroxine sodium|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|methotrexate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|calcium|methotrexate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|paracetamol|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|paracetamol|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|omeprazole|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|omeprazole|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|medroxyprogesterone acetate|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|medroxyprogesterone acetate|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|multivitamin|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|multivitamin|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|methotrexate|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|methotrexate|prednisone|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|ibuprofen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|ibuprofen|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|medroxyprogesterone acetate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|medroxyprogesterone acetate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|levothyroxine sodium|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|levothyroxine sodium|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|methotrexate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|ibuprofen|methotrexate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|omeprazole|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|omeprazole|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|medroxyprogesterone acetate|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|medroxyprogesterone acetate|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|multivitamin|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|multivitamin|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|methotrexate|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|methotrexate|paracetamol|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|medroxyprogesterone acetate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|medroxyprogesterone acetate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|levothyroxine sodium|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|levothyroxine sodium|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|methotrexate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|hydroxychloroquine sulfate|methotrexate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|medroxyprogesterone acetate|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|medroxyprogesterone acetate|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|multivitamin|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|multivitamin|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|methotrexate|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|methotrexate|omeprazole|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|medroxyprogesterone acetate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|medroxyprogesterone acetate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|medroxyprogesterone acetate|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|medroxyprogesterone acetate|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|medroxyprogesterone acetate|methotrexate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|medroxyprogesterone acetate|methotrexate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|methotrexate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|levothyroxine sodium|methotrexate|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|methotrexate|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pilocarpine|N|methotrexate|multivitamin|While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
Pindolol|N|hydrochlorothiazide|hydralazine|Pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions . 
Pindolol|N|pindolol|hydrochlorothiazide|Pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions . 
Pindolol|N|antihypertensive agent|hydrochlorothiazide|Pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions . 
Pindolol|N|hydrochlorothiazide|guanethidine|Pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions . 
Pindolol|N|pindolol|hydralazine|Pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions . 
Pindolol|N|antihypertensive agent|hydralazine|Pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions . 
Pindolol|N|hydralazine|guanethidine|Pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions . 
Pindolol|N|hydralazine|guanethidine|Pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions . 
Pindolol|N|pindolol|antihypertensive agent|Pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions . 
Pindolol|N|pindolol|guanethidine|Pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions . 
Pindolol|N|antihypertensive agent|guanethidine|Pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions . 
Piroxicam|N|coumarin-type anticoagulant|coumarin-type anticoagulant|Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 
Piroxicam|N|coumarin-type anticoagulant|feldene|Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 
Piroxicam|N|coumarin-type anticoagulant|coumarin-type anticoagulant|Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 
Piroxicam|N|coumarin-type anticoagulant|feldene|Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 
Piroxicam|N|coumarin-type anticoagulant|feldene|Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 
Piroxicam|N|coumarin-type anticoagulant|coumarin-type anticoagulant|Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 
Piroxicam|N|feldene|feldene|Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 
Piroxicam|N|feldene|coumarin-type anticoagulant|Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 
Piroxicam|N|piroxicam|aspirin|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|aspirin|nonsteroidal anti-inflammatory agent|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|aspirin|feldene|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|aspirin|antacid|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|aspirin|piroxicam|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|aspirin|lithium|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|piroxicam|feldene|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|feldene|nonsteroidal anti-inflammatory agent|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|feldene|feldene|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|feldene|antacid|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|feldene|piroxicam|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|feldene|lithium|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|piroxicam|nonsteroidal anti-inflammatory agent|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|piroxicam|feldene|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|piroxicam|antacid|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|piroxicam|piroxicam|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|piroxicam|lithium|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|nonsteroidal anti-inflammatory agent|feldene|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|antacid|nonsteroidal anti-inflammatory agent|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|piroxicam|nonsteroidal anti-inflammatory agent|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|antacid|feldene|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|piroxicam|feldene|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|antacid|piroxicam|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|antacid|lithium|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|N|piroxicam|lithium|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Pralidoxime|N|pralidoxime|atropine|When atropine and pralidoxime are used together , the signs of atropinization -LRB- flushing , mydriasis , tachycardia , dryness of the mouth and nose -RRB- may occur earlier than might be expected when atropine is used alone . 
Pralidoxime|N|atropine|atropine|When atropine and pralidoxime are used together , the signs of atropinization -LRB- flushing , mydriasis , tachycardia , dryness of the mouth and nose -RRB- may occur earlier than might be expected when atropine is used alone . 
Pralidoxime|N|atropine|pralidoxime|This is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed . 
Pralidoxime|N|pralidoxime|anticholinesterase|2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of pralidoxime : since barbiturates are potentiated by the anticholinesterases , they should be used cautiously in the treatment of convulsions ; 
Pralidoxime|N|pralidoxime|barbiturate|2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of pralidoxime : since barbiturates are potentiated by the anticholinesterases , they should be used cautiously in the treatment of convulsions ; 
Pralidoxime|N|succinylcholine|phenothiazine-type tranquilizer|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|reserpine|phenothiazine-type tranquilizer|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|theophylline|phenothiazine-type tranquilizer|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|aminophylline|phenothiazine-type tranquilizer|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|morphine|phenothiazine-type tranquilizer|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|succinylcholine|reserpine|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|succinylcholine|reserpine|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|theophylline|succinylcholine|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|theophylline|succinylcholine|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|aminophylline|succinylcholine|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|aminophylline|succinylcholine|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|morphine|succinylcholine|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|theophylline|reserpine|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|theophylline|reserpine|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|aminophylline|reserpine|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|aminophylline|reserpine|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|morphine|reserpine|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|theophylline|aminophylline|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|theophylline|aminophylline|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|morphine|theophylline|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pralidoxime|N|morphine|aminophylline|morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning . 
Pramipexole|N|carbidopa|levodopa|Carbidopa/Levodopa : Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers -LRB- N= 10 -RRB-. 
Pramipexole|N|carbidopa|levodopa|Carbidopa/Levodopa : Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers -LRB- N= 10 -RRB-. 
Pramipexole|N|carbidopa|pramipexole|Carbidopa/Levodopa : Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers -LRB- N= 10 -RRB-. 
Pramipexole|N|carbidopa|levodopa|Carbidopa/Levodopa : Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers -LRB- N= 10 -RRB-. 
Pramipexole|N|carbidopa|levodopa|Carbidopa/Levodopa : Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers -LRB- N= 10 -RRB-. 
Pramipexole|N|levodopa|pramipexole|Carbidopa/Levodopa : Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers -LRB- N= 10 -RRB-. 
Pramipexole|N|carbidopa|levodopa|Carbidopa/Levodopa : Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers -LRB- N= 10 -RRB-. 
Pramipexole|N|levodopa|pramipexole|Carbidopa/Levodopa : Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers -LRB- N= 10 -RRB-. 
Pramipexole|N|carbidopa|levodopa|Carbidopa/Levodopa : Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers -LRB- N= 10 -RRB-. 
Pramipexole|N|carbidopa|pramipexole|Carbidopa/Levodopa : Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers -LRB- N= 10 -RRB-. 
Pramipexole|N|selegiline|pramipexole|Selegiline : In healthy volunteers -LRB- N= 11 -RRB- , selegiline did not influence the pharmacokinetics of pramipexole . 
Pramipexole|N|selegiline|pramipexole|Selegiline : In healthy volunteers -LRB- N= 11 -RRB- , selegiline did not influence the pharmacokinetics of pramipexole . 
Pramipexole|N|selegiline|selegiline|Selegiline : In healthy volunteers -LRB- N= 11 -RRB- , selegiline did not influence the pharmacokinetics of pramipexole . 
Pramipexole|N|amantadine|pramipexole|Amantadine : Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole -LRB- N= 54 -RRB-. 
Pramipexole|N|amantadine|pramipexole|Amantadine : Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole -LRB- N= 54 -RRB-. 
Pramipexole|N|amantadine|amantadine|Amantadine : Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole -LRB- N= 54 -RRB-. 
Pramipexole|N|cimetidine|cimetidine|Cimetidine : Cimetidine , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in pramipexole AUC and a 40 % increase in half-life -LRB- N= 12 -RRB-. 
Pramipexole|N|cimetidine|pramipexole|Cimetidine : Cimetidine , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in pramipexole AUC and a 40 % increase in half-life -LRB- N= 12 -RRB-. 
Pramipexole|N|probenecid|pramipexole|Probenecid : Probenecid , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence pramipexole pharmacokinetics -LRB- N= 12 -RRB-. 
Pramipexole|N|probenecid|pramipexole|Probenecid : Probenecid , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence pramipexole pharmacokinetics -LRB- N= 12 -RRB-. 
Pramipexole|N|probenecid|probenecid|Probenecid : Probenecid , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence pramipexole pharmacokinetics -LRB- N= 12 -RRB-. 
Pramipexole|N|pramipexole|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cephalosporin|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinine|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinine|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cephalosporin|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|cephalosporin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cephalosporin|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cephalosporin|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|pramipexole|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|pramipexole|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|pramipexole|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|pramipexole|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|pramipexole|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinine|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinine|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|penicillin|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|penicillin|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|penicillin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|penicillin|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|penicillin|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|penicillin|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|penicillin|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|verapamil|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|verapamil|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|quinine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|quinine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|quinidine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|quinidine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|verapamil|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|verapamil|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|verapamil|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|verapamil|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|verapamil|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|verapamil|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|quinine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|quinine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|quinidine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|quinidine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|triamterene|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|triamterene|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|triamterene|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|triamterene|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|triamterene|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|triamterene|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|quinine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|quinine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|quinine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinine|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinine|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|quinine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|quinine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|quinine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|quinine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinine|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinine|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinine|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinine|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|quinidine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|quinidine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|quinidine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|quinidine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|quinidine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|quinidine|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|ranitidine|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|diltiazem|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|cimetidine|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|hydrochlorothiazide|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|hydrochlorothiazide|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|indomethacin|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|indomethacin|chlorpropamide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|diltiazem|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|diltiazem|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|ranitidine|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|diltiazem|indomethacin|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|indomethacin|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|indomethacin|hydrochlorothiazide|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|N|pramipexole|pramipexole|CYP interactions : Inhibitors of cytochrome P450 enzymes would not be expected to affect pramipexole elimination because pramipexole is not appreciably metabolized by these enzymes in vivo or in vitro . 
Pramipexole|N|dopamine agonist|dopamine antagonist|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|dopamine agonist|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|pramipexole|dopamine agonist|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine agonist|butyrophenone|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine agonist|thioxanthene|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine agonist|neuroleptic|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine agonist|phenothiazine|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine agonist|metoclopramide|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine agonist|mirapex|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|dopamine antagonist|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|pramipexole|dopamine antagonist|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|butyrophenone|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|thioxanthene|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|neuroleptic|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|phenothiazine|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|metoclopramide|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|pramipexole|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|butyrophenone|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|thioxanthene|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|neuroleptic|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|phenothiazine|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|metoclopramide|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|dopamine antagonist|mirapex|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|pramipexole|butyrophenone|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|pramipexole|thioxanthene|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|pramipexole|neuroleptic|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|pramipexole|phenothiazine|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|pramipexole|metoclopramide|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|pramipexole|mirapex|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|butyrophenone|thioxanthene|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|neuroleptic|butyrophenone|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|phenothiazine|butyrophenone|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|butyrophenone|metoclopramide|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|neuroleptic|thioxanthene|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|phenothiazine|thioxanthene|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|thioxanthene|metoclopramide|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|neuroleptic|phenothiazine|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|neuroleptic|metoclopramide|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|N|phenothiazine|metoclopramide|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramlintide|N|anticholinergic agent|atropine|Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility -LRB- e.g. , anticholinergic agents such as atropine -RRB- and agents that slow the intestinal absorption of nutrients -LRB- e.g. , alpha glucosidase inhibitors -RRB-. 
Pramlintide|N|atropine|alpha glucosidase inhibitor|Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility -LRB- e.g. , anticholinergic agents such as atropine -RRB- and agents that slow the intestinal absorption of nutrients -LRB- e.g. , alpha glucosidase inhibitors -RRB-. 
Pramlintide|N|atropine|alpha glucosidase inhibitor|Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility -LRB- e.g. , anticholinergic agents such as atropine -RRB- and agents that slow the intestinal absorption of nutrients -LRB- e.g. , alpha glucosidase inhibitors -RRB-. 
Pramlintide|N|anticholinergic agent|alpha glucosidase inhibitor|Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility -LRB- e.g. , anticholinergic agents such as atropine -RRB- and agents that slow the intestinal absorption of nutrients -LRB- e.g. , alpha glucosidase inhibitors -RRB-. 
Pramlintide|N|anticholinergic agent|alpha glucosidase inhibitor|Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility -LRB- e.g. , anticholinergic agents such as atropine -RRB- and agents that slow the intestinal absorption of nutrients -LRB- e.g. , alpha glucosidase inhibitors -RRB-. 
Pramlintide|N|biguanide|symlin|In clinical trials , the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN . 
Pramlintide|N|sulfonylurea|symlin|In clinical trials , the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN . 
Pramlintide|N|sulfonylurea|biguanide|In clinical trials , the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN . 
Pramlintide|N|symlin|antidiabetic agent|No formal interaction studies have been performed to assess the effect of SYMLIN on the kinetics of oral antidiabetic agents . 
Pramlintide|N|insulin|symlin|Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular , NPH , and 70/30 premixed formulations of recombinant human insulin immediately prior to injection . 
Pramlintide|N|insulin|human insulin|Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular , NPH , and 70/30 premixed formulations of recombinant human insulin immediately prior to injection . 
Pramlintide|N|symlin|insulin|Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular , NPH , and 70/30 premixed formulations of recombinant human insulin immediately prior to injection . 
Pramlintide|N|symlin|symlin|Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular , NPH , and 70/30 premixed formulations of recombinant human insulin immediately prior to injection . 
Pramlintide|N|symlin|human insulin|Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular , NPH , and 70/30 premixed formulations of recombinant human insulin immediately prior to injection . 
Pramlintide|N|symlin|insulin|Thus , SYMLIN and insulin should not be mixed and must be administered separately . 
Prednisone|N|phenytoin|rifampin|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|N|phenytoin|rifampin|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|N|phenobarbital|rifampin|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|N|phenobarbital|phenytoin|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|N|corticosteroid|corticosteroid|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|N|troleandomycin|ketoconazole|Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance . 
Prednisone|N|salicylate|corticosteroid|This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn . 
Prednisone|N|salicylate|salicylate|This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn . 
Procaine|N|procaine hydrochloride|anticholinesterase|Anticholinesterases : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 
Procaine|N|procaine hydrochloride|procaine hydrochloride|Anticholinesterases : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 
Procaine|N|anticholinesterase|procaine hydrochloride|Anticholinesterases : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 
Procaine|N|anticholinesterase agent|anticholinesterase|Anticholinesterases : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 
Procaine|N|anticholinesterase agent|procaine hydrochloride|Anticholinesterases : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 
Procaine|N|anticholinesterase|anticholinesterase agent|Anticholinesterases : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 
Procaine|N|anticholinesterase|anticholinesterase|Anticholinesterases : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 
Procaine|N|anticholinesterase|procaine hydrochloride|Anticholinesterases : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 
Procaine|N|cns depressant|cns depressant medication|CNS depressant medications : Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects . 
Procaine|N|cns depressant|procaine hydrochloride|CNS depressant medications : Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects . 
Procaine|N|hyaluronidase|hyaluronidase|Hyaluronidase : Hyaluronidase may increase the diffusion rate of procaine hydrochloride , resulting in a decreased time of onset , but an increase in systemic toxicity . 
Procaine|N|hyaluronidase|procaine hydrochloride|Hyaluronidase : Hyaluronidase may increase the diffusion rate of procaine hydrochloride , resulting in a decreased time of onset , but an increase in systemic toxicity . 
Procaine|N|neuromuscular blocking agent|neuromuscular blocking agent|Neuromuscular blocking agents -LRB- such as suxamethonium chloride -RRB- : Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade . 
Procaine|N|suxamethonium chloride|neuromuscular blocking agent|Neuromuscular blocking agents -LRB- such as suxamethonium chloride -RRB- : Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade . 
Procaine|N|neuromuscular blocking agent|procaine hydrochloride|Neuromuscular blocking agents -LRB- such as suxamethonium chloride -RRB- : Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade . 
Procaine|N|neuromuscular blocking agent|suxamethonium chloride|Neuromuscular blocking agents -LRB- such as suxamethonium chloride -RRB- : Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade . 
Procaine|N|suxamethonium chloride|procaine hydrochloride|Neuromuscular blocking agents -LRB- such as suxamethonium chloride -RRB- : Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade . 
Procaine|N|sulfonamide|sulfonamide|Sulfonamides : Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide . 
Procaine|N|procaine hydrochloride|sulfonamide|Sulfonamides : Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide . 
Procaine|N|sulfonamide|sulfonamide|Sulfonamides : Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide . 
Procaine|N|sulfonamide|sulfonamide|Sulfonamides : Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide . 
Procaine|N|sulfonamide|procaine hydrochloride|Sulfonamides : Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide . 
Procaine|N|acetazolamide|procaine hydrochloride|Acetazolamide : Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine . 
Procaine|N|acetazolamide|acetazolamide|Acetazolamide : Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine . 
Procaine|N|acetazolamide|procaine|Acetazolamide : Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine . 
Procaine|N|procaine hydrochloride|procaine|Acetazolamide : Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine . 
Procaine|N|acetazolamide|procaine|Acetazolamide : Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine . 
Procarbazine|N|hypotensive agent|phenothiazine|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|hypotensive agent|phenothiazine|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|antihistamine|phenothiazine|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|antihistamine|phenothiazine|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|narcotic|phenothiazine|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|narcotic|phenothiazine|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|barbiturate|phenothiazine|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|antihistamine|hypotensive agent|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|antihistamine|hypotensive agent|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|narcotic|hypotensive agent|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|narcotic|hypotensive agent|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|barbiturate|hypotensive agent|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|antihistamine|narcotic|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|antihistamine|narcotic|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|barbiturate|antihistamine|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|barbiturate|narcotic|To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution . 
Procarbazine|N|amitriptyline hcl|imipramine hcl|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|N|tricyclic antidepressant|imipramine hcl|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|N|sympathomimetic drug|imipramine hcl|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|N|imipramine hcl|tyramine|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|N|imipramine hcl|tyramine|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|N|tricyclic antidepressant|amitriptyline hcl|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|N|sympathomimetic drug|amitriptyline hcl|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|N|amitriptyline hcl|tyramine|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|N|amitriptyline hcl|tyramine|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|N|sympathomimetic drug|tricyclic antidepressant|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|N|tricyclic antidepressant|tyramine|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|N|tricyclic antidepressant|tyramine|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|N|sympathomimetic drug|tyramine|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|N|chemotherapeutic agent|steroid|No cross-resistance with other chemotherapeutic agents , radiotherapy or steroids has been demonstrated . 
Propofol|N|meperidine|fentanyl|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics -LRB- eg , morphine , meperidine , and fentanyl , etc .-RRB- 
Propofol|N|meperidine|fentanyl|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics -LRB- eg , morphine , meperidine , and fentanyl , etc .-RRB- 
Propofol|N|morphine|fentanyl|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics -LRB- eg , morphine , meperidine , and fentanyl , etc .-RRB- 
Propofol|N|morphine|fentanyl|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics -LRB- eg , morphine , meperidine , and fentanyl , etc .-RRB- 
Propofol|N|narcotic|fentanyl|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics -LRB- eg , morphine , meperidine , and fentanyl , etc .-RRB- 
Propofol|N|morphine|meperidine|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics -LRB- eg , morphine , meperidine , and fentanyl , etc .-RRB- 
Propofol|N|morphine|meperidine|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics -LRB- eg , morphine , meperidine , and fentanyl , etc .-RRB- 
Propofol|N|narcotic|meperidine|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics -LRB- eg , morphine , meperidine , and fentanyl , etc .-RRB- 
Propofol|N|narcotic|morphine|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics -LRB- eg , morphine , meperidine , and fentanyl , etc .-RRB- 
Propofol|N|opioid|barbiturate|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|opioid|chloral hydrate|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|opioid|sedative|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|opioid|benzodiazepine|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|opioid|droperidol|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|barbiturate|chloral hydrate|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|sedative|barbiturate|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|benzodiazepine|barbiturate|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|barbiturate|droperidol|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|sedative|chloral hydrate|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|benzodiazepine|chloral hydrate|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|chloral hydrate|droperidol|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|sedative|benzodiazepine|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|sedative|droperidol|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|benzodiazepine|droperidol|and combinations of opioids and sedatives -LRB- eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc .-RRB-. 
Propofol|N|analgesic agent|opioid|During maintenance of anesthesia or sedation , the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents -LRB- eg , nitrous oxide or opioids -RRB-. 
Propofol|N|nitrous oxide|opioid|During maintenance of anesthesia or sedation , the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents -LRB- eg , nitrous oxide or opioids -RRB-. 
Propofol|N|analgesic agent|nitrous oxide|During maintenance of anesthesia or sedation , the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents -LRB- eg , nitrous oxide or opioids -RRB-. 
Propofol|N|halothane|diprivan|The concurrent administration of potent inhalational agents -LRB- eg , isoflurane , enflurane , and halothane -RRB- during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 
Propofol|N|enflurane|diprivan|The concurrent administration of potent inhalational agents -LRB- eg , isoflurane , enflurane , and halothane -RRB- during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 
Propofol|N|isoflurane|diprivan|The concurrent administration of potent inhalational agents -LRB- eg , isoflurane , enflurane , and halothane -RRB- during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 
Propofol|N|enflurane|halothane|The concurrent administration of potent inhalational agents -LRB- eg , isoflurane , enflurane , and halothane -RRB- during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 
Propofol|N|enflurane|halothane|The concurrent administration of potent inhalational agents -LRB- eg , isoflurane , enflurane , and halothane -RRB- during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 
Propofol|N|isoflurane|halothane|The concurrent administration of potent inhalational agents -LRB- eg , isoflurane , enflurane , and halothane -RRB- during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 
Propofol|N|isoflurane|halothane|The concurrent administration of potent inhalational agents -LRB- eg , isoflurane , enflurane , and halothane -RRB- during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 
Propofol|N|isoflurane|enflurane|The concurrent administration of potent inhalational agents -LRB- eg , isoflurane , enflurane , and halothane -RRB- during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 
Propofol|N|isoflurane|enflurane|The concurrent administration of potent inhalational agents -LRB- eg , isoflurane , enflurane , and halothane -RRB- during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 
Propofol|N|diprivan|neuromuscular blocking agent|DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents -LRB- eg , succinylcholine and nondepolarizing muscle relaxants -RRB-. 
Propofol|N|neuromuscular blocking agent|succinylcholine|DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents -LRB- eg , succinylcholine and nondepolarizing muscle relaxants -RRB-. 
Propofol|N|neuromuscular blocking agent|nondepolarizing muscle relaxant|DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents -LRB- eg , succinylcholine and nondepolarizing muscle relaxants -RRB-. 
Propofol|N|diprivan|succinylcholine|DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents -LRB- eg , succinylcholine and nondepolarizing muscle relaxants -RRB-. 
Propofol|N|diprivan|nondepolarizing muscle relaxant|DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents -LRB- eg , succinylcholine and nondepolarizing muscle relaxants -RRB-. 
Propofol|N|succinylcholine|nondepolarizing muscle relaxant|DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents -LRB- eg , succinylcholine and nondepolarizing muscle relaxants -RRB-. 
Propofol|N|succinylcholine|nondepolarizing muscle relaxant|DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents -LRB- eg , succinylcholine and nondepolarizing muscle relaxants -RRB-. 
Propofol|N|analgesic agent|anesthetic agent|No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation -LRB- including a range of muscle relaxants , inhalational agents , analgesic agents , and local anesthetic agents -RRB- have been observed . 
Propofol|N|analgesic agent|anesthetic agent|No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation -LRB- including a range of muscle relaxants , inhalational agents , analgesic agents , and local anesthetic agents -RRB- have been observed . 
Propofol|N|muscle relaxant|anesthetic agent|No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation -LRB- including a range of muscle relaxants , inhalational agents , analgesic agents , and local anesthetic agents -RRB- have been observed . 
Propofol|N|muscle relaxant|analgesic agent|No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation -LRB- including a range of muscle relaxants , inhalational agents , analgesic agents , and local anesthetic agents -RRB- have been observed . 
Propoxyphene|N|cns depressant|alcohol|The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants , including alcohol . 
Propoxyphene|N|propoxyphene|antidepressant|Such occurrences have been reported when propoxyphene was administered to patients on antidepressants , anticonvulsants , or warfarin-like drugs . 
Propoxyphene|N|antidepressant|warfarin|Such occurrences have been reported when propoxyphene was administered to patients on antidepressants , anticonvulsants , or warfarin-like drugs . 
Propoxyphene|N|antidepressant|anticonvulsant|Such occurrences have been reported when propoxyphene was administered to patients on antidepressants , anticonvulsants , or warfarin-like drugs . 
Propoxyphene|N|propoxyphene|warfarin|Such occurrences have been reported when propoxyphene was administered to patients on antidepressants , anticonvulsants , or warfarin-like drugs . 
Propoxyphene|N|propoxyphene|anticonvulsant|Such occurrences have been reported when propoxyphene was administered to patients on antidepressants , anticonvulsants , or warfarin-like drugs . 
Propoxyphene|N|anticonvulsant|warfarin|Such occurrences have been reported when propoxyphene was administered to patients on antidepressants , anticonvulsants , or warfarin-like drugs . 
Propoxyphene|N|anticonvulsant|warfarin|Such occurrences have been reported when propoxyphene was administered to patients on antidepressants , anticonvulsants , or warfarin-like drugs . 
Pseudoephedrine|N|mao inhibitor|beta adrenergic blocker|MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine . 
Pseudoephedrine|N|methyldopa|mecamylamine|Sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids . 
Pseudoephedrine|N|methyldopa|reserpine|Sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids . 
Pseudoephedrine|N|methyldopa|veratrum alkaloid|Sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids . 
Pseudoephedrine|N|mecamylamine|reserpine|Sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids . 
Pseudoephedrine|N|mecamylamine|reserpine|Sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids . 
Pseudoephedrine|N|mecamylamine|veratrum alkaloid|Sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids . 
Pseudoephedrine|N|reserpine|veratrum alkaloid|Sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids . 
Pyrimethamine|N|pyrimethamine|sulfonamide|Pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics . 
Pyrimethamine|N|pyrimethamine|quinine|Pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics . 
Pyrimethamine|N|pyrimethamine|antimalarial|Pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics . 
Pyrimethamine|N|pyrimethamine|antibiotic|Pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics . 
Pyrimethamine|N|sulfonamide|quinine|Pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics . 
Pyrimethamine|N|sulfonamide|antimalarial|Pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics . 
Pyrimethamine|N|sulfonamide|antibiotic|Pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics . 
Pyrimethamine|N|quinine|antimalarial|Pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics . 
Pyrimethamine|N|quinine|antibiotic|Pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics . 
Pyrimethamine|N|antimalarial|antibiotic|Pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics . 
Pyrimethamine|N|folinic acid|leucovorin|Folinic acid -LRB- leucovorin -RRB- should be administered until normal hematopoiesis is restored . 
Raloxifene|N|raloxifene|evista|Cholestyramine : Cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA . 
Raloxifene|N|cholestyramine|raloxifene|Cholestyramine : Cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA . 
Raloxifene|N|cholestyramine|evista|Cholestyramine : Cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA . 
Raloxifene|N|cholestyramine|cholestyramine|Cholestyramine : Cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA . 
Raloxifene|N|cholestyramine|cholestyramine|Cholestyramine : Cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA . 
Raloxifene|N|warfarin|warfarin|Warfarin : The coadministration of EVISTA and warfarin has not been assessed under chronic conditions . 
Raloxifene|N|warfarin|evista|Warfarin : The coadministration of EVISTA and warfarin has not been assessed under chronic conditions . 
Raloxifene|N|evista|warfarin|Warfarin : The coadministration of EVISTA and warfarin has not been assessed under chronic conditions . 
Raloxifene|N|raloxifene|tamoxifen|In vitro , raloxifene did not affect the binding of warfarin , phenytoin , or tamoxifen . 
Raloxifene|N|warfarin|tamoxifen|In vitro , raloxifene did not affect the binding of warfarin , phenytoin , or tamoxifen . 
Raloxifene|N|phenytoin|tamoxifen|In vitro , raloxifene did not affect the binding of warfarin , phenytoin , or tamoxifen . 
Raloxifene|N|phenytoin|tamoxifen|In vitro , raloxifene did not affect the binding of warfarin , phenytoin , or tamoxifen . 
Raloxifene|N|raloxifene|warfarin|In vitro , raloxifene did not affect the binding of warfarin , phenytoin , or tamoxifen . 
Raloxifene|N|raloxifene|phenytoin|In vitro , raloxifene did not affect the binding of warfarin , phenytoin , or tamoxifen . 
Raloxifene|N|warfarin|phenytoin|In vitro , raloxifene did not affect the binding of warfarin , phenytoin , or tamoxifen . 
Raloxifene|N|clofibrate|indomethacin|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|clofibrate|naproxen|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|clofibrate|diazepam|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|clofibrate|ibuprofen|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|clofibrate|diazoxide|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|indomethacin|naproxen|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|indomethacin|diazepam|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|indomethacin|ibuprofen|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|indomethacin|diazoxide|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|naproxen|diazepam|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|naproxen|diazepam|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|naproxen|ibuprofen|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|naproxen|ibuprofen|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|naproxen|diazoxide|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|naproxen|diazoxide|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|ibuprofen|diazepam|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|ibuprofen|diazepam|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|diazepam|diazoxide|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|diazepam|diazoxide|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|ibuprofen|diazoxide|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|N|ibuprofen|diazoxide|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Ranitidine|N|clarithromycin|14- hydroxy- clarithromycin|Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations -LRB- 57 % -RRB- , increased plasma bismuth trough concentrations -LRB- 48 % -RRB- , and increased 14- hydroxy- clarithromycin plasma concentrations -LRB- 31%-RRB-. 
Ranitidine|N|clarithromycin|ranitidine|Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations -LRB- 57 % -RRB- , increased plasma bismuth trough concentrations -LRB- 48 % -RRB- , and increased 14- hydroxy- clarithromycin plasma concentrations -LRB- 31%-RRB-. 
Ranitidine|N|tritec|14- hydroxy- clarithromycin|Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations -LRB- 57 % -RRB- , increased plasma bismuth trough concentrations -LRB- 48 % -RRB- , and increased 14- hydroxy- clarithromycin plasma concentrations -LRB- 31%-RRB-. 
Ranitidine|N|tritec|ranitidine|Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations -LRB- 57 % -RRB- , increased plasma bismuth trough concentrations -LRB- 48 % -RRB- , and increased 14- hydroxy- clarithromycin plasma concentrations -LRB- 31%-RRB-. 
Ranitidine|N|ranitidine|14- hydroxy- clarithromycin|Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations -LRB- 57 % -RRB- , increased plasma bismuth trough concentrations -LRB- 48 % -RRB- , and increased 14- hydroxy- clarithromycin plasma concentrations -LRB- 31%-RRB-. 
Ranitidine|N|aspirin|salicylate|Coadministration with aspirin results in a slight decrease in the rate of salicylate absorption that is clinically unimportant . 
Ranitidine|N|ranitidine|tritec|Coadministration with a high dose of antacid -LRB- 170 mEq -RRB- results in a 28 % decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC . 
Ranitidine|N|ranitidine|zantac|For information on drug interactions associated with ranitidine , refer to the ZANTAC package insert . 
Retapamulin|N|ketoconazole|retapamulin|Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC -LRB- 0-24 -RRB- and Cmax by 81 % after topical application of retapamulin ointment , 1 % on the abraded skin of healthy adult males . 
Retapamulin|N|retapamulin|retapamulin|Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC -LRB- 0-24 -RRB- and Cmax by 81 % after topical application of retapamulin ointment , 1 % on the abraded skin of healthy adult males . 
Retapamulin|N|retapamulin|retapamulin|Due to low systemic exposure to retapamulin following topical application in patients , dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors , such as ketoconazole . 
Retapamulin|N|retapamulin|ketoconazole|Due to low systemic exposure to retapamulin following topical application in patients , dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors , such as ketoconazole . 
Retapamulin|N|retapamulin|ketoconazole|Due to low systemic exposure to retapamulin following topical application in patients , dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors , such as ketoconazole . 
Retapamulin|N|altabax|retapamulin|Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of ALTABAX , retapamulin is unlikely to affect the metabolism of other P450 substrates . 
Reteplase|N|heparin|abciximab|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|heparin|abciximab|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|vitamin k antagonist|abciximab|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|vitamin k antagonist|abciximab|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|aspirin|abciximab|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|dipyridamole|abciximab|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|dipyridamole|abciximab|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|heparin|vitamin k antagonist|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|heparin|aspirin|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|heparin|aspirin|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|heparin|dipyridamole|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|heparin|dipyridamole|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|vitamin k antagonist|aspirin|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|vitamin k antagonist|aspirin|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|vitamin k antagonist|dipyridamole|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|vitamin k antagonist|dipyridamole|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|N|aspirin|dipyridamole|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Riboflavin|N|riboflavin|riboflavin|Interactions for Vitamin B2 -LRB- Riboflavin -RRB- : Alcohol - impairs the intestinal absorption of riboflavin 
Riboflavin|N|vitamin b2|riboflavin|Interactions for Vitamin B2 -LRB- Riboflavin -RRB- : Alcohol - impairs the intestinal absorption of riboflavin 
Riboflavin|N|riboflavin|alcohol|Interactions for Vitamin B2 -LRB- Riboflavin -RRB- : Alcohol - impairs the intestinal absorption of riboflavin 
Riboflavin|N|vitamin b2|alcohol|Interactions for Vitamin B2 -LRB- Riboflavin -RRB- : Alcohol - impairs the intestinal absorption of riboflavin 
Riboflavin|N|vitamin b2|riboflavin|Interactions for Vitamin B2 -LRB- Riboflavin -RRB- : Alcohol - impairs the intestinal absorption of riboflavin 
Rimantadine|N|cimetidine|rimantadine|Cimetidine : The effects of chronic cimetidine use on the metabolism of rimantadine are not known . 
Rimantadine|N|cimetidine|rimantadine|Cimetidine : The effects of chronic cimetidine use on the metabolism of rimantadine are not known . 
Rimantadine|N|cimetidine|cimetidine|Cimetidine : The effects of chronic cimetidine use on the metabolism of rimantadine are not known . 
Rimantadine|N|cimetidine|rimantadine|When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine -LRB- 300 mg four times a day -RRB- , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % -LRB- compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine -RRB-. 
Rimantadine|N|cimetidine|cimetidine|When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine -LRB- 300 mg four times a day -RRB- , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % -LRB- compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine -RRB-. 
Rimantadine|N|cimetidine|rimantadine|When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine -LRB- 300 mg four times a day -RRB- , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % -LRB- compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine -RRB-. 
Rimantadine|N|rimantadine hcl|rimantadine|When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine -LRB- 300 mg four times a day -RRB- , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % -LRB- compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine -RRB-. 
Rimantadine|N|rimantadine|cimetidine|When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine -LRB- 300 mg four times a day -RRB- , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % -LRB- compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine -RRB-. 
Rimantadine|N|rimantadine|rimantadine|When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine -LRB- 300 mg four times a day -RRB- , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % -LRB- compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine -RRB-. 
Rimantadine|N|rimantadine hcl|cimetidine|When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine -LRB- 300 mg four times a day -RRB- , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % -LRB- compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine -RRB-. 
Rimantadine|N|rimantadine hcl|rimantadine|When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine -LRB- 300 mg four times a day -RRB- , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % -LRB- compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine -RRB-. 
Rimantadine|N|rimantadine|cimetidine|When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine -LRB- 300 mg four times a day -RRB- , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % -LRB- compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine -RRB-. 
Rimantadine|N|acetaminophen|rimantadine hcl|Acetaminophen : Rimantadine HCl , 100 mg , was given twice daily for 13 days to 12 healthy volunteers . 
Rimantadine|N|aspirin|rimantadine hcl|Aspirin : Rimantadine HCl , 100 mg , was given twice daily fro 13 days to 12 healthy volunteers . 
Rivastigmine|N|exelon|rivastigmine tartrate|Drug-Drug Interactions Effect of Exelon -LRB- rivastigmine tartrate -RRB- on the Metabolism of Other Drugs : Rivastigmine is primarily metabolized through hydrolysis by esterases . 
Rivastigmine|N|rivastigmine tartrate|rivastigmine|Drug-Drug Interactions Effect of Exelon -LRB- rivastigmine tartrate -RRB- on the Metabolism of Other Drugs : Rivastigmine is primarily metabolized through hydrolysis by esterases . 
Rivastigmine|N|exelon|rivastigmine|Drug-Drug Interactions Effect of Exelon -LRB- rivastigmine tartrate -RRB- on the Metabolism of Other Drugs : Rivastigmine is primarily metabolized through hydrolysis by esterases . 
Rivastigmine|N|digoxin|warfarin|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|digoxin|warfarin|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|digoxin|diazepam|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|digoxin|diazepam|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|digoxin|fluoxetine|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|digoxin|fluoxetine|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|rivastigmine|digoxin|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|warfarin|diazepam|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|warfarin|diazepam|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|warfarin|fluoxetine|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|warfarin|fluoxetine|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|rivastigmine|warfarin|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|diazepam|fluoxetine|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|diazepam|fluoxetine|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|rivastigmine|diazepam|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|rivastigmine|fluoxetine|No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
Rivastigmine|N|warfarin|exelon|The elevation of prothrombin time induced by warfarin is not affected by administration of Exelon . 
Rivastigmine|N|exelon|rivastigmine|Effect of Other Drugs on the Metabolism of Exelon : Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of rivastigmine . 
Rivastigmine|N|warfarin|diazepam|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine . 
Rivastigmine|N|warfarin|diazepam|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine . 
Rivastigmine|N|digoxin|diazepam|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine . 
Rivastigmine|N|rivastigmine|diazepam|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine . 
Rivastigmine|N|diazepam|fluoxetine|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine . 
Rivastigmine|N|diazepam|fluoxetine|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine . 
Rivastigmine|N|digoxin|warfarin|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine . 
Rivastigmine|N|rivastigmine|warfarin|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine . 
Rivastigmine|N|warfarin|fluoxetine|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine . 
Rivastigmine|N|warfarin|fluoxetine|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine . 
Rivastigmine|N|rivastigmine|digoxin|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine . 
Rivastigmine|N|digoxin|fluoxetine|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine . 
Rivastigmine|N|rivastigmine|fluoxetine|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine . 
Rivastigmine|N|salicylate analgesic|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|salicylate analgesic|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|nonsteroidal anti-inflammatory drug|salicylate analgesic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|nonsteroidal anti-inflammatory drug|salicylate analgesic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|estrogen|salicylate analgesic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|estrogen|salicylate analgesic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|salicylate analgesic|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|salicylate analgesic|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|rivastigmine|salicylate analgesic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|calcium channel blocker|salicylate analgesic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|calcium channel blocker|salicylate analgesic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antidiabetic|salicylate analgesic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antidiabetic|salicylate analgesic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antacid|salicylate analgesic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|salicylate analgesic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|salicylate analgesic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|nonsteroidal anti-inflammatory drug|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|nonsteroidal anti-inflammatory drug|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|estrogen|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|estrogen|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antianginal|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antianginal|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|rivastigmine|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|calcium channel blocker|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|calcium channel blocker|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antidiabetic|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antidiabetic|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antacid|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|antianginal|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|nonsteroidal anti-inflammatory drug|estrogen|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|nonsteroidal anti-inflammatory drug|estrogen|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|nonsteroidal anti-inflammatory drug|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|nonsteroidal anti-inflammatory drug|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|rivastigmine|nonsteroidal anti-inflammatory drug|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|calcium channel blocker|nonsteroidal anti-inflammatory drug|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|calcium channel blocker|nonsteroidal anti-inflammatory drug|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antidiabetic|nonsteroidal anti-inflammatory drug|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antidiabetic|nonsteroidal anti-inflammatory drug|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antacid|nonsteroidal anti-inflammatory drug|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|nonsteroidal anti-inflammatory drug|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|nonsteroidal anti-inflammatory drug|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|estrogen|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|estrogen|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|rivastigmine|estrogen|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|calcium channel blocker|estrogen|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|calcium channel blocker|estrogen|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antidiabetic|estrogen|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antidiabetic|estrogen|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antacid|estrogen|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|estrogen|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|estrogen|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|rivastigmine|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|calcium channel blocker|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|calcium channel blocker|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antidiabetic|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antidiabetic|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antacid|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|antihistamine|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|rivastigmine|calcium channel blocker|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|rivastigmine|antidiabetic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|rivastigmine|antacid|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|rivastigmine|antihypertensive|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|calcium channel blocker|antidiabetic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|calcium channel blocker|antidiabetic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antacid|calcium channel blocker|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|calcium channel blocker|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|calcium channel blocker|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antacid|antidiabetic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|antidiabetic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antihypertensive|antidiabetic|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|antacid|antihypertensive|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids -LRB- n=77 -RRB- , antihypertensives -LRB- n=72 -RRB- , calcium channel blockers -LRB- n=75 -RRB- , antidiabetics -LRB- n=21 -RRB- , nonsteroidal anti-inflammatory drugs -LRB- n=79 -RRB- , estrogens -LRB- n=70 -RRB- , salicylate analgesics -LRB- n=177 -RRB- , antianginals -LRB- n=35 -RRB- , and antihistamines -LRB- n=15-RRB-. 
Rivastigmine|N|anticholinergic|anticholinergic medication|Use with Anticholinergics : Because of their mechanism of action , cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications . 
Rivastigmine|N|anticholinergic|cholinesterase inhibitor|Use with Anticholinergics : Because of their mechanism of action , cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications . 
Rivastigmine|N|cholinesterase inhibitor|cholinesterase inhibitor|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|cholinomimetic|cholinesterase inhibitor|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|cholinomimetic|cholinesterase inhibitor|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|cholinesterase inhibitor|bethanechol|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|cholinesterase inhibitor|cholinergic agonist|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|cholinesterase inhibitor|neuromuscular blocking agent|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|cholinesterase inhibitor|succinylcholine|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|cholinomimetic|bethanechol|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|cholinomimetic|cholinergic agonist|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|cholinomimetic|neuromuscular blocking agent|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|cholinomimetic|succinylcholine|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|cholinergic agonist|bethanechol|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|neuromuscular blocking agent|bethanechol|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|succinylcholine|bethanechol|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|neuromuscular blocking agent|cholinergic agonist|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|succinylcholine|cholinergic agonist|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|N|succinylcholine|neuromuscular blocking agent|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rocuronium|N|zemuron|rocuronium bromide|Drug Interactions : The use of ZEMURON -LRB- rocuronium bromide -RRB- Injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied . 
Rocuronium|N|zemuron|succinylcholine|Drug Interactions : The use of ZEMURON -LRB- rocuronium bromide -RRB- Injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied . 
Rocuronium|N|zemuron|succinylcholine|Drug Interactions : The use of ZEMURON -LRB- rocuronium bromide -RRB- Injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied . 
Rocuronium|N|rocuronium bromide|succinylcholine|Drug Interactions : The use of ZEMURON -LRB- rocuronium bromide -RRB- Injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied . 
Rocuronium|N|rocuronium bromide|succinylcholine|Drug Interactions : The use of ZEMURON -LRB- rocuronium bromide -RRB- Injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied . 
Rocuronium|N|succinylcholine|succinylcholine|Drug Interactions : The use of ZEMURON -LRB- rocuronium bromide -RRB- Injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied . 
Rocuronium|N|zemuron|succinylcholine|If ZEMURON is administered following administration of succinylcholine , it should not be given until recovery from succinylcholine has been observed . 
Rocuronium|N|succinylcholine|succinylcholine|If ZEMURON is administered following administration of succinylcholine , it should not be given until recovery from succinylcholine has been observed . 
Rocuronium|N|zemuron|succinylcholine|The median duration of action of ZEMURON 0.6 mg/kg administered after a 1 mg/kg dose of succinylcholine when T 1 returned to 75 % of control was 36 minutes -LRB- range 14-57 , n=12 -RRB- vs . 
Rocuronium|N|zemuron|nondepolarizing muscle relaxant|There are no controlled studies documenting the use of ZEMURON before or after other nondepolarizing muscle relaxants . 
Ropivacaine|N|ropivacaine|amide-type local anesthetic|Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics , since the toxic effects of these drugs are additive . 
Ropivacaine|N|anesthetic|amide-type local anesthetic|Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics , since the toxic effects of these drugs are additive . 
Ropivacaine|N|ropivacaine|ropivacaine|Thus strong inhibitors of cytochrome P4501A2 , such as fluvoxamine , given concomitantly during administration of Ropivacaine , can interact with Ropivacaine leading to increased ropivacaine plasma levels . 
Ropivacaine|N|ropivacaine|ropivacaine|Thus strong inhibitors of cytochrome P4501A2 , such as fluvoxamine , given concomitantly during administration of Ropivacaine , can interact with Ropivacaine leading to increased ropivacaine plasma levels . 
Ropivacaine|N|fluvoxamine|ropivacaine|Thus strong inhibitors of cytochrome P4501A2 , such as fluvoxamine , given concomitantly during administration of Ropivacaine , can interact with Ropivacaine leading to increased ropivacaine plasma levels . 
Ropivacaine|N|fluvoxamine|ropivacaine|Thus strong inhibitors of cytochrome P4501A2 , such as fluvoxamine , given concomitantly during administration of Ropivacaine , can interact with Ropivacaine leading to increased ropivacaine plasma levels . 
Ropivacaine|N|ropivacaine|ropivacaine|Thus strong inhibitors of cytochrome P4501A2 , such as fluvoxamine , given concomitantly during administration of Ropivacaine , can interact with Ropivacaine leading to increased ropivacaine plasma levels . 
Ropivacaine|N|theophylline|imipramine|Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur . 
Ropivacaine|N|ketoconazole|ropivacaine|Coadministration of a selective and potent inhibitor of CYP3A4 , ketoconazole -LRB- 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole -RRB- caused a 15 % reduction in in-vivo plasma clearance of ropivacaine . 
Ropivacaine|N|ketoconazole|ketoconazole|Coadministration of a selective and potent inhibitor of CYP3A4 , ketoconazole -LRB- 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole -RRB- caused a 15 % reduction in in-vivo plasma clearance of ropivacaine . 
Ropivacaine|N|ropivacaine|ropivacaine|Coadministration of a selective and potent inhibitor of CYP3A4 , ketoconazole -LRB- 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole -RRB- caused a 15 % reduction in in-vivo plasma clearance of ropivacaine . 
Ropivacaine|N|ketoconazole|ropivacaine|Coadministration of a selective and potent inhibitor of CYP3A4 , ketoconazole -LRB- 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole -RRB- caused a 15 % reduction in in-vivo plasma clearance of ropivacaine . 
Ropivacaine|N|ropivacaine|ketoconazole|Coadministration of a selective and potent inhibitor of CYP3A4 , ketoconazole -LRB- 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole -RRB- caused a 15 % reduction in in-vivo plasma clearance of ropivacaine . 
Rosiglitazone|N|gemfibrozil|rosiglitazone|An inhibitor of CYP2C8 -LRB- such as gemfibrozil -RRB- may increase the AUC of rosiglitazone and an inducer of CYP2C8 -LRB- such as rifampin -RRB- may decrease the AUC of rosiglitazone . 
Rosiglitazone|N|gemfibrozil|rifampin|An inhibitor of CYP2C8 -LRB- such as gemfibrozil -RRB- may increase the AUC of rosiglitazone and an inducer of CYP2C8 -LRB- such as rifampin -RRB- may decrease the AUC of rosiglitazone . 
Rosiglitazone|N|rosiglitazone|rosiglitazone|An inhibitor of CYP2C8 -LRB- such as gemfibrozil -RRB- may increase the AUC of rosiglitazone and an inducer of CYP2C8 -LRB- such as rifampin -RRB- may decrease the AUC of rosiglitazone . 
Rosiglitazone|N|rosiglitazone|rifampin|An inhibitor of CYP2C8 -LRB- such as gemfibrozil -RRB- may increase the AUC of rosiglitazone and an inducer of CYP2C8 -LRB- such as rifampin -RRB- may decrease the AUC of rosiglitazone . 
Roxithromycin|N|terfenadine|macrolide|Concomitant administrations not recommended : - Terfenadine and astemizole : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 
Roxithromycin|N|terfenadine|astemizole|Concomitant administrations not recommended : - Terfenadine and astemizole : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 
Roxithromycin|N|terfenadine|astemizole|Concomitant administrations not recommended : - Terfenadine and astemizole : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 
Roxithromycin|N|terfenadine|terfenadine|Concomitant administrations not recommended : - Terfenadine and astemizole : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 
Roxithromycin|N|astemizole|macrolide|Concomitant administrations not recommended : - Terfenadine and astemizole : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 
Roxithromycin|N|astemizole|astemizole|Concomitant administrations not recommended : - Terfenadine and astemizole : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 
Roxithromycin|N|astemizole|terfenadine|Concomitant administrations not recommended : - Terfenadine and astemizole : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 
Roxithromycin|N|terfenadine|astemizole|Concomitant administrations not recommended : - Terfenadine and astemizole : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 
Roxithromycin|N|roxithromycin|terfenadine|Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with terfenadine or astemizole is not recommended . 
Roxithromycin|N|roxithromycin|roxithromycin|Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with terfenadine or astemizole is not recommended . 
Roxithromycin|N|roxithromycin|astemizole|Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with terfenadine or astemizole is not recommended . 
Roxithromycin|N|terfenadine|astemizole|Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with terfenadine or astemizole is not recommended . 
Roxithromycin|N|pimozide|macrolide antibacterial|- Cisapride , pimozide : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias -LRB- typically torsades de pointe -RRB- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
Roxithromycin|N|cisapride|macrolide antibacterial|- Cisapride , pimozide : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias -LRB- typically torsades de pointe -RRB- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
Roxithromycin|N|cisapride|pimozide|- Cisapride , pimozide : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias -LRB- typically torsades de pointe -RRB- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
Roxithromycin|N|pimozide|pimozide|- Cisapride , pimozide : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias -LRB- typically torsades de pointe -RRB- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
Roxithromycin|N|cisapride|pimozide|- Cisapride , pimozide : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias -LRB- typically torsades de pointe -RRB- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
Roxithromycin|N|pimozide|cisapride|- Cisapride , pimozide : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias -LRB- typically torsades de pointe -RRB- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
Roxithromycin|N|cisapride|cisapride|- Cisapride , pimozide : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias -LRB- typically torsades de pointe -RRB- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
Roxithromycin|N|cisapride|pimozide|- Cisapride , pimozide : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias -LRB- typically torsades de pointe -RRB- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
Roxithromycin|N|roxithromycin|roxithromycin|Although such a risk is not verified for roxithromycin , combination of roxithromycin with such drugs is not recommended . 
Salsalate|N|salicylate drug|salicylic acid|ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS . 
Salsalate|N|salicylate drug|salicylic acid|ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS . 
Salsalate|N|aspirin|salicylate drug|ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS . 
Salsalate|N|disalcid|salicylic acid|ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS . 
Salsalate|N|aspirin|salicylic acid|ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS . 
Salsalate|N|penicillin|thyroxine|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|penicillin|thiopental|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|penicillin|phenytoin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|penicillin|triiodothyronine|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|penicillin|naproxen|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|penicillin|sulfinpyrazone|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|penicillin|corticosteroid|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|penicillin|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|penicillin|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|thyroxine|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|thyroxine|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thyroxine|phenytoin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thyroxine|phenytoin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thyroxine|triiodothyronine|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thyroxine|triiodothyronine|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thyroxine|naproxen|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thyroxine|naproxen|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thyroxine|sulfinpyrazone|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thyroxine|sulfinpyrazone|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thyroxine|corticosteroid|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thyroxine|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thyroxine|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thyroxine|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thyroxine|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|phenytoin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|phenytoin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|triiodothyronine|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|triiodothyronine|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|naproxen|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|naproxen|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|sulfinpyrazone|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|sulfinpyrazone|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|corticosteroid|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|thiopental|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|triiodothyronine|phenytoin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|triiodothyronine|phenytoin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|phenytoin|naproxen|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|phenytoin|naproxen|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|phenytoin|sulfinpyrazone|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|phenytoin|sulfinpyrazone|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|phenytoin|corticosteroid|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|phenytoin|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|phenytoin|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|phenytoin|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|phenytoin|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|triiodothyronine|naproxen|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|triiodothyronine|naproxen|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|triiodothyronine|sulfinpyrazone|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|triiodothyronine|sulfinpyrazone|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|triiodothyronine|corticosteroid|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|triiodothyronine|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|triiodothyronine|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|triiodothyronine|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|triiodothyronine|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|sulfinpyrazone|naproxen|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|sulfinpyrazone|naproxen|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|naproxen|corticosteroid|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|naproxen|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|naproxen|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|naproxen|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|naproxen|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|sulfinpyrazone|corticosteroid|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|sulfinpyrazone|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|sulfinpyrazone|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|sulfinpyrazone|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|sulfinpyrazone|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|methotrexate|corticosteroid|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|warfarin|corticosteroid|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|warfarin|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|N|warfarin|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Sargramostim|N|lithium|corticosteroid|Drugs which may potentiate the myeloproliferative effects of Leukine , such as lithium and corticosteroids , should be used with caution . 
Scopolamine|N|tranquilizer|alcohol|Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or alcohol . 
Scopolamine|N|tranquilizer|alcohol|Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or alcohol . 
Scopolamine|N|sedative|tranquilizer|Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or alcohol . 
Scopolamine|N|sedative|alcohol|Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or alcohol . 
Scopolamine|N|belladonna alkaloid|antihistamine|e.g. , other belladonna alkaloids , antihistamines -LRB- including meclizine -RRB- , tricyclic antidepressants , and muscle relaxants . 
Scopolamine|N|antihistamine|muscle relaxant|e.g. , other belladonna alkaloids , antihistamines -LRB- including meclizine -RRB- , tricyclic antidepressants , and muscle relaxants . 
Scopolamine|N|antihistamine|tricyclic antidepressant|e.g. , other belladonna alkaloids , antihistamines -LRB- including meclizine -RRB- , tricyclic antidepressants , and muscle relaxants . 
Scopolamine|N|antihistamine|meclizine|e.g. , other belladonna alkaloids , antihistamines -LRB- including meclizine -RRB- , tricyclic antidepressants , and muscle relaxants . 
Scopolamine|N|belladonna alkaloid|muscle relaxant|e.g. , other belladonna alkaloids , antihistamines -LRB- including meclizine -RRB- , tricyclic antidepressants , and muscle relaxants . 
Scopolamine|N|belladonna alkaloid|tricyclic antidepressant|e.g. , other belladonna alkaloids , antihistamines -LRB- including meclizine -RRB- , tricyclic antidepressants , and muscle relaxants . 
Scopolamine|N|belladonna alkaloid|meclizine|e.g. , other belladonna alkaloids , antihistamines -LRB- including meclizine -RRB- , tricyclic antidepressants , and muscle relaxants . 
Scopolamine|N|tricyclic antidepressant|muscle relaxant|e.g. , other belladonna alkaloids , antihistamines -LRB- including meclizine -RRB- , tricyclic antidepressants , and muscle relaxants . 
Scopolamine|N|meclizine|muscle relaxant|e.g. , other belladonna alkaloids , antihistamines -LRB- including meclizine -RRB- , tricyclic antidepressants , and muscle relaxants . 
Scopolamine|N|meclizine|tricyclic antidepressant|e.g. , other belladonna alkaloids , antihistamines -LRB- including meclizine -RRB- , tricyclic antidepressants , and muscle relaxants . 
Secobarbital|N|corticosteroid|anticoagulant|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|corticosteroid|anticoagulant|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|anticoagulant|beta blocker|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|anticoagulant|beta blocker|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|antibiotic|anticoagulant|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|antibiotic|anticoagulant|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|contraceptive|anticoagulant|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|theophylline|anticoagulant|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|theophylline|anticoagulant|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|quinidine|anticoagulant|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|quinidine|anticoagulant|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|corticosteroid|beta blocker|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|corticosteroid|beta blocker|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|antibiotic|corticosteroid|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|antibiotic|corticosteroid|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|contraceptive|corticosteroid|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|theophylline|corticosteroid|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|theophylline|corticosteroid|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|quinidine|corticosteroid|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|quinidine|corticosteroid|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|antibiotic|beta blocker|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|antibiotic|beta blocker|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|contraceptive|beta blocker|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|theophylline|beta blocker|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|theophylline|beta blocker|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|quinidine|beta blocker|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|quinidine|beta blocker|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|contraceptive|antibiotic|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|antibiotic|theophylline|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|antibiotic|theophylline|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|antibiotic|quinidine|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|antibiotic|quinidine|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|contraceptive|theophylline|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|contraceptive|quinidine|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|quinidine|theophylline|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|N|quinidine|theophylline|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Selegiline|N|eldepryl|eldepryl|Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL . 
Selegiline|N|tricyclic antidepressant|eldepryl|Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL . 
Selegiline|N|eldepryl|selective serotonin reuptake inhibitor|Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL . 
Selegiline|N|tricyclic antidepressant|selective serotonin reuptake inhibitor|Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL . 
Selegiline|N|sympathomimetic medication|ephedrine|One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication -LRB- ephedrine-RRB-. 
Sitagliptin|N|digoxin|sitagliptin|Digoxin : There was a slight increase in the area under the curve -LRB- AUC , 11 % -RRB- and mean peak drug concentration -LRB- Cmax , 18 % -RRB- of digoxin with the co-administration of 100 mg sitagliptin for 10 days . 
Sitagliptin|N|digoxin|digoxin|Digoxin : There was a slight increase in the area under the curve -LRB- AUC , 11 % -RRB- and mean peak drug concentration -LRB- Cmax , 18 % -RRB- of digoxin with the co-administration of 100 mg sitagliptin for 10 days . 
Sitagliptin|N|digoxin|januvia|No dosage adjustment of digoxin or JANUVIA is recommended . 
Sodium bicarbonate|N|norepinephrine|dobutamine|norepinephrine and dobutamine are incompatible with sodium bicarbonate solution . 
Sodium bicarbonate|N|sodium bicarbonate|calcium|The addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided , except where compatibility has been previously established . 
Solifenacin|N|solifenacin|solifenacin|Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women , the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg -LRB- three times the maximum recommended dose -RRB- , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose . 
Solifenacin|N|solifenacin|solifenacin|Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women , the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg -LRB- three times the maximum recommended dose -RRB- , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose . 
Solifenacin|N|solifenacin|moxifloxacin|Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women , the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg -LRB- three times the maximum recommended dose -RRB- , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose . 
Solifenacin|N|solifenacin|solifenacin|Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women , the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg -LRB- three times the maximum recommended dose -RRB- , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose . 
Solifenacin|N|solifenacin|moxifloxacin|Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women , the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg -LRB- three times the maximum recommended dose -RRB- , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose . 
Solifenacin|N|solifenacin|solifenacin|Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women , the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg -LRB- three times the maximum recommended dose -RRB- , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose . 
Solifenacin|N|solifenacin|moxifloxacin|Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women , the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg -LRB- three times the maximum recommended dose -RRB- , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose . 
Somatropin recombinant|N|glucocorticoid|glucocorticoid|If glucocorticoid replacement is required , the glucocorticoid dose should be carefully adjusted . 
Somatropin recombinant|N|corticosteroid|sex steroid|These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes -LRB- e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin -RRB-. 
Somatropin recombinant|N|corticosteroid|anticonvulsant|These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes -LRB- e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin -RRB-. 
Somatropin recombinant|N|corticosteroid|cyclosporin|These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes -LRB- e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin -RRB-. 
Somatropin recombinant|N|sex steroid|anticonvulsant|These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes -LRB- e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin -RRB-. 
Somatropin recombinant|N|sex steroid|cyclosporin|These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes -LRB- e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin -RRB-. 
Somatropin recombinant|N|anticonvulsant|cyclosporin|These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes -LRB- e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin -RRB-. 
Stavudine|N|doxorubicin|ribavirin|In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin . 
Streptokinase|N|streptase|streptokinase|The interaction of Streptase , Streptokinase , with other drugs has not been well studied . 
Streptokinase|N|streptase|streptokinase|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|N|antiplatelet agent|streptase|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|N|anticoagulant|streptase|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|N|antiplatelet agent|streptokinase|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|N|anticoagulant|streptokinase|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|N|antiplatelet agent|anticoagulant|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|N|antiplatelet agent|antiplatelet agent|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|N|anticoagulant|antiplatelet agent|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|N|antiplatelet agent|anticoagulant|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|N|anticoagulant|anticoagulant|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|N|anticoagulant|antiplatelet agent|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|N|aspirin|streptokinase|In the treatment of acute MI , aspirin , when not otherwise contraindicated , should be administered with Streptokinase -LRB- see below -RRB- . 
Streptokinase|N|antiplatelet|aspirin|Anticoagulation and Antiplatelets After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction , the use of aspirin has been shown to reduce the incidence of reinfarction and stroke . 
Streptozocin|N|phenytoin|streptozocin|The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity . 
Streptozocin|N|streptozocin|streptozocin|The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity . 
Succimer|N|chemet|iron|CHEMET is not known to interact with other drugs including iron supplements ; 
Sulfamethizole|N|barbiturate|tolbutamide|Sulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sulfamethizole|N|tolbutamide|uricosuric|Sulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sulfamethizole|N|tolbutamide|uricosuric|Sulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sulfamethizole|N|barbiturate|uricosuric|Sulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sulfamethizole|N|thiazide|cyclosporine|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|cyclosporine|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|cyclosporine|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|cyclosporine|warfarin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|cyclosporine|sulfonylurea agent|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|cyclosporine|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|cyclosporine|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|thiazide|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|thiazide|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|thiazide|warfarin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|thiazide|sulfonylurea agent|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|thiazide|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|thiazide|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|methotrexate|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|warfarin|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|sulfonylurea agent|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|methotrexate|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|methotrexate|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|warfarin|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|sulfonylurea agent|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|methotrexate|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|methotrexate|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|sulfonylurea agent|warfarin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|warfarin|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|warfarin|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|sulfonylurea agent|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|sulfonylurea agent|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethizole|N|phenytoin|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfamethoxazole|N|diuretic|thiazide|In elderly patients concurrently receiving certain diuretics , primarily thiazides , an increased incidence of thrombopenia with purpura has been reported . 
Sulfamethoxazole|N|anticoagulant|warfarin|It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin . 
Sulfamethoxazole|N|sulfamethoxazole|anticoagulant|It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin . 
Sulfamethoxazole|N|sulfamethoxazole|anticoagulant|It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin . 
Sulfamethoxazole|N|methotrexate|methotrexate|Sulfonamides can also displace methotrexate from plasma protein-binding sites , thus increasing free methotrexate concentrations . 
Sulfamethoxazole|N|sulfonamide|methotrexate|Sulfonamides can also displace methotrexate from plasma protein-binding sites , thus increasing free methotrexate concentrations . 
Sulfasalazine|N|folic acid|digoxin|Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine . 
Sulfasalazine|N|sulfasalazine|methotrexate|When daily doses of sulfasalazine 2 g and weekly doses of methotrexate 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study , the pharmacokinetic disposition of the drugs was not altered . 
Sulfasalazine|N|sulfasalazine|methotrexate|Daily doses of sulfasalazine 2 g -LRB- maximum 3 g -RRB- and weekly doses of methotrexate 7.5 mg -LRB- maximum 15 mg -RRB- were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies . 
Sulfoxone|N|tolbutamide|uricosuric|Sulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sulfoxone|N|tolbutamide|uricosuric|Sulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sulfoxone|N|barbiturate|tolbutamide|Sulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sulfoxone|N|barbiturate|uricosuric|Sulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sulfoxone|N|thiazide|cyclosporine|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|thiazide|sulfonylurea agent|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|thiazide|warfarin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|thiazide|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|thiazide|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|thiazide|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|thiazide|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|cyclosporine|sulfonylurea agent|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|cyclosporine|warfarin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|cyclosporine|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|cyclosporine|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|cyclosporine|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|cyclosporine|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|sulfonylurea agent|warfarin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|sulfonylurea agent|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|sulfonylurea agent|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|sulfonylurea agent|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|sulfonylurea agent|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|warfarin|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|warfarin|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|warfarin|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|warfarin|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|methotrexate|methotrexate|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|methotrexate|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|methotrexate|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|methotrexate|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|methotrexate|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sulfoxone|N|phenytoin|phenytoin|It may also interact with thiazides -LRB- increased thrombocytopenia -RRB- , cyclosporine -LRB- increased nephrotoxicity -RRB- , sulfonylurea agents -LRB- increased hypoglycemic response -RRB- , warfarin -LRB- increased anticoagulant effect -RRB- , methotrexate -LRB- decreased renal excretion of methotrexate -RRB- , phenytoin -LRB- decreased hepatic clearance of phenytoin -RRB-. 
Sumatriptan|N|dihydroergotamine|methysergide|Because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications -LRB- like dihydroergotamine or methysergide -RRB- and sumatriptan within 24 hours of each other should be avoided . 
Sumatriptan|N|ergotamine|dihydroergotamine|Because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications -LRB- like dihydroergotamine or methysergide -RRB- and sumatriptan within 24 hours of each other should be avoided . 
Sumatriptan|N|ergot-type medication|dihydroergotamine|Because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications -LRB- like dihydroergotamine or methysergide -RRB- and sumatriptan within 24 hours of each other should be avoided . 
Sumatriptan|N|ergotamine|methysergide|Because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications -LRB- like dihydroergotamine or methysergide -RRB- and sumatriptan within 24 hours of each other should be avoided . 
Sumatriptan|N|ergot-type medication|methysergide|Because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications -LRB- like dihydroergotamine or methysergide -RRB- and sumatriptan within 24 hours of each other should be avoided . 
Sumatriptan|N|ergotamine|ergot-type medication|Because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications -LRB- like dihydroergotamine or methysergide -RRB- and sumatriptan within 24 hours of each other should be avoided . 
Sumatriptan|N|mao-a inhibitor|sumatriptan|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|sumatriptan succinate|sumatriptan|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|paroxetine|sertraline|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|fluvoxamine|paroxetine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|fluoxetine|paroxetine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|ssri|paroxetine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|selective serotonin reuptake inhibitor|paroxetine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|mao-a inhibitor|paroxetine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|sumatriptan succinate|paroxetine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|fluvoxamine|sertraline|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|fluoxetine|sertraline|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|ssri|sertraline|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|selective serotonin reuptake inhibitor|sertraline|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|mao-a inhibitor|sertraline|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|sumatriptan succinate|sertraline|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|fluoxetine|fluvoxamine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|ssri|fluvoxamine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|selective serotonin reuptake inhibitor|fluvoxamine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|mao-a inhibitor|fluvoxamine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|sumatriptan succinate|fluvoxamine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|ssri|fluoxetine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|selective serotonin reuptake inhibitor|fluoxetine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|mao-a inhibitor|fluoxetine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|sumatriptan succinate|fluoxetine|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|selective serotonin reuptake inhibitor|ssri|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|mao-a inhibitor|ssri|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|sumatriptan succinate|ssri|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|mao-a inhibitor|selective serotonin reuptake inhibitor|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|N|sumatriptan succinate|selective serotonin reuptake inhibitor|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sunitinib|N|ketoconazole|clarithromycin|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ketoconazole|itraconazole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ketoconazole|saquinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ketoconazole|sunitinib|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ketoconazole|ritonavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ketoconazole|voriconizole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ketoconazole|indinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ketoconazole|atazanavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ketoconazole|nelfinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ketoconazole|telithromycin|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ketoconazole|nefazodone|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|sutent|sunitinib|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|itraconazole|clarithromycin|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|clarithromycin|saquinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|clarithromycin|sunitinib|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|clarithromycin|ritonavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|clarithromycin|voriconizole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|clarithromycin|indinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|clarithromycin|atazanavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|clarithromycin|nelfinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|clarithromycin|telithromycin|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|clarithromycin|nefazodone|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|itraconazole|saquinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|itraconazole|sunitinib|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|itraconazole|ritonavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|itraconazole|voriconizole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|itraconazole|indinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|itraconazole|atazanavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|itraconazole|nelfinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|itraconazole|telithromycin|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|itraconazole|nefazodone|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|saquinavir|sunitinib|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ritonavir|saquinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|saquinavir|voriconizole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|indinavir|saquinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|atazanavir|saquinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|nelfinavir|saquinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|saquinavir|telithromycin|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|nefazodone|saquinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ritonavir|sunitinib|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|voriconizole|sunitinib|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|indinavir|sunitinib|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|atazanavir|sunitinib|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|nelfinavir|sunitinib|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|telithromycin|sunitinib|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|nefazodone|sunitinib|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ritonavir|voriconizole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|indinavir|ritonavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|atazanavir|ritonavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|nelfinavir|ritonavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|ritonavir|telithromycin|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|nefazodone|ritonavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|indinavir|voriconizole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|atazanavir|voriconizole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|nelfinavir|voriconizole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|telithromycin|voriconizole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|nefazodone|voriconizole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|atazanavir|indinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|indinavir|nelfinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|indinavir|telithromycin|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|indinavir|nefazodone|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|atazanavir|nelfinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|atazanavir|telithromycin|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|atazanavir|nefazodone|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|nelfinavir|telithromycin|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|nefazodone|nelfinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|nefazodone|telithromycin|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|N|rifapentin|phenobarbital|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|phenobarbital|sunitinib|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|carbamazepine|phenobarbital|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|phenytoin|phenobarbital|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|rifabutin|phenobarbital|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|rifampin|phenobarbital|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|dexamethasone|phenobarbital|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|rifapentin|sunitinib|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|carbamazepine|rifapentin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|phenytoin|rifapentin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|rifabutin|rifapentin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|rifampin|rifapentin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|dexamethasone|rifapentin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|carbamazepine|sunitinib|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|phenytoin|sunitinib|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|rifabutin|sunitinib|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|rifampin|sunitinib|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|dexamethasone|sunitinib|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|sutent|sunitinib|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|phenytoin|carbamazepine|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|carbamazepine|rifabutin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|carbamazepine|rifampin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|dexamethasone|carbamazepine|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|phenytoin|rifabutin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|phenytoin|rifampin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|dexamethasone|phenytoin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|rifampin|rifabutin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|dexamethasone|rifabutin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|N|dexamethasone|rifampin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Suprofen|N|acetylcholine chloride|miochol|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Suprofen|N|miochol|carboptic|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Suprofen|N|miochol|carbachol|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Suprofen|N|miochol|isopto carbachol|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Suprofen|N|acetylcholine chloride|carboptic|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Suprofen|N|acetylcholine chloride|carbachol|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Suprofen|N|acetylcholine chloride|isopto carbachol|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Suprofen|N|carbachol|carboptic|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Suprofen|N|carboptic|isopto carbachol|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Suprofen|N|carbachol|isopto carbachol|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Tamsulosin|N|flomax|alpha-adrenergic blocking agent|Drug-Drug Interactions : The pharmacokinetic and pharmacodynamic interactions between FLOMAX capsules and other alpha-adrenergic blocking agents have not been determined . 
Tamsulosin|N|cimetidine|flomax|The pharmacokinetic interaction between cimetidine and FLOMAX capsules was investigated . 
Tamsulosin|N|tamsulosin hci|warfarin|Results from limited in vitro and in vivo drug-drug interaction studies between tamsulosin HCI and warfarin are inconclusive . 
Tenecteplase|N|tnkase|heparin|Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin . 
Tenecteplase|N|tnkase|aspirin|Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin . 
Tenecteplase|N|heparin|aspirin|Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin . 
Tenecteplase|N|acetylsalicylic acid|dipyridamole|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Tenecteplase|N|vitamin k antagonist|dipyridamole|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Tenecteplase|N|heparin|dipyridamole|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Tenecteplase|N|anticoagulant|dipyridamole|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Tenecteplase|N|vitamin k antagonist|acetylsalicylic acid|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Tenecteplase|N|heparin|acetylsalicylic acid|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Tenecteplase|N|anticoagulant|acetylsalicylic acid|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Tenecteplase|N|heparin|vitamin k antagonist|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Tenecteplase|N|anticoagulant|vitamin k antagonist|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Tenecteplase|N|anticoagulant|heparin|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Teniposide|N|sodium salicylate|sulfamethizole|In a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent . 
Teniposide|N|sodium salicylate|sulfamethizole|In a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent . 
Teniposide|N|tolbutamide|sodium salicylate|In a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent . 
Teniposide|N|tolbutamide|sulfamethizole|In a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent . 
Teniposide|N|vumon|teniposide|Therefore , caution should be used in administering VUMON -LRB- teniposide injection -RRB- to patients receiving these other agents . 
Teniposide|N|teniposide|methotrexate|There was no change in the plasma kinetics of teniposide when coadministered with methotrexate . 
Terbinafine|N|terbinafine|ethoxycoumarin|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
Terbinafine|N|terbinafine|cyclosporine|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
Terbinafine|N|terbinafine|tolbutamide|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
Terbinafine|N|terbinafine|ethinylestradiol|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
Terbinafine|N|ethoxycoumarin|cyclosporine|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
Terbinafine|N|ethoxycoumarin|cyclosporine|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
Terbinafine|N|tolbutamide|ethoxycoumarin|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
Terbinafine|N|ethinylestradiol|ethoxycoumarin|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
Terbinafine|N|ethinylestradiol|ethoxycoumarin|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
Terbinafine|N|tolbutamide|cyclosporine|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
Terbinafine|N|ethinylestradiol|cyclosporine|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
Terbinafine|N|ethinylestradiol|cyclosporine|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
Terbinafine|N|tolbutamide|ethinylestradiol|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
Terbinafine|N|tricyclic antidepressant|selective serotonin reuptake inhibitor|This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , -blockers , selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- , and monoamine oxidase inhibitors -LRB- MAO-Is -RRB- Type B , if they have a narrow therapeutic window . 
Terbinafine|N|tricyclic antidepressant|ssri|This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , -blockers , selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- , and monoamine oxidase inhibitors -LRB- MAO-Is -RRB- Type B , if they have a narrow therapeutic window . 
Terbinafine|N|tricyclic antidepressant|monoamine oxidase inhibitors (mao-is) type b|This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , -blockers , selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- , and monoamine oxidase inhibitors -LRB- MAO-Is -RRB- Type B , if they have a narrow therapeutic window . 
Terbinafine|N|selective serotonin reuptake inhibitor|ssri|This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , -blockers , selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- , and monoamine oxidase inhibitors -LRB- MAO-Is -RRB- Type B , if they have a narrow therapeutic window . 
Terbinafine|N|selective serotonin reuptake inhibitor|monoamine oxidase inhibitors (mao-is) type b|This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , -blockers , selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- , and monoamine oxidase inhibitors -LRB- MAO-Is -RRB- Type B , if they have a narrow therapeutic window . 
Terbinafine|N|ssri|monoamine oxidase inhibitors (mao-is) type b|This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , -blockers , selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- , and monoamine oxidase inhibitors -LRB- MAO-Is -RRB- Type B , if they have a narrow therapeutic window . 
Terbinafine|N|terbinafine|digoxin|In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin . 
Terbinafine|N|antipyrine|digoxin|In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin . 
Terbinafine|N|terbinafine|antipyrine|In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin . 
Terbinafine|N|terbinafine|lamisil|There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin , however , a causal relationship between LAMISIL Tablets and these changes has not been established . 
Terbinafine|N|warfarin|lamisil|There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin , however , a causal relationship between LAMISIL Tablets and these changes has not been established . 
Terbinafine|N|rifampin|cimetidine|Terbinafine clearance is increased 100 % by rifampin , a CyP450 enzyme inducer , and decreased 33 % by cimetidine , a CyP450 enzyme inhibitor . 
Terbinafine|N|terbinafine|cyclosporine|Terbinafine clearance is unaffected by cyclosporine . 
Terbinafine|N|contraceptive|hypoglycemic|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|contraceptive|hypoglycemic|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|hypoglycemic|phenytoin|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|hypoglycemic|phenytoin|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|hypoglycemic|theophylline|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|hypoglycemic|theophylline|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|hypoglycemic|beta blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|hypoglycemic|beta blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|hypoglycemic|thiazide diuretic|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|hypoglycemic|thiazide diuretic|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|hypoglycemic|calcium channel blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|hypoglycemic|calcium channel blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|contraceptive|phenytoin|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|contraceptive|phenytoin|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|contraceptive|theophylline|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|contraceptive|theophylline|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|contraceptive|beta blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|contraceptive|beta blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|contraceptive|thiazide diuretic|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|contraceptive|thiazide diuretic|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|contraceptive|calcium channel blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|contraceptive|calcium channel blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|theophylline|phenytoin|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|theophylline|phenytoin|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|phenytoin|beta blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|phenytoin|beta blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|phenytoin|thiazide diuretic|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|phenytoin|thiazide diuretic|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|phenytoin|calcium channel blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|phenytoin|calcium channel blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|theophylline|beta blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|theophylline|beta blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|theophylline|thiazide diuretic|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|theophylline|thiazide diuretic|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|theophylline|calcium channel blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|theophylline|calcium channel blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|thiazide diuretic|beta blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|thiazide diuretic|beta blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|beta blocker|calcium channel blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|beta blocker|calcium channel blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|thiazide diuretic|calcium channel blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terbinafine|N|thiazide diuretic|calcium channel blocker|There is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
Terfenadine|N|ketoconazole|ketoconazole|Ketoconazole : Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events , e.g. . 
Terfenadine|N|ketoconazole|terfenadine|Ketoconazole : Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events , e.g. . 
Terfenadine|N|ketoconazole|terfenadine|Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine , resulting in elevated plasma terfenadine levels . 
Terfenadine|N|terfenadine|terfenadine|Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine , resulting in elevated plasma terfenadine levels . 
Terfenadine|N|itraconazole|itraconazole|Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources . 
Terfenadine|N|itraconazole|itraconazole|Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources . 
Terfenadine|N|terfenadine|itraconazole|Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources . 
Terfenadine|N|itraconazole|itraconazole|Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources . 
Terfenadine|N|terfenadine|itraconazole|Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources . 
Terfenadine|N|terfenadine|itraconazole|Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources . 
Terfenadine|N|itraconazole|terfenadine|Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources . 
Terfenadine|N|itraconazole|terfenadine|Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources . 
Terfenadine|N|terfenadine|terfenadine|Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources . 
Terfenadine|N|azole-type antifungal agent|fluconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|azole-type antifungal agent|ketoconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|azole-type antifungal agent|itraconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|azole-type antifungal agent|metronidazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|azole-type antifungal agent|miconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|fluconazole|ketoconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|fluconazole|itraconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|fluconazole|metronidazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|fluconazole|miconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|ketoconazole|terfenadine|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|itraconazole|terfenadine|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|ketoconazole|itraconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|metronidazole|ketoconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|miconazole|ketoconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|metronidazole|itraconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|miconazole|itraconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|metronidazole|miconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|metronidazole|miconazole|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|N|macrolide|clarithromycin|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|N|macrolide|erythromycin|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|N|macrolide|ketoconazole|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|N|macrolide|ketoconazole|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|N|macrolide|terfenadine|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|N|erythromycin|clarithromycin|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|N|clarithromycin|ketoconazole|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|N|clarithromycin|ketoconazole|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|N|erythromycin|ketoconazole|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|N|erythromycin|ketoconazole|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|N|terfenadine|ketoconazole|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|N|terfenadine|ketoconazole|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|N|erythromycin|troleandomycin|A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes , have been reported in patients receiving erythromycin or troleandomycin . 
Terfenadine|N|macrolide antibiotic|azithromycin|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|erythromycin|azithromycin|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|clarithromycin|azithromycin|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|troleandomycin|azithromycin|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|terfenadine|azithromycin|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|erythromycin|macrolide antibiotic|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|clarithromycin|macrolide antibiotic|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|troleandomycin|macrolide antibiotic|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|terfenadine|macrolide antibiotic|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|clarithromycin|erythromycin|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|erythromycin|terfenadine|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|erythromycin|troleandomycin|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|erythromycin|troleandomycin|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|clarithromycin|terfenadine|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|clarithromycin|troleandomycin|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|troleandomycin|terfenadine|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|terfenadine|terfenadine|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|N|terfenadine|azithromycin|Studies to evaluate potential interactions of terfenadine with azithromycin are in progress . 
Thalidomide|N|thalidomide|reserpine|Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . 
Thalidomide|N|thalidomide|alcohol|Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . 
Thalidomide|N|thalidomide|chlorpromazine|Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . 
Thalidomide|N|barbiturate|reserpine|Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . 
Thalidomide|N|barbiturate|alcohol|Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . 
Thalidomide|N|barbiturate|chlorpromazine|Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . 
Thalidomide|N|alcohol|reserpine|Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . 
Thalidomide|N|alcohol|reserpine|Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . 
Thalidomide|N|chlorpromazine|reserpine|Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . 
Thalidomide|N|chlorpromazine|reserpine|Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . 
Thalidomide|N|alcohol|chlorpromazine|Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . 
Thalidomide|N|alcohol|chlorpromazine|Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . 
Thalidomide|N|ethinyl estradiol|norethindrone acetate|Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . 
Thalidomide|N|norethindrone|norethindrone acetate|Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . 
Thalidomide|N|contraceptive|norethindrone acetate|Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . 
Thalidomide|N|norethindrone acetate|ethinyl estradiol|Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . 
Thalidomide|N|norethindrone|ethinyl estradiol|Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . 
Thalidomide|N|contraceptive|ethinyl estradiol|Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . 
Thalidomide|N|ethinyl estradiol|ethinyl estradiol|Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . 
Thalidomide|N|contraceptive|norethindrone|Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . 
Thalidomide|N|norethindrone|ethinyl estradiol|Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . 
Thalidomide|N|contraceptive|ethinyl estradiol|Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . 
Thalidomide|N|hiv-protease inhibitor|griseofulvin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hiv-protease inhibitor|modafinil|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hiv-protease inhibitor|penicillin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hiv-protease inhibitor|rifampin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hiv-protease inhibitor|rifabutin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hiv-protease inhibitor|phenytoin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hiv-protease inhibitor|carbamazepine|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hormonal contraceptive|hiv-protease inhibitor|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|thalidomide|hiv-protease inhibitor|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|griseofulvin|modafinil|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|griseofulvin|penicillin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|griseofulvin|rifampin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|griseofulvin|rifabutin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|griseofulvin|phenytoin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|griseofulvin|carbamazepine|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hormonal contraceptive|griseofulvin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|thalidomide|griseofulvin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|modafinil|penicillin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|modafinil|rifampin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|modafinil|rifabutin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|modafinil|phenytoin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|modafinil|carbamazepine|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hormonal contraceptive|modafinil|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|thalidomide|modafinil|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|penicillin|rifampin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|penicillin|rifabutin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|penicillin|phenytoin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|penicillin|carbamazepine|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hormonal contraceptive|penicillin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|thalidomide|penicillin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|rifampin|rifabutin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|rifampin|phenytoin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|rifampin|carbamazepine|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hormonal contraceptive|rifampin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|thalidomide|rifampin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|rifabutin|phenytoin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|rifabutin|phenytoin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|rifabutin|carbamazepine|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|rifabutin|carbamazepine|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hormonal contraceptive|rifabutin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|thalidomide|rifabutin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|phenytoin|carbamazepine|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|phenytoin|carbamazepine|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hormonal contraceptive|phenytoin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|thalidomide|phenytoin|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|hormonal contraceptive|carbamazepine|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|thalidomide|carbamazepine|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thalidomide|N|thalidomide|hormonal contraceptive|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St. . 
Thiamine|N|stavudine|tricyclic antidepressant|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiamine|N|loop diuretic|tricyclic antidepressant|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiamine|N|contraceptive|tricyclic antidepressant|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiamine|N|loop diuretic|stavudine|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiamine|N|contraceptive|stavudine|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiamine|N|loop diuretic|contraceptive|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiamine|N|vitamin b1|thiamine|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiethylperazine|N|cns depressant|opiate|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|N|cns depressant|alcohol|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|N|cns depressant|barbiturate|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|N|cns depressant|anesthetic|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|N|opiate|alcohol|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|N|barbiturate|opiate|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|N|anesthetic|opiate|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|N|barbiturate|alcohol|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|N|anesthetic|alcohol|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|N|barbiturate|anesthetic|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|N|atropine|phosphorous insecticide|as well as atropine and phosphorous insecticides . 
Thioguanine|N|purinethol|mercaptopurine|There is usually complete cross-resistance between PURINETHOL -LRB- mercaptopurine -RRB- and TABLOID brand Thioguanine . 
Thioguanine|N|tabloid|thioguanine|There is usually complete cross-resistance between PURINETHOL -LRB- mercaptopurine -RRB- and TABLOID brand Thioguanine . 
Thioguanine|N|aminosalicylate derivative|olsalazine|As there is in vitro evidence that aminosalicylate derivatives -LRB- e.g. , olsalazine , mesalazine , or sulphasalazine -RRB- inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
Thioguanine|N|olsalazine|mesalazine|As there is in vitro evidence that aminosalicylate derivatives -LRB- e.g. , olsalazine , mesalazine , or sulphasalazine -RRB- inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
Thioguanine|N|olsalazine|sulphasalazine|As there is in vitro evidence that aminosalicylate derivatives -LRB- e.g. , olsalazine , mesalazine , or sulphasalazine -RRB- inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
Thioguanine|N|aminosalicylate derivative|mesalazine|As there is in vitro evidence that aminosalicylate derivatives -LRB- e.g. , olsalazine , mesalazine , or sulphasalazine -RRB- inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
Thioguanine|N|aminosalicylate derivative|sulphasalazine|As there is in vitro evidence that aminosalicylate derivatives -LRB- e.g. , olsalazine , mesalazine , or sulphasalazine -RRB- inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
Thioguanine|N|mesalazine|sulphasalazine|As there is in vitro evidence that aminosalicylate derivatives -LRB- e.g. , olsalazine , mesalazine , or sulphasalazine -RRB- inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
Thioguanine|N|mesalazine|sulphasalazine|As there is in vitro evidence that aminosalicylate derivatives -LRB- e.g. , olsalazine , mesalazine , or sulphasalazine -RRB- inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
Tigecycline|N|contraceptive|contraceptive|Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective . 
Tigecycline|N|antibacterial drug|contraceptive|Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective . 
Tiludronate|N|skelid|magnesium|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|aluminum|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|calcium|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|calcium|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|antacid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|magnesium|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|aluminum|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|calcium|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|calcium|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|antacid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|aluminum|magnesium|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|magnesium|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|magnesium|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|magnesium|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|magnesium|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|magnesium|antacid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|aluminum|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|aluminum|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|aluminum|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|aluminum|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|aluminum|antacid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|antacid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|antacid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|antacid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|calcium|antacid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|antacid|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|N|skelid|skelid|Aspirin may decrease bioavailability of SKELID by up to 50 % when taken 2 hours after SKELID . 
Tiludronate|N|aspirin|skelid|Aspirin may decrease bioavailability of SKELID by up to 50 % when taken 2 hours after SKELID . 
Tiludronate|N|skelid|diclofenac|The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac . 
Tiludronate|N|indomethacin|diclofenac|The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac . 
Tiludronate|N|digoxin|skelid|The pharmacokinetic parameters of digoxin are not significantly modified by SKELID coadministration . 
Tiludronate|N|tiludronate|warfarin|In vitro studies show that tiludronate does not displace warfarin from its binding site on protein . 
Tiotropium|N|methylxanthine|steroid|These include sympathomimetic bronchodilators , methylxanthines , and oral and inhaled steroids . 
Tiotropium|N|methylxanthine|steroid|These include sympathomimetic bronchodilators , methylxanthines , and oral and inhaled steroids . 
Tiotropium|N|sympathomimetic bronchodilator|steroid|These include sympathomimetic bronchodilators , methylxanthines , and oral and inhaled steroids . 
Tiotropium|N|sympathomimetic bronchodilator|methylxanthine|These include sympathomimetic bronchodilators , methylxanthines , and oral and inhaled steroids . 
Tiotropium|N|anticholinergic|ipratropium|However , the co administration of SPIRIVA with other anticholinergic containing drugs -LRB- e.g. , ipratropium -RRB- has not been studied and is therefore not recommended . 
Tirofiban|N|aspirin|heparin|AGGRASTAT has been studied on a background of aspirin and heparin . 
Tirofiban|N|aggrastat|aspirin|AGGRASTAT has been studied on a background of aspirin and heparin . 
Tirofiban|N|aggrastat|heparin|AGGRASTAT has been studied on a background of aspirin and heparin . 
Tirofiban|N|heparin|heparin|The use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone -LRB- see 
Tirofiban|N|heparin|aspirin|The use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone -LRB- see 
Tirofiban|N|heparin|aspirin|The use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone -LRB- see 
Tirofiban|N|aggrastat|heparin|The use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone -LRB- see 
Tirofiban|N|aggrastat|aspirin|The use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone -LRB- see 
Tirofiban|N|aspirin|heparin|The use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone -LRB- see 
Tirofiban|N|heparin|aspirin|The use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone -LRB- see 
Tirofiban|N|aspirin|aspirin|The use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone -LRB- see 
Tobramycin|N|anti-pseudomonal antibiotic|aminoglycoside|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|anti-pseudomonal antibiotic|aminoglycoside|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|corticosteroid|aminoglycoside|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|corticosteroid|aminoglycoside|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|(beta)-agonist|aminoglycoside|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|(beta)-agonist|aminoglycoside|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|pulmozyme|aminoglycoside|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|dornase alfa|aminoglycoside|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|tobi|aminoglycoside|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|corticosteroid|anti-pseudomonal antibiotic|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|corticosteroid|anti-pseudomonal antibiotic|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|(beta)-agonist|anti-pseudomonal antibiotic|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|(beta)-agonist|anti-pseudomonal antibiotic|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|pulmozyme|anti-pseudomonal antibiotic|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|dornase alfa|anti-pseudomonal antibiotic|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|tobi|anti-pseudomonal antibiotic|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|(beta)-agonist|corticosteroid|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|(beta)-agonist|corticosteroid|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|pulmozyme|corticosteroid|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|dornase alfa|corticosteroid|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|tobi|corticosteroid|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|pulmozyme|(beta)-agonist|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|dornase alfa|(beta)-agonist|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|tobi|(beta)-agonist|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|dornase alfa|pulmozyme|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|tobi|pulmozyme|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|tobi|dornase alfa|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|tobi|tobi|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|N|aminoglycoside|antibiotic|Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue . 
Tobramycin|N|diuretic|antibiotic|Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue . 
Tobramycin|N|ethacrynic acid|furosemide|TOBI should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol . 
Tobramycin|N|furosemide|urea|TOBI should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol . 
Tobramycin|N|furosemide|urea|TOBI should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol . 
Tobramycin|N|furosemide|mannitol|TOBI should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol . 
Tobramycin|N|furosemide|mannitol|TOBI should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol . 
Tobramycin|N|ethacrynic acid|urea|TOBI should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol . 
Tobramycin|N|ethacrynic acid|mannitol|TOBI should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol . 
Tobramycin|N|urea|mannitol|TOBI should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol . 
Tobramycin|N|urea|mannitol|TOBI should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol . 
Tolmetin|N|warfarin|tolmetin|The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin , and tolmetin does not alter the prothrombin time of normal volunteers . 
Tolmetin|N|warfarin|tolmetin|The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin , and tolmetin does not alter the prothrombin time of normal volunteers . 
Tolmetin|N|tolmetin|tolmetin|The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin , and tolmetin does not alter the prothrombin time of normal volunteers . 
Tolmetin|N|tolectin|hypoglycemic agent|In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents . 
Tolmetin|N|insulin|hypoglycemic agent|In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents . 
Tolmetin|N|sulfonylurea|hypoglycemic agent|In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents . 
Tolmetin|N|insulin|tolectin|In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents . 
Tolmetin|N|sulfonylurea|tolectin|In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents . 
Tolmetin|N|sulfonylurea|insulin|In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents . 
Tolmetin|N|methotrexate|methotrexate|TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate . 
Tolmetin|N|nonsteroidal anti-inflammatory drug|methotrexate|TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate . 
Tolmetin|N|tolectin|methotrexate|TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate . 
Tolmetin|N|tolectin|nonsteroidal anti-inflammatory drug|TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate . 
Tolterodine|N|cyclosporine|vinblastine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|clarithromycin|vinblastine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|erythromycin|vinblastine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|macrolide antibiotic|vinblastine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|miconazole|vinblastine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|azole antifungal|vinblastine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|itraconazole|vinblastine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|ketoconazole|vinblastine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|clarithromycin|cyclosporine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|clarithromycin|cyclosporine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|erythromycin|cyclosporine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|erythromycin|cyclosporine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|macrolide antibiotic|cyclosporine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|macrolide antibiotic|cyclosporine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|miconazole|cyclosporine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|miconazole|cyclosporine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|azole antifungal|cyclosporine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|azole antifungal|cyclosporine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|itraconazole|cyclosporine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|itraconazole|cyclosporine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|ketoconazole|cyclosporine|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|erythromycin|clarithromycin|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|macrolide antibiotic|clarithromycin|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|miconazole|clarithromycin|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|azole antifungal|clarithromycin|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|itraconazole|clarithromycin|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|ketoconazole|clarithromycin|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|macrolide antibiotic|erythromycin|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|miconazole|erythromycin|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|azole antifungal|erythromycin|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|itraconazole|erythromycin|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|ketoconazole|erythromycin|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|miconazole|macrolide antibiotic|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|azole antifungal|macrolide antibiotic|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|itraconazole|macrolide antibiotic|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|ketoconazole|macrolide antibiotic|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|azole antifungal|miconazole|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|itraconazole|miconazole|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|ketoconazole|miconazole|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|azole antifungal|itraconazole|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|ketoconazole|azole antifungal|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|N|ketoconazole|itraconazole|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Trastuzumab|N|herceptin|herceptin|Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies . 
Trastuzumab|N|herceptin|herceptin|Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies . 
Trastuzumab|N|paclitaxel|herceptin|Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies . 
Trastuzumab|N|herceptin|herceptin|Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies . 
Trastuzumab|N|paclitaxel|herceptin|Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies . 
Trilostane|N|aminoglutethimide|mitotane|Trilostane may interact with aminoglutethimide or mitotane -LRB- causing too great a decrease in adrenal function -RRB-. 
Trimethoprim|N|phenytoin|phenytoin|Trimethoprim , given at a common clinical dosage , increased the phenytoin half-life by 51 % and decreased the phenytoin metabolic clearance rate by 30 %. 
Trimetrexate|N|trimetrexate|trimetrexate|Since trimetrexate is metabolized by a P450 enzyme system , drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter trimetrexate plasma concentrations . 
Trimetrexate|N|trimetrexate|trimetrexate|Since trimetrexate is metabolized by a P450 enzyme system , drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter trimetrexate plasma concentrations . 
Trimetrexate|N|erythromycin|fluconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|erythromycin|ketoconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|erythromycin|rifabutin|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|erythromycin|rifampin|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|ketoconazole|fluconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|ketoconazole|fluconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|rifabutin|fluconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|rifabutin|fluconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|rifampin|fluconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|rifampin|fluconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|rifabutin|ketoconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|rifabutin|ketoconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|rifampin|ketoconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|rifampin|ketoconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|rifampin|rifabutin|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|rifampin|rifabutin|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|N|cimetidine|acetaminophen|In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites . 
Trimetrexate|N|trimetrexate|acetaminophen|In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites . 
Trimetrexate|N|ketoconazole|miconazole|Based on an in vitro rat liver model , nitrogen substituted imidazole drugs -LRB- clotrimazole , ketoconazole , miconazole -RRB- were potent , non-competitive inhibitors of trimetrexate metabolism . 
Trimetrexate|N|imidazole drug|ketoconazole|Based on an in vitro rat liver model , nitrogen substituted imidazole drugs -LRB- clotrimazole , ketoconazole , miconazole -RRB- were potent , non-competitive inhibitors of trimetrexate metabolism . 
Trimetrexate|N|clotrimazole|ketoconazole|Based on an in vitro rat liver model , nitrogen substituted imidazole drugs -LRB- clotrimazole , ketoconazole , miconazole -RRB- were potent , non-competitive inhibitors of trimetrexate metabolism . 
Trimetrexate|N|imidazole drug|miconazole|Based on an in vitro rat liver model , nitrogen substituted imidazole drugs -LRB- clotrimazole , ketoconazole , miconazole -RRB- were potent , non-competitive inhibitors of trimetrexate metabolism . 
Trimetrexate|N|clotrimazole|miconazole|Based on an in vitro rat liver model , nitrogen substituted imidazole drugs -LRB- clotrimazole , ketoconazole , miconazole -RRB- were potent , non-competitive inhibitors of trimetrexate metabolism . 
Trimetrexate|N|imidazole drug|clotrimazole|Based on an in vitro rat liver model , nitrogen substituted imidazole drugs -LRB- clotrimazole , ketoconazole , miconazole -RRB- were potent , non-competitive inhibitors of trimetrexate metabolism . 
Triprolidine|N|sedative|tranquilliser|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|sedative|tranquilliser|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|barbiturate|tranquilliser|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|barbiturate|tranquilliser|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|alcohol|tranquilliser|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|narcotic analgesic|tranquilliser|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|narcotic analgesic|tranquilliser|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|hypnotic|tranquilliser|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|hypnotic|tranquilliser|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|central nervous system depressant|tranquilliser|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|barbiturate|sedative|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|barbiturate|sedative|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|alcohol|sedative|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|narcotic analgesic|sedative|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|narcotic analgesic|sedative|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|hypnotic|sedative|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|hypnotic|sedative|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|central nervous system depressant|sedative|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|alcohol|barbiturate|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|barbiturate|narcotic analgesic|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|barbiturate|narcotic analgesic|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|barbiturate|hypnotic|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|barbiturate|hypnotic|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|central nervous system depressant|barbiturate|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|alcohol|narcotic analgesic|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|alcohol|hypnotic|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|central nervous system depressant|alcohol|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|hypnotic|narcotic analgesic|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|hypnotic|narcotic analgesic|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|central nervous system depressant|narcotic analgesic|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|central nervous system depressant|hypnotic|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|N|anticholinergic drug|atropine|The effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine . 
Triprolidine|N|anticholinergic drug|tricyclic antidepressant|The effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine . 
Triprolidine|N|atropine|tricyclic antidepressant|The effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine . 
Trospium|N|sanctura|vancomycin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|sanctura|morphine|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|sanctura|tenofovir|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|sanctura|metformin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|sanctura|digoxin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|sanctura|sanctura|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|sanctura|pancuronium|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|sanctura|procainamide|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|morphine|vancomycin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|morphine|vancomycin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|vancomycin|tenofovir|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|vancomycin|tenofovir|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|vancomycin|metformin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|vancomycin|metformin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|digoxin|vancomycin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|pancuronium|vancomycin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|pancuronium|vancomycin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|procainamide|vancomycin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|procainamide|vancomycin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|morphine|tenofovir|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|morphine|tenofovir|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|morphine|metformin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|morphine|metformin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|digoxin|morphine|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|pancuronium|morphine|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|pancuronium|morphine|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|procainamide|morphine|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|procainamide|morphine|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|metformin|tenofovir|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|metformin|tenofovir|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|digoxin|tenofovir|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|pancuronium|tenofovir|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|pancuronium|tenofovir|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|procainamide|tenofovir|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|procainamide|tenofovir|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|digoxin|metformin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|pancuronium|metformin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|pancuronium|metformin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|procainamide|metformin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|procainamide|metformin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|digoxin|pancuronium|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|digoxin|procainamide|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|procainamide|pancuronium|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|procainamide|pancuronium|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|N|sanctura|sanctura|Coadministration of Sanctura with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of Sanctura and/or the coadministered drug due to competition for this elimination pathway . 
Vancomycin|N|amphotericin b|aminoglycoside|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|amphotericin b|bacitracin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|amphotericin b|polymyxin b|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|amphotericin b|colistin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|amphotericin b|viomycin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|amphotericin b|cisplatin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|aminoglycoside|bacitracin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|aminoglycoside|polymyxin b|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|aminoglycoside|colistin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|aminoglycoside|viomycin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|aminoglycoside|cisplatin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|bacitracin|polymyxin b|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|bacitracin|polymyxin b|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|bacitracin|colistin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|bacitracin|colistin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|bacitracin|viomycin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|bacitracin|viomycin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|bacitracin|cisplatin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|bacitracin|cisplatin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|polymyxin b|colistin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|polymyxin b|colistin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|polymyxin b|viomycin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|polymyxin b|viomycin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|polymyxin b|cisplatin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|polymyxin b|cisplatin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|colistin|viomycin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|colistin|viomycin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|colistin|cisplatin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|colistin|cisplatin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|viomycin|cisplatin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vancomycin|N|viomycin|cisplatin|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
Vigabatrin|N|phenytoin|phenytoin|In 1984 , Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy . 
Vigabatrin|N|vigabatrin|phenytoin|In 1984 , Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy . 
Vindesine|N|vindesine|vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|vindesine|vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|phenytoin|live virus vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|live virus vaccine|mitomycin-c|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|live virus vaccine|vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|live virus vaccine|vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|live virus vaccine|killed virus vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|phenytoin|mitomycin-c|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|phenytoin|vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|phenytoin|vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|phenytoin|killed virus vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|vaccine|mitomycin-c|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|vaccine|mitomycin-c|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|mitomycin-c|vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|mitomycin-c|killed virus vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|vaccine|vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|vaccine|killed virus vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|vaccine|killed virus vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|N|killed virus vaccine|vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vorinostat|N|coumarin-derivative anticoagulant|zolinza|Coumarin-Derivative Anticoagulants : Prolongation of prothrombin time -LRB- PT -RRB- and International Normalized Ratio -LRB- INR -RRB- were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants . 
Vorinostat|N|coumarin-derivative anticoagulant|coumarin-derivative anticoagulant|Coumarin-Derivative Anticoagulants : Prolongation of prothrombin time -LRB- PT -RRB- and International Normalized Ratio -LRB- INR -RRB- were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants . 
Vorinostat|N|hdac inhibitor|valproic acid|Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors -LRB- e.g. , valproic acid -RRB-. 
Vorinostat|N|hdac inhibitor|hdac inhibitor|Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors -LRB- e.g. , valproic acid -RRB-. 
Vorinostat|N|hdac inhibitor|valproic acid|Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors -LRB- e.g. , valproic acid -RRB-. 
Vorinostat|N|hdac inhibitor|zolinza|Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors -LRB- e.g. , valproic acid -RRB-. 
